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In the Nordic countries, people with severe mental illness die 15-20 years younger than 
others. Substance use and higher level of undiagnosed/untreated somatic diseases contribute 
to this disparity. We aimed to investigate; (i) mortality among people with schizophrenia 
and/or substance use disorder, with emphasis on the impact of a dual diagnosis; whether 
people with schizophrenia or bipolar disorder had (ii) higher odds of not being diagnosed with 
cardiovascular disease prior to cardiovascular death, and; (iii) equal prevalence of diagnostic 
testing and treatment of cardiovascular disease prior to cardiovascular death, compared to 
people without such disorders who died due to cardiovascular disease.  
We used nationwide registries to calculate standardized mortality ratios in a 7-year 
open cohort study including 125,744 residents of Norway aged 20-79 with schizophrenia 
and/or substance use disorders diagnosed in specialized care (i). We applied multivariate 
logistic (ii) and log-binomial regression (iii) to study undiagnosed cardiovascular disease and 
uptake of cardiovascular health care services prior to cardiovascular death among 
approximately 72,400 residents aged 18 and above with and without schizophrenia or bipolar 
disorder diagnosed in primary or specialized health care in Norway.  
We found a four-fold (schizophrenia only) to seven-fold (substance use disorder with 
or without schizophrenia) increased mortality compared to the general population, with the 
highest excess mortality observed for poisoning, suicides and respiratory diseases. The excess 
mortality implicated that five out of six persons with schizophrenia and/or substance use 
disorder died prematurely. Despite many health care contacts, people with schizophrenia and 
women with bipolar disorder were more likely to die from undiagnosed cardiovascular 
disease. People with schizophrenia or bipolar disorder also had lower prevalence of 
specialized cardiovascular examinations and invasive treatment prior to cardiovascular death, 
compared to individuals without such disorders. We found, however, no difference in uptake 
of invasive treatment in those diagnosed with cardiovascular disease prior to death. 
The large and persistent mortality gap between people with severe mental illness and 
the general population highlights the need of securing proper access to specialized somatic 
care, and a more effective prevention of deaths from unnatural causes in this group. Our 
findings suggest that underdiagnosis and underutilization of specialized cardiovascular 
examinations are among the main obstacles to achieve more equal access to cardiovascular 





I Norden dør personer med alvorlige psykiske lidelser 15-20 år yngre enn andre. Ruslidelser 
og udiagnostisert/ubehandlet somatisk sykdom bidrar til denne ulikheten. Formålet i denne 
studien var å undersøke; (i) dødelighet blant personer med schizofreni og/eller ruslidelse, med 
særlig vekt på betydningen av en dobbeltdiagnose; (ii) om personer med schizofreni eller 
bipolar lidelse hadde høyere odds for ikke å bli diagnostisert med kardiovaskulær sykdom før 
kardiovaskulær død, og (iii) om personer med schizofreni eller bipolar lidelse hadde samme 
forekomst av diagnostisk testing og invasiv behandling av kardiovaskulær sykdom før 
kardiovaskulær død sammenlignet med personer uten slike lidelser. 
Vi brukte landsdekkende registre til å beregne standardiserte mortalitetsratioer i en 7-
årig åpen kohortstudie, som inkluderte 125 744 innbyggere i alderen 20-79 år med schizofreni 
og/eller ruslidelse diagnostisert i norsk spesialisthelsetjeneste. Vi benyttet multivariat 
logistisk (ii) og log-binomisk regresjon (iii) for å studere udiagnostisert kardiovaskulær 
sykdom og bruk av hjerte-/karrelaterte helsetjenester forut for kardiovaskulær død blant circa 
72 400 innbyggere i alderen 18 og over med og uten schizofreni eller bipolar lidelse 
diagnostisert i primær- eller spesialisthelsetjenesten i Norge. 
Dødeligheten var firedoblet blant personer med schizofreni (uten samtidig ruslidelse) 
og syv ganger høyere blant personer med ruslidelser (med eller uten schizofreni) 
sammenlignet med den generelle befolkningen, med særlig høy risiko knyttet til forgiftninger, 
selvmord og respirasjonssykdommer. Overdødeligheten innebar at fem av seks personer med 
schizofreni og/eller ruslidelse døde prematurt. Vi fant også at personer med schizofreni og 
kvinner med bipolar lidelse hadde høyere odds for å dø av udiagnostisert kardiovaskulær 
sykdom. Personer med schizofreni eller bipolar lidelse hadde også lavere forekomst av 
spesialiserte kardiovaskulære undersøkelser og invasiv kardiovaskulær behandling 
sammenlignet med personer uten slike lidelser. Vi fant ingen forskjell i tilgang til invasiv 
behandling blant de som ble diagnostisert med kardiovaskulær sykdom før de døde.  
Det store gapet i forventet levealder mellom personer med alvorlige psykiske lidelser 
og den generelle befolkningen understreker behovet for bedret tilgang til spesialisert somatisk 
diagnostikk og behandling, og en mer effektiv forebygging av unaturlige dødsfall i denne 
gruppen. Våre funn tyder på at underdiagnostikk og underutnyttelse av spesialisert 
diagnostikk er viktige hindre for å oppnå likere tilgang til kardiovaskulær behandling for 
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In the Nordic countries, people with severe mental illness (SMI) die 15-20 years younger [1, 
2], and people with substance use disorder (SUD) 24-28 years younger [1, 3] than people 
without such conditions. Although the risk of death from external causes of death such as 
suicides, poisoning and accidents is highly increased in people with SMI, most life years lost 
is due to premature deaths from potentially modifiable somatic causes such as cardiovascular 
disease (CVD) [4]. The Norwegian health minister recently referred to this gap in life 
expectancy as "one of the biggest and ugliest differences we have in our country" [5]. As a 
possible explanation for this inequity, the minister argued that ".. often [] somatic diseases 
and lifestyle challenges are not seen or captured". Besides pinpointing a major social 
injustice and public health challenge, these statements also provide a good summary of the 
topics of this thesis, which aims were to investigate mortality among patients with SCZ and/or 
SUD in nationwide Norwegian data, especially the effect of concomitant SUD among those 
with schizophrenia (SCZ)), and to examine the impact of SMI on underdiagnosis and under-
treatment of CVD prior to cardiovascular death (see section 1.7, page 43 for detailed aims). 
All these topics seem to be understudied. 
Further motivation for this thesis was that there had not been published nationwide studies of 
mortality among persons with SCZ in Norway since the 1970s [6]. Also, accumulating 
evidence suggested both increasing rates of concurrent SUD among persons with SMI [7], 
and a possible rising mortality gap between persons with and without SMI [8-18]. 
The WHO's multilevel model of risk for excess mortality in persons with SMI, reproduced in 
Table 1, summarizes the many factors likely involved in the pathway leading to excess 
mortality among people with SMI, and offers as such a central framework for the current 
thesis. Paper I-III examined a few of these potential explanations for excess mortality at the 
individual and provider level (in red letters in Table 1), specifically the effect of SUD (paper 
I), and health care seeking and provision (paper II and III) among persons with SMI.  
Disease- and patients-specific characteristics are of great importance in understanding health 
care seeking and provision, as well as increased mortality. A brief description of the four 
patient groups included in this study (i.e. SCZ, bipolar disorder (BD), SUD and CVD) is 




Table 1 - The World Health Organization’s multilevel model of risk for excess mortality in persons with severe mental illness 
INDIVIDUAL FACTORS HEALTH SYSTEMS SOCIAL DETERMINANTS OF HEALTH 
Disorder-specific 
 • Severity of disorder 
 • Family history 
 • Symptoms/pathophysiology 
 • Early age of onset 
 • Recency of diagnosis 
 • Stigma 
 
Behavior-specific 
 • Tobacco use 
 • Poor diet 
 • Inadequate physical activity 
 • Sexual and other risk behaviors 
 • Substance use (alcohol and drugs) 
 • Low motivation (e.g., treatment seeking, 
adherence) 
Leadership 
 • Absence of relevant policies and guidelines 
 
Financing 
 • Low investment in quality care 
 
Information 
 • Limited health information systems 
 
Service delivery 
 • Verticalization and fragmentation of health 
services 
 • Lack of care coordination and management 
 • Limited access to services 
 
Human resources 
 • Poor quality service provision 
 • Negative beliefs/attitudes of workforce 
 • Poor communication 
 
Medications 
 • Antipsychotic medications (no treatment, 
polypharmacy, higher than recommended dosages) 
 
Public policies 
 • Discriminating policies 
 • Low financial protection and limited 
coverage in health packages 
 
Socio-economic position 
 • Unemployment 
 • Homelessness 
 • Low health literacy 
 
Culture and societal values 
 • Stigma and discrimination in society 
 • Negative perceptions about persons with SMI 
 
Environmental vulnerabilities 
 • Infections, malnutrition 
 • Access to means of suicide 
 • Impoverished or unsafe neighborhoods 
 
Social support 







1.1 Severe mental illness 
Mental illnesses involve abnormal changes in emotions, thinking or behavior. Mental and 
addictive disorders affect a significant portion of the population and were among the top 
leading causes of disability in 2017 [19, 20], with increasing prevalence the past decades [21]. 
Definitions of severe mental illness (SMI) differ across authors, but share a common feature 
in trying to capture mental disorders characterized by long duration and significant disability. 
Some apply a narrow definition of nonorganic psychosis (i.e. SCZ or BD), some include SCZ, 
BD and moderate to severe depression (e.g. The World Health Organization (WHO)), some 
also include diagnoses such as organic mental disorder, severe anxiety disorders, severe 
eating disorders and severe panic disorder, while others apply criteria such as severity, 
duration and dysfunction [22]. We defined SMI in a narrow sense of the term, i.e. as any 
diagnosis of either narrow SCZ (code F20 in the International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10) or code P72 in the 
International Classification of Primary Care 2nd Edition (ICPC-2)) or BD (ICD-10 codes F30-
F31/ICPC-2 code P73). 
1.1.1 Schizophrenia spectrum disorder 
SCZ involves fundamental and characteristic changes of perception, cognition, emotion and 
behavior, affecting cognitive abilities [23], psychosocial functioning, work ability and every-
day life. Common symptoms include hallucinations and delusions, agitation, disturbed 
behavior (so called positive symptoms), social withdrawal, affect flattening, lack of 
motivation, attention deficit and stereotyped behavior (so called negative symptoms). While 
positive symptoms usually vary over time, negative symptoms often persist in all stages of the 
disease. SCZ was ranked as the 11th most disabling condition globally in 2013 [20]. 
The term schizophrenia spectrum disorder reflects that SCZ, rather than one distinct unitary 
disorder, is a group of related disorders that share some symptoms and underlying causal 
mechanisms. For the sake of simplicity, we have used the abbreviation SCZ both to describe 
schizophrenia spectrum disorders (ICD-10 codes F20-F29, paper I), and narrow schizophrenia 






1.1.1.1 Risk factors for SCZ 
SCZ is believed to result from an interplay between genes [24, 25] and a range of 
environmental and behavioral factors. Many genes are probably involved, with each gene 
only contributing small effects to the overall susceptibility. Estimates of heritability varies 
from 31% [26] to nearly 80% [27]. The non-genetic risk factors with the highest quality 
evidence, reporting medium effect sizes, are advanced paternal age, obstetric and perinatal 
complications, and cannabis use [28-30]. Other environmental risk factors for SCZ, with 
small effect sizes, include childhood adversities [31], living in urbanized communities [32] 
and a personal or family history of migration [33, 34].  
1.1.1.2 Incidence and prevalence 
SCZ-spectrum is a relatively rare condition, with a median incidence of 15-18 per 100,000 
person-year [35-37], and a median lifetime prevalence of 0.4-0.7% [37-39], with varying 
incidence across places and population groups [37]. In Norway, the one-year prevalence of 
SCZ in specialized treatment is estimated to be 0.17% [40], and the five-year prevalence in 
persons aged 24 to 63 years estimated to be 0.34% [41].  
Onset of disease, defined as the first psychotic episode, typically occurs in late adolescence or 
young adulthood [35]. About one in four receive the diagnosis after age 40 [42]. Incidence 
rates are higher in men up to age 39, and higher in women from 50 years and above [35]. 
Meta-analyses report a slightly higher lifetime morbidity risk in men, compared to women 
[35, 43].  
1.1.1.3 Treatment of SCZ 
Most people with SCZ receive pharmacological treatment with second-generation 
antipsychotic agents, which offer symptom relief but no cure. Treatment efforts therefore 
focus on early diagnosis, rapid treatment of acute psychiatric episodes, reintegration into 
society and prevention of new acute psychiatric events and complications [44]. The national 
guidelines for the treatment of psychosis in Norway recommend antipsychotic medication as 
the first-line treatment both in acute psychosis and in the prevention of relapse. About 20-
30% of patients do not have a positive treatment response using newer antipsychotic drugs in 





Supplementary psychosocial interventions can help ameliorate symptoms, improve 
functioning and patient satisfaction, and prevent relapse [44]. In a recent review, assertive 
community treatment, cognitive behavioral therapy, family interventions, psycho-education, 
social skills training, supported employment, and early interventions for first episode 
psychosis, were all found to improve various functional outcomes compared to usual care 
[46]. Hospitalization, sometimes involuntary, may also be required in situations involving risk 
of harm to oneself or others. 
1.1.1.4 Prognosis 
The clinical course of SCZ is heterogeneous, but for most patients the disease is chronic with 
periodic exacerbations and hospitalizations. Estimates of recurrence varies considerably, 
depending on time span studied and definitions used. A recent review found that most patients 
(57%) had a chronic course and that 39% had episodic relapses [47]. Another review found 
that approximately 1 in 7 could be expected to recover over 10 years [48], while a review of 
outcome in the long run (follow-up period 5-20 years), found symptomatic remission in 16% 
of never-treated patients and 38% in patients treated with antipsychotics [49]. 
Early diagnosis, intensive treatment of the first psychotic episode, as well as access to 
continued psychosocial treatment and support in the following years are associated with better 
outcomes [49]. Men tend to have more negative symptoms and a more severe disease course 
than women [50], and people with early onset of the disease often have worse functioning and 
more cognitive impairment than those with a later onset [51]. A concurrent diagnosis of SUD 
is associated with particular poor prognosis (see section 1.3.1, page 22). Many persons with 
SCZ also have additional mental health disorders such as depressive disorder [52], personality 
disorder [53], anxiety disorder [54, 55] or dementia [56], and also substantial physical 
comorbidity (see section 1.3, page 22).  
1.1.2 Bipolar disorder 
BD describes a group of affective disorders characterized by episodes of depression and 
abnormal mood elevation (mania or hypomania), separated by periods of normal mood. 
Manic episodes are typically associated with elevated or irritable mood, overactivity, 
grandiose self-esteem and decreased need for sleep. The clinical manifestations differ, from 




hypomania or mild depression, but no manic episodes (bipolar II), to cyclothymic disorder 
(hypomanic and depressive symptoms that do not meet the criteria for depressive episodes). 
Rapid cycling is a particularly disabling form of BD, characterized by four or more episodes 
within a year [57]. Since a diagnosis of BD requires a manic or hypomanic episode and there 
is no objective biomarker, many patients with BD are initially diagnosed with severe 
depression. The average delay in diagnosis is reported to be 8-10 years after the onset of 
symptoms, with a longer delay in women [58].Women have a higher frequency of depression, 
a later onset, more seasonal variations in mood disturbance, and increased susceptibility to 
relapse, and are more often diagnosed with BD II disorder than men [59].  
Persons with BD are generally less impaired, cognitively, clinically and socially than persons 
with SCZ. Still, BD is a severe illness due to its early onset, chronicity and high suicide rates, 
and was ranked among the 20 most disabling conditions globally in 2013 [60]. 
1.1.2.1 Risk factors for BD 
As for SCZ, the causes of BD are multifactorial, including both genetic, psychosocial and 
environmental contributors. Susceptibility to BD is most likely influenced by many genetic 
risk factors with individually small effects [61]. Heritability is estimated to be around 70% 
[62], and life time risk for BD in first-degree relatives is estimated to be 5–10%, seven times 
higher than the general population [63]. Family studies and genome-wide studies show strong 
evidence for shared genetic risk factors for BD and SCZ [64, 65], with a considerable 
crossover between the two disorders. Numerous environmental risk factors have been 
identified as potential risk factors for BD, but the effect sizes are often small and most are not 
specific to BD but associated with SMI in general. Among these, early life stressors, cannabis 
abuse, certain infectious diseases and inflammation, seem to be supported by the strongest 
evidence [66-69]. 
1.1.2.2 Incidence and prevalence 
Like SCZ, BD is a relatively rare disease, with an incidence of 28 per 100,000 per person-
years [70] and a lifetime prevalence of 1-2% [60, 71, 72], with marked variation between 
geographic areas [72], but no differences according to sex [57]. Lifetime worldwide 
prevalence is slightly higher for BD I, compared to BD II [72]. Five-year prevalence of 




Norwegian study, 75% of incident BD cases were diagnosed in late adolescence or young 
adulthood, with 23 years as the mean age of onset [73].  
1.1.2.3 Treatment of BD 
Treatment of BD usually include a combination of pharmacotherapy and psychotherapy. Due 
to high risk of suicide and relapse [74], a prolonged prophylactic pharmacological treatment is 
often initiated, typically with a mood stabilizer (lithium or an anticonvulsant) as the first 
choice. Antipsychotics, antidepressants and electrostimulation are also used in the 
management of psychotic symptoms and depression. Non-adherence to medication is 
common in BD [75], partly due to side effects such as weight gain and cognitive 
consequences. 
1.1.2.4 Prognosis 
For most people with BD, a chronic course is the rule, characterized by periods of partial or 
full recovery between recurrent episodes of relapse [74]. Prospective studies investigating the 
long-term symptomatic status of treated BD over a mean 13 year follow-up, found that 
persons with BD were symptomatically ill approximately half the time, with depression as the 
dominating symptom in both BD I and II [76, 77]. Early recognition and intervention may 
improve prognosis, as the symptoms in earlier stages often are less severe and more 
responsive to treatment [78]. Early onset, rapid cycling, psychotic features and longer 
duration of affective episodes are associated with worse outcomes [57]. Depression and 
persistent cognitive impairment are also strongly correlated with functional impairment [79]. 
A high degree of somatic (see section 1.3.2, page 23) and psychiatric comorbidity [80] is 
often observed in patients with BD, and also very high (8%-19%) suicide rates [81].  
1.1.3 Substance use disorder 
SUD describes harmful or hazardous use of alcohol or other psychoactive substances, 
typically with an impact on mental and physical health, ability to work, participation in 
society, financial security and interpersonal relationships. In ICD-10, a diagnosis of SUD is 
justified if three or more of the following criteria are met within one year: (i) a strong desire 
to take the substance, (ii) impaired capacity to control the substance consumption, (iii) 
abstinence symptoms when intake of substances is reduced, (iv) increased tolerance to the 




because of substance use, and (vi) despite harmful consequences the substance use continues. 
Both harmful use and dependence syndrome are included in this definition. The substances 
may be legal (e.g. alcohol and tobacco), illegal (e.g. heroin, amphetamine, cocaine and 
cannabis) or licensed for medical purposes (e.g. sedatives).  
1.1.3.1 Risk factors for SUD 
Like SCZ and BD, a complex interplay between genetic [82, 83] and psychosocial factors 
[84] is involved in the development of SUD. Also, the availability of substances, as well as 
how addictive the drug is, is important in the development of SUD. Environmental factors 
unique to the individual play an significant role in exposure and initial use of substances, 
while genetic factors have a major influence on the progression of substance use to 
dependence [85]. Male sex [86], young age [86], having other mental problems, a family 
history of SUD [87, 88], as well as adverse family conditions [84], are all known risk factors 
for SUD. Early adolescent substance use substantially increases the risk of lifelong SUD [88, 
89].  
1.1.3.2 Incidence and prevalence 
SUD is one of the most prevalent mental disorders in Norway. Globally, SUDs account for 
11% of total health burden [90]. In high-income countries such as Norway, alcohol use 
disorder and illegal drug use disorders contribute equally to the burden of disease [91].  
 
The incidence of SUD is highest in men and the youngest [92], with adolescence as the key 
period for development of SUD [85]. Estimates of SUD incidence and prevalence are 
somewhat uncertain, as the majority of individuals with SUD receive no treatment for their 
disorder, and reliable statistics for illegal use are difficult to achieve. A review of European 
studies found the prevalence of SUD to be more than 4% within the last year [93]. In Norway, 
the 1-year incidence of harmful use or dependence on alcohol estimated to be about 8% for 
men and 3% for women, based on surveys in the mid-90s [86, 94]. Cannabis is the most 
widely used illegal drug in Norway. In 2018, about 5 percent of Norwegians aged 16-64 
reported using cannabis in the last 12 months [95], while approximately 20% stated that they 
had used cannabis one or more times during their lives [96]. The use of illicit drugs is 
concentrated among young adults and is highest among men, with high-risk drug use mainly 




inject illegal drugs in Norway. This number has stabilized since 2012, following a decline in 
2008-12. Surveys show that the use of illicit drugs in Norway is somewhat lower than in most 
other European countries, with the exception of amphetamine. The consequence of illegal 
drug use in Norway are nevertheless serious, due to high rates of fatal overdoses [98].  
1.1.3.3 Treatment of SUD 
The multidimensional nature of SUD is reflected in diversified approaches to target the many 
treatment needs in this group. Treatment of SUD includes assessment, detoxification, 
stabilization, short- and long-term residential treatments and medication assisted treatment. 
The Norwegian national guidelines emphasize a client-oriented approach, early intervention, 
diversification of services and reintegration. This includes various psychological interventions 
(e.g. cognitive behavioral therapy, motivational interview and mindfulness), social 
interventions (e.g. involvement of family and network, issues related to adequate housing, 
predictable economy and job training), and medical interventions (e.g. substitution therapy for 
opioids and medication for severe alcohol dependence) [99]. Often long-term interdisciplinary 
interventions are needed to addresses the psychiatric, medical, legal and social implications of 
addiction. 
In 2016, approximately 18,000 Norwegians were treated in specialized SUD treatment 
facilities, most of whom were outpatients [97]. The largest group had opioid dependency as 
their primary diagnosis, followed by those who received treatment for cannabis use disorder 
and poly-drug use. A meta-analysis of psychosocial treatments for illicit drugs showed 
moderate effect sizes, with the most efficacious interventions for cannabis use disorder and 
the least efficacious interventions for poly-substance use. Overall, one third achieved 
clinically significant abstinence, compared to 13% among controls [100]. Younger samples 
had larger treatment effect sizes, but higher drop-out rates [100]. 
1.1.3.4 Prognosis 
SUD has a heterogeneous, but often chronic course with varying intensity over time, and a 
tendency to relapse after remission [101]. A meta-analysis of 21 studies published between 
2000 and 2015 suggested that 35-54% of individuals with SUDs achieved remission during a 




SUD is associated with a significant increased risk of physical [103] and mental [104] health 
problems (see also section 1.3.1), and is also associated with poverty, social exclusion and 
criminal behavior. 
1.2 Cardiovascular disease 
CVD is an umbrella term for diseases involving the heart (cardiac disease), the blood vessels 
(vascular disease) or both. Globally CVD is the leading cause of loss of disability-adjusted 
life years and accounts for nearly one third of all deaths [105]. Atherosclerosis (a build-up of 
fatty deposits in the arteries) is involved in many of these diseases, leading to impaired 
circulation and lack of oxygen supply to the heart muscle and surrounding tissue. Ischemic 
heart disease (IHD, congestive heart failure, cardiac arrhythmias, cerebrovascular disease and 
peripheral vascular disease are among the most common CVDs, and are briefly described 
below.  
 Ischemic heart disease (IHD), also called coronary heart disease, is a condition with 
insufficient supply of blood and oxygen to the heart and surrounding tissue, due to 
narrowing (stenosis) of the arteries. This increases the burden on the heart and can 
cause angina (chest pain caused by restricted blood flow to the heart muscle), 
myocardial infarction (MI, where the blood flow to the heart muscle is suddenly 
blocked) or heart failure (see below). MI subgroups include STEMI (with 
electrocardiography (ECG) changes) and NSTEMI (without ECG changes), of which 
STEMI is the most acute and life threatening. NSTEMI amounts to approximately 
70% off all heart attacks in Norway [106]. 
 Congestive heart failure is a condition where the heart's pumping function is 
impaired. There are many causes of heart failure, with MI or prolonged stress due to 
hypertension as the most common causes.  
 Cardiac arrhythmias describes conditions with irregular heartbeats or heart rhythm. 
Atrial fibrillation is the most common type, characterized by irregularly and faster 
than normal heart beats. 
 Cerebrovascular disease results from an impeded blood supply to the brain. A stroke 
may result either from a blockage (brain infarction or ischemic stroke), or a rupture of 




 Peripheral vascular disease are diseases caused by atherosclerosis that affect non-
cardiac and non-intracranial arteries. 
 
Acutely life-threatening CVDs include MI, stroke and ruptured aneurysm. In Norway, annual 
cardiovascular mortality has decreased from 772 to 230 per 100,000 men, and from 450 to 
161 per 100,000 women during the past three decades [107]. The decreased mortality is 
assumed to result from advancement in CVD treatment, decreased out-of-hospital sudden 
deaths, as well as an overall improvement in lifestyle factors, particularly cholesterol levels, 
smoking prevalence and blood pressure levels [108, 109]. Nevertheless, CVD mortality is still 
a leading cause of death in Norway, responsible for about 25% of total mortality in men and 
women in 2017. 
1.2.1 Risk factors for CVD 
Very many factors (> 270) have been suggested implicated in the development of CVD [110], 
including both demographic, behavioral, metabolic, psychosocial and environmental factors. 
Male sex and older age are demographic risk factors, while behavioral risk factors include 
smoking, physical inactivity, excessive alcohol consumption and unhealthy diet (i.e. diets that 
are high in fat combined with carbohydrates). Metabolic risk factors include hypertension, 
diabetes, raised blood cholesterol (hyperlipidemia), overweight and abdominal obesity. Other 
known risk factors are low socioeconomic status, stress and genetic predisposition/family 
history of CVD. Of all these risk factors, hypertension, diabetes, dyslipidemia, smoking, 
obesity and a sedentary lifestyle, as well as stress, older age, male gender, and a family 
history of CHD seem to be most important [108, 111].  
1.2.2 Prevention of CVD 
Some of the risk factors for CVD, such as age, male sex, ethnicity, low birth weight or genetic 
predisposition/family history of CVD, are given, but many important risk factors are 
modifiable by lifestyle change or medical treatment. WHO estimates that 80% of premature 
CVD is preventable [112], through healthy eating, exercise, avoidance of tobacco and limited 
alcohol intake, and treatment of hypertension, dyslipidemia and diabetes. Smoking cessation 
is the single most cost-effective intervention in CVD prevention [113]. Drug therapy (such as 




high risk of having one [112]. Clinical trials have shown that statins reduce the risk of CVD 
events by 25% and all-cause mortality by 14% [114].  
1.2.3 Diagnostic tests and treatment of CVD 
1.2.3.1 CVD-related diagnostic tests 
We included ECG, echocardiography, heart catheterization (e.g. coronary angiography), 
vascular ultrasound and cardio-metabolic blood tests in the measurement of CVD-related 
diagnostic tests in our study. A brief description of these procedures is given in Table 2.  
Table 2 - CVD-related diagnostic test included in the current study 
Procedure Description 
ECG Electrical signals are recorded to detect irregularities in heart rhythm and structure, 
such as arrhythmias, heart muscle changes caused by inflammation (myocarditis), 
oxygen deficiency due to atherosclerosis, or clot formation in coronary arteries 
(angina pectoris, MI).  
Echocardiography Ultrasound waves and their different reflections ("echo") from the various parts of 
the heart are used to show and analyze detailed images of the heart's structure and 
function.  
Heart catheterization  An invasive procedure where a thin, flexible plastic tube (catheter) is passed into an 
artery or vein, and forwarded to the heart under X-ray disclosure. This allows 
measurement of blood pressure and oxygen content in the vessels. The most 
common heart catheterization procedure is coronary angiography, where an X-ray 
is taken using injected contrast agents to visualize the coronary arteries in order to 
detect atherosclerosis. 
Vascular ultrasound Sound waves are used to evaluate the body's circulatory system and help identify 
blockages in the arteries and veins, and detect blood clots (such as deep venous 
thrombosis) in the major extremity veins. 
Cardiometabolic blood 
tests  
Measurement of total cholesterol, blood glucose and glycated hemoglobin (HbA1c). 
 
CT or MR technics may also be used to detect significant arterial disease, but data on these 
procedures were not available in the current study.  
1.2.3.2 Invasive cardiovascular treatment 
We included common procedures for invasive treatment of MI or angina pectoris, arrhythmia 













intervention (PCI)  
A non-surgical procedure used to open coronary arteries that are 
narrowed or blocked by atherosclerotic plaque. A small tube (stent) is 
usually implanted to prevent the artery from narrowing again.  
 Coronary artery 
bypass graft 
(CABG) 
A surgical technique used to improve blood flow to the coronary arteries 
by using normal arteries from the chest wall and veins from the legs to 
bypass blocked arteries, often performed with the help of a heart-lung 
machine. The procedure provides more effective symptom relief than 








Devices that sends electrical impulses to the heart muscle to keep up a 
suitable heart rate and rhythm.  
 Ablation A non-surgical procedure where high-frequency radio waves are used to 
destroy a small area of heart tissue that is causing rapid and irregular 
heartbeats.  




Surgical treatments of conditions in arterial, venous and lymphatic 
systems, excluding intracranial and coronary arteries. Main procedures 
include carotid artery surgery, aneurysm surgery and thrombectomy. 
 
1.3 Comorbidity in individuals with severe mental illness 
1.3.1 Schizophrenia and concurrent substance use disorder 
Comorbid SUD in people with SCZ is highly prevalent [41, 115-119]. A recent meta-analysis 
of 123 studies including nearly 166,000 subjects in in- or out-patient settings found a 
prevalence of any SUD of 42% among patients with SCZ or first episode psychosis [120]. 
Illicit drugs (28%), cannabis (26%) and alcohol (24%) were present in every fourth individual 
with SCZ or first episode psychosis. Comorbid SUD was more frequent in men (48%) than in 
women (22%), and associated with an earlier age of onset of SCZ [120]. A previous review 
found cannabis use disorder to be especially common in younger patients and in first episode 
psychosis [118]. A registry-based study from Norway examining the prevalence of SUD in 
patients aged 24-63 with SCZ treated in specialized health care, reported a 5-year prevalence 
of 25% for any SUD, 5% for alcohol use disorder, 7% for cannabis use, 8% for stimulants and 
15% for poly-substance use[41]. The prevalence reported in the Norwegian study are, with 





Comorbid SMI is likewise significantly overrepresented in individuals with SUD [115]. Two 
recent meta-analysis found a doubled risk of psychosis among cannabis users [121, 122], with 
other studies suggesting also an increasing prevalence [7, 123]. Persons with illicit drug 
disorders have especially high rates of comorbid mental disorders [124], and are 3-4 times 
more likely to be diagnosed with major depression or anxiety disorder [104] compared to 
controls. Persons with alcohol use disorder are also at increased risk of major depression and 
any anxiety disorder [104], and almost half meet criteria for at least one other mental disorder 
[125].  
 
Having a concurrent diagnosis of SCZ and SUD is associated with a variety of detrimental 
outcomes, such as increased symptom severity [126-128], poorer functional outcomes of SCZ 
[129-133], non-adherence with treatment [75, 134-136], increased somatic [137-139] and 
psychiatric comorbidity [140, 141], increased risk of victimization [142, 143], violent 
behavior [144-147], and suicides [148-150].  
1.3.2 Severe mental illness and physical health 
People with SMI have an increased risk of a wide range of medical conditions, but are 
especially burdened by CVD, metabolic syndrome, diabetes, cancer, pulmonary conditions 
and infections [151-153]. Between 50% and 90% of persons with SMI have at least one 
chronic physical illness, and these typically develop at a younger age [154]. Recent literature 
reviewing risk of CVD, diabetes and cardio-metabolic conditions in persons with SMI is 
outlined below, and findings regarding risk of other medical diseases briefly summarized at 
the end of the section.  
1.3.2.1 Risk of CVD in persons with SMI 
Persons with SMI are at particular high risk of CVD [153]. A large meta-analysis of 92 
studies including 3.2 million individuals with SMI found that one out of ten individuals with 
SMI (i.e. SCZ, BD or major depression) had at least one comorbid CVD at a mean age of 50 
[155]. Table 4 shows risk estimates for CVD in individuals with SMI reported in recent meta-
analytic studies [155-161]. In the largest meta-analysis to date [155], persons with SMI had a 
78% higher risk of developing CVD and a 53% higher risk of having a CVD, compared to 





Prospective studies included in the meta-analysis referred to above showed a 54% and 59% 
increased risk of IHD in individuals with SMI and SCZ, respectively, but no increased risk in 
individuals with BD [155]. Increased risk of IHD has also been documented in users of 
antipsychotic medications [160, 161]. Estimates of risk of cerebrovascular disease or stroke 
showed a 64% increased risk in individuals with SMI, and an approximately 50-74% 
increased risk in individuals with SCZ [155, 158, 159] or BD [157, 159]. The risk of 
congestive heart failure was reported to be doubled in individuals with SMI [155], and 88% 
increased in individuals with SCZ [158], while hypertension was found to be increased in BD, 
but not SCZ [156].  
 










65/38 3,211,768 113,383,368 CVD SMI pooled  1.78 (1.60-1.98) 1.53 (1.27-1.83) 
14/13    SCZ 1.95 (1.41-2.70)  
10/12    BD 1.57 (1.28-1.93)  
18/5   IHD SMI pooled 1.54 (1.30-1.82) 1.51 (1.47-1.55) 
5    SCZ 1.59 (1.08-2.35)  
4    BD 1.16 (0.76-1.78)  
11/6   Cerebro SMI pooled 1.64 (1.26-2.14) 1.42 (1.21-1.66) 
5    SCZ 1.57 (1.09-2.25)  
4    BD 1.60 (0.99-2.57)  




5 27,092 13,088,819 MI BD 1.09 (0.96-1.24)  




5 NA NA Hypertension SCZ 0.94 (0.75-1.14)  




13  422,698 CVD SCZ 1.53 (1.27-1.86)  
NA   IHD SCZ 1.20 (0.93-1.53)  
NA   Stroke SCZ 1.71 (1.19–2.46)  
NA   CHF SCZ 1.81 (1.42–2.29)  
Li 2014 
[159] 
6 NA NA Stroke SCZ 1.50 (1.25-1.80)  
Abbrevations: BD, bipolar disorder; Cerebro, cerebrovascular disease; CHF, congestive heart disease; CI, 
confidence interval; CVD, cardiovascular disease; IHD, ischemic heart disease; MI, myocardial infarction; NA, 
not available; OR, odds ratio; RR, relative risk; SCZ, schizophrenia; SMI, severe mental illness 
 
Excess CVD risk in people with SMI has been explained partly by an increased prevalence of 




and SUD), and which may emerge shortly after diagnosis, and at a young age [162, 163]. 
Smoking is particularly important, with rates up to 5.3 times higher than in the general 
population [164]. In a recent study from Norway, 47% of SCZ individuals and 43% of BD 
individuals reported daily smoking [165], compared to 12% in the general Norwegian 
population [95]. Genetic studies have also found overlapping genes associated with both SCZ 
and CVD risk factors, implying shared pathological mechanisms between SCZ and CVD 
[25]. 
1.3.2.2 Risk of metabolic syndrome and diabetes in individuals with SMI 
Metabolic syndrome (MetS) describes a clustering of metabolic factors (i.e. central obesity, 
hypertension, dyslipidemia and glucose intolerance) which are highly predictive of CVD [2]. 
MetS is associated with a five times higher risk of developing diabetes [166] and a doubled 
risk of CVD, MI and stroke [167]. Meta-analyses report that one in three people with SCZ 
[168], and nearly two out of five persons with BD [169], meet the criteria for MetS. 
 
Table 5 shows estimated relative risk for MetS and diabetes in individuals with SMI reported 
in recent meta-analytic studies. These studies show that persons with SMI had a 58% 
increased risk of MetS, and a 33-58% increased risk of its components, except for 
hypertension [170]. Meta-analyses and large cohort studies have reported a prevalence of type 
2 diabetes of about 10% among individuals with SMI [151, 171-173], which is twice the 
estimated prevalence in Norway [174]. The prevalence was only about 3%, however, in anti-
psychotic drug-naïve individuals with SMI [172]. The risk of diabetes was 70-153% increased 
risk in people with SMI compared to controls, with the highest increased risk when rigorous 
criteria for diabetes was applied [171]. Individuals with SCZ and BD seem to have similar 
risk of diabetes, despite higher education, better social functioning, less severe psychiatric 
symptoms and lower use of antipsychotic medication in individuals with BD. 
The increased risk of MetS is partly due to side effects of antipsychotic medication. Both 
newer and older antipsychotics are associated with metabolic side effects that can lead to 
weight gain, glucose intolerance and dyslipidemia [170]. These adverse metabolic effects 
occur shortly after first-time exposure to antipsychotic medication [175]. Antipsychotic 




Mood stabilizers and antidepressants are also associated with metabolic side effects [176], but 
these side effects are considered less severe than for antipsychotic medication. 
 
Table 5 - Risk of metabolic syndrome (MetS) and diabetes in individuals with severe mental illness reported in 





Patients Controls Disease SMI patent 
group 
RR (95% CI) 
Vancamp
fort 2015 
30 6,610  MetS SMI 1.58 (1.35-1.86) 
18   Abdominal obesity SMI 1.43 (1.23-1.66) 
19   Low HDL cholesterol SMI 1.33 (1.15-1.54) 
19   Hypertriglyceridemia  SMI 1.49 (1.28-1.73) 
20   Hyperglycaemia  SMI 1.51 (1.24-1.84) 
12   Hypertension SMI 1.12 (0.99-1.28) 
Osborn 
2008 
12 2,333/6,249 261,228/2,169,371 Hypertension SMI 1.11 (0.91-1.35) 
26 9,612 3,449,677 Diabetes SMI 1.70 (1.21-2.37) 
NA NA NA Diabetes SCZ 1.87 (1.68-2.09) 
Vancamp
fort 2016 
13 438,245 5,622,664 Diabetes II SMI 1.85 (1.45-2.37) 
22   Diabetes II SCZ 2.04 (1.69-2.49) 
17   Diabetes II BD 1.89 (1.29-2.77) 
Stubbs 
2015 
25 145,718 4,343,407 Diabetes II SCZ 1.82 (1.56–2.13) 
8   Diabetes II 
(recognized criteria) 
SCZ 2.53 (1.68–3.80) 
13   Diabetes II (medical 
records) 
SCZ 1.65 (1.34–2.03)  
Abbrevations: BD, bipolar disorder; CI, confidence interval; HDL, high-density lipoprotein; MetS, metabolic 
syndrome; NA, not available; RR, relativ risk; SCZ, schizophrenia; SMI, severe mental illness 
 
1.3.2.3 Risk of other physical diseases in individuals with SCZ or BD 
Meta-analytic studies also document that individuals with SCZ or BD are at increased risk of 
respiratory diseases [177, 178], obstructive sleep apnea [179], hepatitis C [180, 181], poor 
oral health [178, 182], fractures [183, 184] and dementia [56, 185] compared to controls. 
Individuals with SCZ also have higher risk of breast cancer [186-188], infectious diseases 
(e.g. HIV and hepatitis B), osteoporosis [189, 190], as well as altered pain sensitivity, sexual 
dysfunction and obstetric complications [189] compared to controls. Individuals with BD also 





1.4 Mortality in individuals with SMI and/or SUD 
People with SMI have a life expectancy that is decades shorter than others. A recent meta-
analysis documented a 15 years reduced life expectancy among persons with SCZ, compared 
to the general population [2, 193], and a large Nordic study including more than 270,000 
patients with recent onset SMI found a reduced life expectancy of 20 and 15 years in men and 
women with SMI, respectively, compared to the general population [1]. In the latter study, 
life expectancy was reduced by 21-24 years for those with SUD, 16-20 years for those with 
SCZ and 16-17 years for those with affective disorders.  
While life expectancy in developed countries has increased by nearly a decade in the general 
population since the 1970s [17], most studies suggest that people with SMI have benefited 
less from this development. Recent reviews and meta-analyses [8, 17, 194] report a rising 
mortality gap between those with and without SCZ. Studies from Northern Norway [10] and 
Denmark also report a rising mortality gap in patients with SCZ compared to the general 
population [13, 195], whereas Finnish studies have reported a flattening out of the mortality 
gap [196, 197] or a declining trend [198] between those with and without SMI. 
1.4.1 Mortality in individuals with schizophrenia spectrum disorder 
A worldwide systematic review in 2007, including approximately 22,000 deaths, found that 
persons with SCZ had a 2.6 times increased mortality risk compared to the general population 
[8]. Another worldwide meta-analysis published eight years later found similar results for 
psychosis [199], while a worldwide review from 2018 including more than 1.7 million 
community-dwelling participants, found that people with psychosis had a 3.1 increased 
mortality compared to the general population [17]. Cohort studies from the Nordic countries 
have reported standardized mortality ratios (SMRs, see section 2.6.1, page 51 for a definition) 
for SCZ in comparable ranges. Nationwide all-cause SMRs reported since 2000 in studies 
from Denmark, Sweden or Finland [1, 195, 200-204] are shown in Table 6, together with all-




Table 6 - Standardized Mortality Ratios (SMRs) in individuals with schizophrenia reported in Nordic countries 
since 2000.  











al 2008 [204] 
Finland Hospital-
based; in- and 
outpatients  
3,837 1993-2005 18–64 SCZ (F20–F29) 3.9 3 6.1 
Kiviniemi et 





pension due to 
SCZ 
7,591 1995-2001 NA Incident SCZ 



















































































233 1995-2008 15-64 Incident SCZ 
(F20) 
4.6   
Lomholt et 




38,500 1995-2014 < 65 SCZ (F20–F29) 4.6   
Abbrevations: No, Number; SCZ, schizophrenia; SMR, Standardized mortality ratio; NA, not available;  
 
In these Nordic studies, estimates of all-cause SMR for men with SCZ range from 2.3 [201] 
to 4.5 [203], while all-cause SMR for women with SCZ range from 1.9 [201] to 4.6 [10]. In 
Norway and Denmark, the highest SMRs were reported in the most recent studies [10, 195], 
whereas SMRs in recent Swedish and Finnish studies seem stable or possibly declining 
compared to those found in previous studies.  
The majority of deaths in individuals with SCZ are caused by somatic diseases, especially 




the shorter life expectancy in SCZ than deaths from external causes of death such as 
accidents, suicides or homicides [4]. A recent study from the UK estimated that natural causes 
of death accounted for nearly 80% of lost life-years among persons with SMI [207]. Studies 
from the Nordic countries show that excess mortality from natural causes of death is 2-to 3-
fold increased in individuals with SCZ, compared to the general population [1, 202-204, 208]. 
Studies from Europe and the US show that excess mortality from CVD is of the same 
magnitude [205, 208], and possibly increasing [8, 11, 15, 197]. 
SMRs from unnatural causes of death are substantially elevated in persons with SCZ, and 
range from approximately 5 to 8 in the Nordic countries [202, 203, 208], with higher SMRs in 
women [208]. SMRs for suicide are 11- to 15-fold increased in individuals with SCZ in 
Nordic studies [202-204]. A recent Finnish study reported that SMRs for suicidal deaths 
decreased from 11 in 1984 to less than seven in 2014 [197].  
1.4.2 Mortality in people with substance use disorder 
A meta-review found that SUD, together with anorexia nervosa, had the highest risk of 
premature death of all SMIs [209]. In meta-analyses addressing specific SUDs, excess 
mortality risk ranged from a four-fold increased mortality risk among persons with alcohol 
use disorder [209, 210] to a 15-fold increased mortality risk among opioid users [211] and 
persons who inject drugs [209, 212]. Studies from Nordic countries also show high SMRs 
among those with SUD, with varying estimate sizes according to inclusion criteria, patient 
group and length of follow up. A recent 19-year follow up study of mortality among 291 
Norwegians receiving specialized treatment for poly-SUD or alcohol use disorder only, found 
SMRs of 3.8 among those with any SUD, 3.4 among those with alcohol use disorder-only and 
5.2 among those with poly-SUDs [213]. Much higher SMRs were reported in a 13-year 
follow up study of 172 injecting drug users in Norway [214], reporting an all-cause SMR of 
39 in women and 21 in men, and in a previous study of mortality among hospitalized opioid 
addicts in Norway, reporting a SMR of more than 13 in the years 1995-1999 [215].  
A Danish study reported SMRs of 4.9 for cannabis use, 6.4 for cocaine use, 6.0 for 
amphetamine use, 9.1 for heroin use, and 7.7 for other opioids [216], and a Swedish study 
reported an all-cause SMR of 5.9 among 561 illicit substance abusers followed up to 37 years 




found a SMR of 12.7 in men and 10.3 in women, with the highest mortality risk in opiates 
users (SMR 16.7) and persons with alcohol use disorder (SMR 13.1), followed by stimulants, 
cannabis and “other SUD”, all with SMRs around 10 [218]. While natural causes of death 
accounted for about 70% of deaths among patients with alcohol use disorder in a recent meta-
analysis, substance related deaths and unnatural causes of death are often reported as the most 
common cause of death among those with illicit SUD [213, 215, 217]. 
1.4.3 Mortality in people with SMI and comorbid SUD 
Although comorbidity between SMI and SUD is very common, relatively few studies have 
focused on the impact of SMI and comorbid SUD on premature mortality [130, 217, 219]. 
Existing studies on this topic are heterogeneous, both in terms of patient groups and settings 
that are studied, and with regard to results. Estimates of all-cause mortality among patients 
with SMI and/or SUD identified in studies published after year 2000 are shown in Table 7 . 
Of these studies, most [12, 130, 220-226], but not all [151], reported an increased risk of 
mortality in the dually diagnosed, compared to SCZ-only/SMI-only. Estimates of excess 
mortality risk in those with SMI and comorbid SUD ranged from about 50% increased risk to 
a 2- to 3-fold increased risk, compared to those with only SCZ/SMI. In the two studies that 
reported sex-specific results, the increased risk in the dually diagnosed was somewhat more 
pronounced in men than in women [12, 222].  
There are few studies investigating cause-specific mortality risk in the dually diagnosed, with 
partly conflicting results. Mortality from natural causes of death was found to be both similar 
[151, 224] and increased [226] in those with both SMI and SUD, compared to those with SMI 
only. Likewise, risk of cardiovascular death was reported to be both similar [151] and 
increased [226] in patients with SCZ and comorbid SUD, compared to those with SCZ only. 
Also, diverging gender-specific results has been reported for unnatural causes of death [151, 




Table 7 - Summary of studies comparing all-cause mortality in persons with SMI and/or SUD. 












State-wide Inpatients 1996–2001 Mental  
illness +/- 
SUD 








Ref OR 1.55  
Schmidt 2011 
Denmark [130] 
Hospital Inpatients 1993-2008 SCZ+/- SUD Ref HR 1.74  
Nome 2012 
Norway [12] 




SMR 6.6 (m)  




Nationwide In- and 
outpatients 
2006-2007 Mental  
illness +/- 
SUD 
RR 4.2 (m) 
RR 3.6 (w) 
RR 12.5 (m) 
RR 10.8 (w) 
RR 6.1 (m)  
RR 7.9 (w)  
Crump 2013 
Sweden [151] 
Nationwide In- and 
outpatients 
2003–2007 SCZ+/- SUD HR 2.4 
(m) 
HR 2.8 (w) 
HR 2.2 (m)  HR 2.7 (w)  
Hjorthøj 2015 
Denmark [223] 
Nationwide In- and 
outpatients 
1990-2012 SCZ+/- SUD SMR 3.6 SMR 8.5  
Reininghaus 
2015 UK [224] 
Hospital In- and 
outpatients 






2005–2007 SCZ+/- SUD SMR 5.0 SMR 18.0  
Lumme 2016 
Finland [226] 
Nationwide Inpatients 2008-2010 SMI+/-SUD Ref RR ≈1.8 (m)  
RR ≈2.1 (w)  
Sørensen 2005 
Denmark [228] 
Hospital In- and 
outpatients 











Nationwide Patients in 
specialized SUD 
treatment 
1996-2006 DUD+/- SCZ 
 
 SMR 7.9 SMR 7.0 
Koola 2012 
USA [219] 






2015 UK [141] 
Hospital In- and 
outpatients 











HR 1.8  
 
HR 0.9 




Nationwide Inpatients 1983-2007 SUD+/- SCZ  HR 1.1 (m) 
HR 0.9 (w) 
Ref  
Abbrevations: AUD, alcohol use disorder; CUD, cannabis use disorder; DUD, drug use disorder; FEP, first 
episode psychosis; HR, hazard ratio; m, men; OR, odds ratio; OUD, opioid use disorder, Ref, reference category 
in the statistical model; RR, relativ risk; SCZ, scgizophrenia; SMI, severe mental illness; SMR, standardized 





Identified studies comparing all-cause mortality in persons with SUD and comorbid SCZ/SMI 
are heterogenous both with regard to settings, patients included, type of SUD studied and 
results. All-cause mortality is reported to be both higher [222, 226, 232], similar [231] and 
lower [217, 233], among those with any SUD and concurrent SMI, compared to those with 
SUD-only.  
Studies report similar mortality risk in patients with alcohol use disorder with and without 
concurrent SCZ [219, 229] and similar mortality risk in persons with drug use disorder with 
and without concurrent SMI [141, 216, 228]. Studies of mortality in people with cannabis use 
disorder and concurrent SMI report both decreased [219], similar [230] and increased 
mortality risk, compared to those with cannabis use disorder only [230]. 
1.5 Uptake of cardiovascular health care in people with SMI 
The organization and funding of health care services is of great importance when studying 
access to health care services, particularly for vulnerable populations. This section therefore 
starts with a brief overview of the Norwegian health care system. We also define key concepts 
such as inequity and quality of care, before summarizing some of the literature regarding 
uptake of cardiovascular health care in people with SMI. 
1.5.1 The organization of health care services in Norway 
The health care services in Norway is mainly publicly funded, with free admission to hospital 
and a maximum annual cost of 2,370 NOK in 2016 (approximately €293) for outpatient 
treatment (e.g. general practitioner (GP) visits, psychologist visits, x-ray examinations, patient 
travel costs and prescription medicines with preapproved reimbursement). The responsibility 
for primary care services is assigned to the approximately 420 municipalities, while four 
Regional Health Authorities are responsible for the provision of specialist health services to 
all inhabitants in their respective regions. Publicly funded private specialist health services, 
including in- and outpatient facilities, private practitioners, laboratory and radiology services, 
accounted for 12% of public health expenditures in the period 2010-2014 [234]. These private 
providers performed a significant proportion of services within SUD treatment, rehabilitation 
and planned orthopedic surgery. Most private health care providers are funded mainly through 
agreements on service provision on behalf of municipalities or Regional Health Authorities, 




by the public health service. GPs are usually organized as private enterprises. About 2/3 of the 
funding comes from activity-based funding (fee-for-service), while the remaining is capitation 
paid by the municipalities. Approximately 14% of total health expenditures are financed by 
deductibles. The use of privately financed private health care services is unknown, but is 
assumed to constitute a small part of the total health services. 
To promote continuity of care for patients with chronic disorders, all Norwegians who want it 
has a named accountable GP (currently 99% [235]). The GP is responsible for general 
medical services for all persons on their list, including acute care during daytime. GPs are in 
contact with a large proportion of patients with SMI, and prescribe almost 70% of all 
antipsychotic drugs [236]. GPs also acts as gatekeepers for referrals to the publicly funded 
specialized health services. A mentally ill patient may be referred to one of approximately 75 
District Psychiatric Centers, which offers specialized mental health in- and outpatient 
services. The more severely ill may be admitted to emergency wards at psychiatric hospitals, 
while persons with SUD may be referred to outpatient treatment or admission at a SUD 
treatment facility. Pre-hospital services (i.e. ambulance service including helicopters with 
physician staff) is part of the specialist health service, and often initiate treatment on the way 
to hospital.  
1.5.2 Definitions of health inequity and quality of care 
Studies of inequality in health outcomes or health care use are based on a premise of 
avoidable injustice [237], as well as a perception that it is a social responsibility to try to 
remedy this. As differences in health outcomes resulting from free personal choice or chance 
alone would not be considered unjust per se, the notion of inequity in health or health care 
relates to circumstances largely beyond the individual’s control, such as differences in access 
to, or quality of, health care services. Variation in health service provision also requires that 
there is a certain amount of physician’s discretion with regard to whether a specific procedure 
is indicated or not in a particular patient [238]. 
While inequality is suggested used as a descriptive term for variations in health outcomes or 
health care uptake, inequity has a normative interpretation [239]. Equity in health care has 
been defined as “equal access to available care for equal need, equal utilization for equal 




persons that are alike in relevant aspects, should be treated in alike fashion (horizontal 
equity), and that persons who are unlike in relevant aspects should be treated differently 
(vertical equity). Loosely stated, this implies that equitable health care requires equally 
accessible health care services of similar quality to all in equal need, and greater provision to 
those who demonstrate greater need.  
Quality of care is, however, an elusive concept, partly because of its multidimensional 
character and context-dependency, and partly because quality never can be better than the 
knowledge we have about the relationship between treatment and effect. Quality of health 
care has been defined as: “.. the degree to which health services for individuals and 
populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge» [240]. Following Donabedian [241], quality of health care 
can be assessed on the basis of three different domains: structure, process and outcome. 
Structure measures deal with the context and attributes in, and with which, care is provided 
(e.g. resources, organization, reward systems, staff, facilities and equipment), process 
measures deal with the services provided, as well as the interaction between patients and 
providers, while outcomes refer to overall effects on patients' and populations' health. 
Process-based measures can be operationalized using readily available administrative data, 
and provide actionable information as to where performance falls short and quality 
improvements should be targeted. 
In addition to these dimensions, the attainment of timely and appropriate healthcare (access), 
and patients’ experiences and shared decision making are important quality domains.  
1.5.3 Undiagnosed CVD among persons with SMI 
The excess mortality due to somatic diseases in SMI patients may be caused by poorer access 
to somatic health care. Crump et al reported that the proportion of individuals who died from 
IHD undiagnosed one month prior to an IHD death was higher in individuals with SCZ than 
in others who died from IHD [151], but not significantly different between individuals with or 
without BD [152]. Importantly, when restricting the analysis to people who were previously 
diagnosed with IHD, SCZ was only modestly associated with higher IHD mortality, which 
indicates that premature cardiovascular deaths in individuals with SMI may be prevented if 




With the exception of the studies by Crump et al [151, 152], underdiagnosis of CVD in 
patients with SMI seems to be little documented, especially in relation to premature mortality. 
Exceptions include a recent Danish study, where patients with SCZ and a history of 
psychiatric admissions had 45% reduced odds of being diagnosed with CVD at least 30 days 
prior to cardiovascular death [245]. Also, in a study of US veterans, patients with SCZ had 
twice the risk of unforeseen death compared to patients without SCZ, with CVD as the most 
common cause [246].  
More often, underdiagnosis of CVD has been indirectly indicated, for example in studies 
showing lower levels of screening and monitoring of risk factors for CVD [156, 247, 248], 
and studies showing lower use of CVD-related health services [249, 250]. Further indirect 
evidence is offered in a survey of mental health service users, in which 39% reported not 
having discussed CVD risk factors with health care professionals the previous year [251].  
Also, large population based cohort studies have reported lower or similar rates of recorded 
CVDs such as atrial fibrillation, hypertension and IH) in individuals with SMI, compared to 
others [151, 252-255], in spite of increased risk of CVD. Lower prescriptions rates for 
cardiovascular medication in individuals with SMI compared to others have also been 
reported [255-259], possibly implying underdiagnosis and undertreatment of CVD in these 
individuals. 
1.5.4 Inequalities in health care provision for patients with SMI 
1.5.4.1 Screening/monitoring of cardio-metabolic risk factors in individuals with SMI 
Current guidelines for management of psychosis recommend regular assessments of smoking, 
diet, physical activity, weight, waist circumference, blood pressure, fasting blood glucose, 
HbA1c and fasting lipids [260]. Still, meta-analyses report inferior preventive care of CVD in 
individuals with SMI regarding metabolic monitoring [247, 248], blood pressure monitoring 
[247] and hypertension treatment [156]. These meta-analyses mainly included studies from 
the US, where universal health care is lacking. Case studies from countries with universal 
health care also document low levels of screening for diabetes and other metabolic 
abnormalities [261-265], and studies from the UK and Italy found that a minority of patients 
in primary care using antipsychotic medication were screened for MetS in accordance with 





Table 8 summarizes identified comparative European studies investigating the uptake of 
screening/monitoring of cardiovascular risk factors in primary care settings among those with 
and without SMI. The majority of these studies are from the UK [266-271], and many of them 
investigated quality of care among patients with SMI and acknowledged somatic disease, 
particularly diabetes [266, 270, 272, 273]. Most studies reported similar or higher uptake of 
screening/monitoring of cardiovascular risk factors in patients with SMI, compared to 
controls. Among these studies is a Norwegian one reporting higher levels of diagnostic 
testing/monitoring of diabetes and CVD in younger persons with SCZ and acknowledged 
diabetes or CVD, compared to diabetes only or CVD only [272]. Similar findings are reported 
also from other countries [266, 271, 273]. While few studies found differences in diabetes 
care, several indicate challenges with regard to cholesterol measurements [267-269] and 




Table 8 - Summary of results in studies investigating uptake of screening/monitoring of cardiovascular risk factors 



















Gen pop +/- 
SCZ 
195 18+ Patients with SCZ were half as likely as asthma controls to 
have blood pressure and cholesterol levels recorded, and 
also less likely than general population controls to have 










1,043 17+ The presence of SMI did not reduce the quality of 
diabetes care received , and patients with SMI were more 







SCZ/BD + IHD 
 
701 25+ The majority of CVD care indicators were achieved equally 
for patients with and without SMI, but identification and 
treatment of raised cholesterol was suboptimal among 







SMI 18,696 18+ Prior to 2004, all people with SMI were significantly less 
likely to receive measurements of blood pressure, 
glucose, cholesterol and body mass index. By 2007 people 
with SMI under 60 were equally likely receive BMI and 
cholesterol measurements, while people with SMI aged 








386 NA Twenty-one % of patients with SMI received a full CVD 
screen compared with the 96% of those with diabetes. 
Patients with SMI received fewer than two (from four) 
screening interventions and less than one (from three) 





2009 Diabetes +/- 
SCZ 
CVD +/- SCZ 
10,112 25–
60 
Diagnostic tests (e.g. HbA1c, ECG) were equally or more 
frequent used among patients with SCZ and comorbid 










4,056 16+ For most quality indicators, there were no difference 
between patients with and without SMI. Among patients 
with hypertension, SMI status was associated with greater 
recording of BMI and HbA1c. Patients with SMI with CHD 
were less likely to have a BP record, whereas those with 










1,321 NA There is no evidence that type2 diabetes patients with 
SCZ have worse diabetes control than those without SCZ 




2016 CVD +/- SCZ 8,208 40+ Individuals with SCZ were less likely to meet similar 
indexes of care as their counterparts regarding 









19,258 40+ Persons with SCZ had slightly lower measures of 
cholesterol and stress tests, whereas persons with BD had 
similar or higher health care use compared to controls. No 
disparities were noted in the health services provided to 










106 18+ Screening rates for cardiovascular risk factors were similar 
in patients with and without SMI. 
→ 
Abbrevations: BD, bipolar disorder; BMI, Body mass index; CVD, cardiovascular disease; ECG, electrocardiography; IHD, 
ischemic heart disease; NA, not available; SCZ, schizophrenia; SMI, severe mental illness 
→↓↑: Indicates similiar, lower and higher uptake, respectively, of CVD-related procedures among patients with SMI 




Table 9 gives a summary of identified comparative studies investigating uptake of specialized 
cardiovascular examinations in countries with universal health care. We were not able to 
identify many studies on this topic, and the majority of these studies only investigated uptake 
of cardiac catheterizations, including coronary angiography [274, 277-279], or access to 
cardiologists [280, 281]. Both cardiac catheterizations and access to cardiologists were found 
to be reduced in persons with SMI in these studies, compared to controls. A small Danish 
study found increased use of exercise-ECG in patients with SCZ and incident MI [279], 
compared to patients without SCZ. 
 
Table 9 - Summary of results in comparative studies investigating uptake of specialized cardiovascular 




















1,285 15+ Patients with psychosis and comorbid IHD were less likely 












28,755 20+ Individuals with SCZ and established coronary artery 
disease were less likely to have seen a cardiologist (OR 
0.76; 95% CI 0.72-0.80), but more likely to se an internist 











Individuals with SCZ and incident acute MI were less likely 
to see a cardiologist within 30 days of discharge (OR 0.53, 










834 18+ Patients with SCZ and acute MI had 62-67% lower odds, 
and patients with BD and acute MI 59-64% lower odds, of 
receiving cardiac catheterizations, compared to patients 
without SCZ or BD.  
↓ 
Gal [274] 2016, 
Israel 
SCZ versus matched 
controls 
 
40+ Service users with SCZ had lower rates of cardiac 











47 NA Patients with SCZ and incident MI received lower levels of 
coronary angiography than controls (91.1% among SCZ 
individuals and 97.9% among controls), but this difference 
was statistically insignificant. Individuals with SCZ 
received higher levels of exercise-ECG (8.9% among SCZ 
and 1.1% among controls, p: 0.04). 
→↑ 
Abbrevations: BD, bipolar disorder; BMI, Body mass index; CVD, cardiovascular disease; IHD, ischemic heart disease; MI, 
myocardial infarction; NA, not available; SCZ, schizophrenia; SMI, severe mental illness 






1.5.4.2 Uptake of cardiovascular treatment in individuals with SMI 
Meta-analyses have reported lower levels of cardiovascular prescriptions in persons with SMI 
[250]. A large Danish cohort study also found lower prescription of cardioprotective 
medications among individuals with SCZ than in the general population, particularly lipid 
lowering and antihypertensive medication [257]. A recent Danish study found lower 
prescribing of cardioprotective medications following MI among patients with SCZ, 
contributing to higher post-MI mortality among those with SCZ [259]. A recent UK study, 
however, found higher rates of statin prescriptions to younger individuals with SMI, but lower 
rates of statin initiation for older individuals with SCZ, both relative to individuals without 
SMI [282]. 
Many previous studies have focused on uptake of invasive treatment after incident MI among 
patients with SMI, and meta-analyses, mainly based on studies from the US, have reported 
lower likelihood of invasive coronary treatment such as PCI and CABG among patients with 
SMI compared to patients without SMI [249]. Lower receipt of invasive treatment of CVD 
have also been reported in comparative studies from countries with universal health care. A 
summary of identified studies on this topic is shown in Table 10. All of the identified studies 
investigated uptake of revascularizations in patients with IHD and comorbid SMI. Most [11, 
274, 278, 280, 281, 283], but not all [279, 284], reported lower uptake of revascularization in 
those with SCZ, compared to those without SCZ. Patients with BD were found to have similar 
[11, 284] or lower [278] uptake of revascularizations, and patients with mood disorder higher, 
similar or lower uptake depending on age, with decreasing likelihood with increasing age 
[283].  
Invasive cardiovascular treatment other than revascularization among those with SMI seems 
to be little studied. Studies from Canada [277], the US [285] and Israel [274] have, however, 
reported that ischemic stroke patients with comorbid psychiatric disease had lower likelihood 
of intravenous thrombolysis [285] and cerebrovascular arteriography [277], but similar 
likelihood of carotid endarterectomy [277]. Lower likelihood of pacemaker implantation in 






Table 10 - Summary of results in studies investigating uptake of invasive treatment for CVD in comparative 




















1,285 15+ Patients with psychosis and comorbid IHD were less likely 
to receive revascularization. Patients with psychosis and 
comorbid stroke were less likely to receive 
cerebrovascular arteriography, but were equally likely to 









4,997 15+ The fraction undergoing invasive procedures within 5 
years was reduced among patients with SMI and incident 
IHD as compared with the non-psychiatric general 










1,854 15+ The entire period saw a lower hospitalization rate and 
fewer invasive cardiac procedures (i.e. CABG and PTCA) 















40+ Patients with SCZ had lower likelihood of receiving 
revascularizations in all age groups. Persons with mood 
disorders aged 40-59 years had increased likelihood of 
receiving revascularizations, while persons with mood 












Individuals with SCZ and incident acute MI were less likely 









28,755 20+ Individuals with SCZ and coronary artery disease were less 










834 18+ Patients with SCZ and BD were half as likely to receive 










983 15+ The use of different acute treatment modalities for 
STEMI/LBBB was similar for patients with and without SMI 










2,277 40+ Lower rates of CABG and pacemaker implantation were 
recorded among service users with SCZ compared with 











47 NA Patients with and without SCZ received similar levels of 
PCI (83% of SCZ patients, compared to 76% of controls) 
and CABG (2.4% of SCZ individuals, compared to 8.8% of 
controls). 
→ 
Abbrevations: BD, bipolar disorder; CABG, coronary artery bypass graft; IHD, ischemic heart disease; MI, myocardial 
infarction; NA, not available; PCI, percutaneous coronary intervention; SCZ, schizophrenia; SMI, severe mental illness 
→↓↑: Indicates similiar, lower and higher uptake, respectively, of invasive cardiovascular treatment among patients with 






1.6 Gaps in the current knowledge base 
Relatively few studies have investigated mortality in individuals with SMI and comorbid 
SUD (cf. section 1.4.3, age 30), despite the high comorbidity between SMI and SUD. The 
identified studies also show contradictory findings. Studies assessing the impact of comorbid 
SUD in individuals with SCZ or SMI have found both increased [12, 130, 220-226] and 
decreased [219] all-cause mortality, similar [130] and increased [227, 287] suicide mortality, 
and increased [226] and similar [151, 254] cardiovascular mortality compared to SCZ 
individuals without SUD. Studies of SUD individuals report both higher [229, 231], similar 
[141, 216, 228, 231, 288, 289], and lower [217] mortality in individuals also diagnosed with a 
psychotic disorder, compared to individuals with SUD-only, depending on type of SUD and 
gender [231]. Of the identified studies on this topic, only four studies [130, 220, 221, 223] 
had mortality in the dually diagnosed as the main topic, while other studies examined the 
topic in secondary or subgroup analyses. Only a few studies with complete national coverage 
have investigated all-cause [151, 222, 223, 226, 231], cause-specific [222, 226] or sex-
specific [222] mortality in patients with SCZ and/or SUD. Neither of these reported results for 
different age groups. 
There is also a scarcity of comparative studies investigating undiagnosed CVD in persons 
with and without SMI, particularly in older persons and those in a severe phase of CVD (i.e. 
close to cardiovascular death), cf. section 1.5 (page 32). Two previous nationwide studies 
have reported on the proportion of unrecognized CVD among people with SMI who died of 
CVD, but only in unadjusted sub-analyses [151, 152]. Previous studies [151, 152, 246] on this 
topic did not differentiate between sexes, although sex is associated with severity of both SMI 
[50, 290, 291], CVD [292] and health care utilization [293, 294]. As premature death from 
CVD mainly is due to modifiable causes, premature cardiovascular deaths in individuals with 
SMI may be prevented if CVDs are timely identified and treated. It is thus important to 
investigate to what extent individuals with SMI are in contact with and treated in primary or 
specialized somatic health care prior to cardiovascular death. 
 
In line with this, a recent meta-analysis noted that it is unclear at what stage along the clinical 
pathway persons with SMI lose access to CVD prevention and care [295]. Previous studies on 
uptake of prevention and treatment of CVD have mainly been conducted in the UK or the 




hamper the generalizability of findings to other settings. With the exception of post-MI 
treatment, there is also a scarcity of studies on uptake of specialized examinations and 
treatment for CVD among persons with SMI (see section 1.5.4, page 35). While many 
previous studies have focused on prevention and treatment of CVD in relatively young 
persons with SMI, likely to be in an early and probably less severe phase of CVD [268, 270, 
272, 296], less is known about whether the lower uptake of CVD-related diagnostic tests and 
cardiovascular treatment persists in the more severe phase of CVD, i.e. in the period prior to 
cardiovascular death. As far as we know, no previous studies on this topic have investigated 
uptake of diagnostic tests and invasive treatment of CVD for individuals with SCS or BD 
across health care sectors. Studies that can help answer the question of where along the 






1.7 Aims of the thesis 
The overall aim of this thesis was to investigate mortality among patients with SCZ and/or 
SUD in nationwide Norwegian data, and to explore the impact of SMI on detection and 
treatment of CVD. The specific aims of the thesis were:  
1. To investigate SMRs for all-cause mortality in patients with SCZ, SCZ-only, SUD-
only and comorbid SCZ and SUD, diagnosed in Norwegian psychiatric or somatic 
specialist health care (paper I) 
2. To describe how much of the excess mortality that could be attributed to a concurrent 
diagnosis of SCZ and SUD (paper I) 
3. To investigate age-, sex-, and cause-specific SMRs in patients with SCZ-only, SUD-
only or SCZ+SUD (paper I) 
4. To examine if individuals with and without SCZ or BD had equal likelihood of not 
being diagnosed with CVD prior to cardiovascular death, compared to those without 
SCZ or BD who died from CVD (paper II) 
5. To describe characteristics of individuals with SCZ or BD undiagnosed with CVD 
prior to CVD death (paper II) 
6. To examine whether SCZ and BD were associated with lower prevalence of diagnostic 
testing and invasive treatment of CVD prior to cardiovascular death, compared to 
patients without SCZ or BD who died from CVD (paper III) 
7. To investigate in which setting (i.e. primary or specialist health care) any disparities in 





2 Materials and methods 
2.1 Data sources  
We utilized national diagnostic data and information on health care utilization from the 
Norwegian Patient Registry (NPR) [297] and the Norwegian Directorate of Health’s system 
for control and payment of health reimbursements in primary care (the KUHR database) 
[298], and mortality data from the Norwegian Cause of Death Registry (CDR) [299]. 
Accurate linkage across data sources was obtained using the unique and encrypted 11-digit 
personal ID number included in all registries. 
Annual number of deaths in gender-stratified five-year age groups for the Norwegian 
population were obtained from the Norwegian Institute of Public Health [300], and annual 
population figures in the age groups 20-79 in the years 2009-2015 were obtained from 
Statistics Norway [301].  
2.1.1 The Norwegian Patient Registry 
The NPR is a national administrative register covering all specialized health care in Norway, 
with person-identifiable data since April 2007. The registry contains all contacts in 
government-owned hospitals and outpatient clinics, as well as private hospitals and health 
clinics with governmental reimbursement. The coverage in the NPR is almost complete for 
the years 2008-2016, with the exception that about 15% of contacts with private somatic 
health clinics with governmental imbursement are missing in the period, mainly due to 
technical problems with reporting [302, 303], and that data for SUD treatment institutions is 
missing for 2008 (included in the NPR from 2009).  
Diagnostic codes in the NPR are recorded according to ICD-10, with up to 20 codes per 
episode. Medical, surgical and radiological procedure codes are recorded according to The 
Norwegian Classification of Medical Procedures (NCMP), the NOMESKO Classification of 
Surgical Procedures (NCSP), and the Norwegian Classification of Radiological Procedures 
(NCRP), respectively, all allowing up to 20 procedures per episode. Radiological procedure 
codes are available only from 2016. Outpatient fees are recorded according to national tariff 





2.1.2 The KUHR database 
The KUHR database, person-identifiable from 2006, is a national administrative register 
containing claims data for primary care providers and private specialists with public funding, 
as well as laboratory claims for both primary and specialized health care. As these health care 
services are funded mainly on a fee-for-service basis, the completeness of reported episodes 
in the KUHR database is considered to be almost 100%. The data quality, including 
registration of the national identity number, is assumed to have improved after the 
introduction of electronic registration of deductibles in 2009. 
In the present thesis, we had access to data on procedures provided by GPs and private 
specialists, and laboratory tests performed in primary and specialized health care. Diagnostic 
codes for GP contacts follow the ICPC-2, while diagnostic codes for private specialists with 
governmental reimbursement, and laboratory claims from specialized heath care, follow the 
ICD-10. At least one diagnosis per patient contact must be recorded to receive refunding. 
2.1.3 The Cause of Death Registry 
The CDR contains information regarding underlying, contributing and immediate cause of 
death since 1951, and also patient demographics and information on circumstances 
surrounding the death. All deceased residents are included, irrespective of whether they died 
in Norway or abroad, and since 2012 also non-residents (tourists, workers, migrants etc.) who 
died in Norway have been included [304].  
The basis of cause of death statistics is the mandatory medical death certificate issued by the 
physician who certified the death. Immediate, underlying and contributing causes of death are 
stated in a standardized certificate, using medical terminology and common language. The 
key concept is the underlying cause of death, defined as the disease or injury that started the 
series of morbid conditions that led to death, or the external circumstances (e.g. accidents, 
violence) that caused death. The term “contributing cause of death” refers to other significant 
conditions contributing to the death, but not related to the disease or condition causing it. 
In some cases (currently 2%) [304], the CDR may request supplementary information from 
doctors, hospitals or other institutions (such as nursing homes). In addition, the CDR receives 
diagnostic information from the Cancer Registry (cancer deaths) and the Medical Birth 




notifications of autopsy findings conducted in departments of pathology or at the Forensic 
Institute. During the period 2008-2013, the proportion of autopsies in Norway remained 
stable at 7.5%, equally distributed between medical and forensic autopsies [305]. In 
approximately half of all cases, the underlying cause of death is determined using the 
Automated Classification of Medical Entities (ACME) software (since 2005) or the IRIS 
software (since 2011) [304, 306], which processes data according to the rules of the ICD-10. 
Underlying cause of death in the remaining cases are set by professional coders in the CDR 
(supervised by medical doctors) based on the death certificate and any supplementary 
information. The CDR is linked to the Norwegian Population Register to capture deaths that 
are only registered in the latter registry. 
In Norway the coverage and completeness in the CDR is high (98%), with missing death 
certificates mainly for residents who died abroad [304]. In the most recent quality assessment 
of cause of death statistics covering the period 2005-2012, the CDR was ranked in the best 
group, but below the other Nordic countries [307].  
2.2 Study samples 
The papers included in the current thesis utilized two different linked datasets. Dataset 1 
(study I) included all episodes in all in- and outpatient settings within Norwegian specialized 
health care for all residents in Norway with a registered diagnosis of SCZ or SUD (see 
definitions on page 50). In studies II and III, we utilized another dataset that included all 
episodes for all patients who had a CVD diagnosis recorded on the death certificate. Figure 1 
and Figure 2 give an overview of data sources, selection criteria, included variables and 
























Figure 1 - Data sources, number of participants and variables in dataset 1 
Source: NPR 
Selection criteria: 
 ICD-10 codes F10-F39, F60 or somatic diagnosis 
indicating SUD 
 Age 20-79 years 
 Period 2009-2015 
 Any treatment site (mental, somatic, SUD treatment 
facility, private specialists with governmental 
reimbursement) 
 
Source: The Norwegian Population Registry 
Variables: 
 Birth year 
 Sex 
 Emigration date(s) 
 Date of death 
 
 




 Encrypted patient ID 
 Sex  
 Month and year of birth  
 County of residence  
 Encrypted provider ID  
 Health care provider type (hospital or private specialist)  
 Health care sector  
 Admission and discharge dates 
 Admission emergency type 
 Contact type (inpatient, day patient or outpatient) 
 Type of outpatient contact (direct or indirect contacts)  
 Diagnostic codes 
 Medical procedure codes 
 Surgical procedure codes 
 Radiological procedure codes  




 Underlying cause of death 
 Contributing causes of death 
 Immediate cause of death 
 Date of death 
Excluding patients with: 
 Invalid ID number (n = 6,178) 
 Diagnosis of intellectual disability 
(n = 1,632) 
 Inconsistent data regarding age, 
gender or emigration date  
(n = 666)  
Study sample paper I: N=125,744 
 
Dataset 1:  
N=134,198 
 

























 CVD as underlying, contributing or immediate cause 
of death 
 Year of death 2011-2016 
 Age 18 and above 
 Valid ID 
Extended dataset 2: N = 119,138 
 
Variables: 
 Encrypted patient ID 
 Underlying cause of death 
 Contributing causes of death 
 Immediate cause of death  
 Year of birth 
 Date of death 
 Place of death 
 Status in the Norwegian Population registry (not 
registered, emigrated, dead) 
Source: NPR 
Variables: see Fig 1 
Source: KUHR 
Variables: 
 Encrypted patient ID 
 Patient age  
 Patient sex 
 Encrypted provider ID  
 Date and time of contact 
 Fees according to type of 
contact  
 Fees for diagnostic procedures 
 Fees for laboratory tests  
Dataset 2: N=72,583 
Selection criteria: CVD as underlying cause of death  
Variables: 
 Encrypted patient ID 
 Underlying cause of death 
 Year of birth 
 Date of death 
 Place of death 
 Status in the Norwegian Population registry 
Excluding individuals without 
permanent residency in Norway and 
individuals who died abroad (n = 132) 
 
Study sample paper II: N=72,451 
Excluding individuals without health 
care contacts in the study period  
(n = 66) 
 





2.3 Study design 
Classifications of epidemiological studies usually distinguish between designs according to 
the directionality or timing of data collection (i.e. prospective, retrospective or cross-sectional 
studies), and according to whether the study involve sampling on an outcome (case-control 
study). These classification schemes are less relevant in studies utilizing linked and complete 
secondary population-wide data, as in our case. Pearce et al [308] proposed an alternative 
classification for epidemiologic studies with dichotomous outcomes, using two criteria; (i) the 
type of outcome measure under study (incidence or prevalence), and (ii) whether there is 
sampling on the basis of the outcome. According to this classification scheme, there are only 
four basic study designs when the outcome is binary, namely incidence studies, incidence 
case-control studies, prevalence studies and prevalence case-control studies [308]. Adopting 
this terminology, the design in study I can be described as an incidence study, and the designs 
in paper II and III as prevalence studies.  
Alternatively, in the more conventional terminology, the study design in paper I could be 
described as a population-based open historical cohort study (prospective design). A cohort is 
here defined as any designated group of persons who are followed or traced over a period of 
time. The study designs in and in paper II and III could, in the conventional terminology, be 
described as national cross-sectional studies.  
The design in paper II and III, a follow-back of deceased persons, is not a classic 
epidemiological design. When we chose to do this, it was because it identifies people who all 
had CVD with approximately the same severity (since they died of it), allowing comparison 
of groups with CVD with and without SMI. It also enabled us to identify people with CVD 
who did not use health care services before death, which increased the generalizability. 
An overview of included patient groups, methods applied, covariates and outcome measures 




Table 11 - Overview of patient groups, methods, covariates and outcome measures in paper I-III 
 Patient groups Methods Covariates  
(main model) 
Outcome measure 










Paper II SCZ 
BD 
No SMI 




Odds Ratio (OR) 




Poisson regression with 







2.4 Definitions of diagnostic groups 
In paper I, patients were included in the SCZ group if a SCZ-spectrum diagnosis (F20-F29) 
was recorded in the NPR during 2009-2015. The SUD group included patients with a 
diagnosis of mental and behavioral disorders due to use of psychoactive substances (F10-F19, 
excluding tobacco (F17)), and patients with at least one somatic diagnosis strongly indicating 
substance abuse (ICD-10 codes E24.4, E52, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K86.0, 
O35.4, O35.5, Z50.2, Z50.3, Z71.4, Z71.5, Z72.1 and Z72.2). Patients identified by somatic 
diagnoses only constituted 4.1% of the SUD group. A total of 275 patients treated in 
substance use treatment facilities, with a diagnosis of SCZ, but no registered diagnosis of 
SUD (excluding pathological gambling (ICD-10 code F63.0)), were included in the 
SCZ+SUD group. In subgroup analyses, we differentiated between patients with a non-
alcohol SUD (F11-F16, F18-F19, Z50.3, Z71.5 and Z72.2), and patients with alcohol use 
disorder only. Hard drug use disorder was deemed present if the patient was diagnosed with 
disorders due to use of opioids (F11), cocaine (F14), other stimulants (mostly amphetamines, 
F15), hallucinogens (F16), and multiple drug use and use of other psychoactive substances 
(F19). Volatile solvents (F18) were also included in the latter definition, although not strictly 
qualified for the term "hard drug use disorder”.  
In paper II and III, deceased individuals aged 18 years or older were included if a diagnosis of 
CVD (ICD-10 codes I00-I82) was recorded as underlying cause of death in the death 




code F20 or ICPC-2 code P72) or BD (ICD-10 codes F30-F31 or ICPC-2 code P73) was 
recorded in the NPR or the KUHR database during the years 2008-2016, or in the death 
certificate. Individuals diagnosed with both SCZ and BD (N=97) were included in the SCZ 
group only. In paper II and III, a diagnosis of CVD (recorded before death) was considered 
present if ICD-10-codes I00-I82 or G45, or corresponding ICPC-2 diagnoses (codes K70-
K71, K74-K80, K82-K84, K86-K87 and K89-K94) were recorded in the NPR or the KUHR 
database in the period from inclusion (January 1, 2008) and up to one month prior to death. In 
paper II, diagnoses of CVD recorded only within the last month prior to death were not 
counted to avoid including CVDs secondary to other fatal diseases.  
2.5 Outcome measures 
All-cause and cause-specific mortality, which was the outcome measure in study I, is 
commonly used as a quality indicator at the population level [309], and as a mean to identify 
treatment deficiencies and disadvantaged population subgroups. Due to this, and its 
indisputable character, mortality has been termed “the gold standard of clinical outcome” 
[310]. 
In paper II and III we used process measures (see section 1.5.2, page 33) as study endpoints 
(i.e. receipt of diagnosis or certain health care services). These measures make it possible to 
identify deficiencies in relation to best practice, and are as such valuable from an equity and 
policy perspective in aiding decisions how to target and improve services.  
2.6 Statistical methods  
Statistical methods are broadly of two types: Stratification and regression techniques. We 
used a stratification method in paper I (SMR), and regression methods in paper II and III 
(logistic regression, log-binomial regression and Poisson regression, see descriptions below).  
2.6.1 Standardized Mortality Ratio 
The SMR reflects the relative mortality of the patient group compared to that of the general 
population and is computed as the ratio of the observed to the expected number of deaths. The 
expected number of deaths was calculated as the total number of person-years at risk in each 




groups), sex- and calendar-year specific (2009-2015) death rate in the general population. A 
SMR of one indicates that the study population had the same mortality as the reference 
population, while a SMR greater than one indicate increased mortality in the study 
population. Age was defined as attained age at the end of each calendar year, as we did not 
have access to exact birth dates. Person-years at risk contributed by persons who moved from 
one age band to the next during follow-up was assigned to the respective sex-, age group- and 
calendar year bands, using the “lexis” method [311]. The number of excess deaths was 
calculated as the difference between observed and expected deaths.  
 
The study cohort in paper I was followed from the admission date of the index episode (their 
first consultation during 2009-2015). Patients already hospitalized before January 1, 2009 
(n=2,633), were followed from this date. To account for diagnostic instability in SCZ patients, 
we defined an extended diagnostic spectrum covering SCZ (F20-F29), affective disorders 
(F30-F39), and personality disorder (F60). If a diagnosis of SCZ was ever recorded, the index 
episode was defined as the first episode with a diagnosis within the extended diagnostic 
spectrum. Follow-up ended on December 31, 2015, on the date of emigration from Norway, 
on December 31 in the year of the 79th birthday, or on the date of death, whichever came first.  
Biased SMRs may be a major problem when the exposure is common, and the general 
population is used as reference [312]. In contrast to SCZ, unnatural deaths in the SUD 
subgroup constitute a large proportion of unnatural deaths in the general population, 
implicating risk of biased SMRs for unnatural causes of death in this subgroup. We 
consequently investigated the impact on SMRs for poisoning, suicide and all-cause mortality 
in patients with SUD (with and without SCZ), using an unexposed comparison group (i.e. no 
recorded SUD in specialized care), rather than the general population, for calculation of the 
expected number of deaths. This unexposed comparison group constituted the Norwegian 
population excluding subjects with recorded SUD in specialized health care and 
corresponding deaths from the relevant age-/gender group in the reference population. The 
mortality rates in this unexposed population was calculated and applied when computing the 
expected number of deaths. 
 
Comparisons of SMRs between different populations are, strictly speaking, invalid unless all 




assumption of proportionality) [313]. The extent of this bias will be small, however, unless 
large departures from multiplicativity is present [314]. A simulation study that investigated 
the impact on SMRs when different age-adjustment standards were used, found that the 
resulting differences were too small to change conclusions [315]. In these simulations, the 
SMRs changed by 6-8% when the age distribution was changed from an extreme, but 
realistic, young distribution to an extreme, but realistic, old age distribution. 
2.6.2 Logistic regression 
Logistic regression is a commonly used, robust and efficient method to study the effect of 
independent variables on a binary outcome. The outcome of the logistic regression is the odds 
ratio (OR). The odds is defined as the probability of an event to the probability of a non-event 
(i.e. logit(p)=log(p/(1-p)), where p is the probability of the outcome)[316]. An OR of one 
means that the odds are the same in the two comparison groups, while an OR greater than one 
indicates that the event is more likely to occur in the first group. A 95% confidence interval 
(CI) is routinely reported with the OR as a measure of precision. 
Logistic regression typically requires a large sample size, and is based on the following 
assumptions: (i) independent observations (i.e. no repeated measurements or matched data), 
(ii) absence of multicollinearity (little or no correlation between independent variables), (iii) 
no extreme values (outliers) in continuous predictors, and (iv) independent variables are 
linearly related to the log odds. Logistic regression does not require normally distributed 
residuals and homoscedasticity (i.e. constant variance), which are key assumptions in linear 
regression and general linear models.  
2.6.3 Log-binomial regression / Poisson regression with robust error 
variance  
In epidemiologic research, the relative risk (RR) is often the parameter of interest. Logistic 
regression, Cox and Poisson regression tend to provide comparable estimates of RR, leading 
to similar conclusions, when the outcome is rare. However, when the outcome is common 
(>10%), the OR substantially overestimates the RR, and also produce overly wide confidence 
intervals [317]. Although the use of OR is correct if interpreted appropriately, the RR 
interpretation often given to the OR is misleading when the outcome is common. Several 




regression with robust error variance [320] in cross-sectional or prospective designs with 
common outcomes, since the outcome measures (i.e. RR in prospective studies and 
prevalence ratios (PR) in cross-sectional data) in these studies are considered more 
interpretable and easier to communicate to non-specialists than the OR. The log-binomial 
regression yields more efficient estimators, while the Poisson model with robust error 
variance is less affected by outliers [323]. The log-binomial model is known to be less stable 
than the logistic model, and sometimes fail to converge [320]. When this is the case, Poisson 
regression with robust error variance may be applied [322]. Like logistic regression, but 
unlike Poisson regression, the log-binomial method always gives estimates of probabilities 
between 0 and 1. 
Based on the arguments above (i.e. misinterpretation of ORs, and overly wide confidence 
intervals in logistic regression when the outcome is common) we used log-binomial 
regression to examine the common outcomes in paper III. For one specific endpoint (i.e. 
presence of diagnostic tests in primary care), the model did not converge, and Poisson 
regression with robust error variance was applied in this particular analysis [317].  
2.7 Statistical modeling 
2.7.1 Covariate selection 
In observational studies, covariate selection (i.e. adjusting for potential confounders and 
avoiding over-adjustment) is a major concern. Confounding is defined as a distortion of the 
estimated effect of an exposure on an outcome due to uncontrolled common causes of both 
the exposure and the outcome [324, 325]. As confounding can both strengthen, attenuate and 
eliminate the actual relationship between the exposure and the outcome, it is essential to 
control for confounding in observational studies. If identified and measured, confounding can 
be controlled for in several ways, by restriction, matching, stratification or multivariate 
adjustment techniques. 
In study I, which applied a stratification method, we only included age, gender and calendar-
year, as there are limitations on covariates due to limitations in available nationwide data. 




In regressions methods, such as those used in paper II and III, confounding has often been 
identified through statistical associations, using stepwise selection methods or the change-in-
estimate criterion. However, many authors have emphasized that confounder identification 
should be grounded on an a priori understanding of the causal relationship between the 
variables under study, and not on statistical associations [314, 325]. Another approach has 
thus been to check whether some necessary criteria for confounding are met, applying a 
somewhat weaker definition of confounding than the definition referred to above. In this 
approach, for a variable to be considered a confounder, the variable must be an independent 
risk factor for the outcome, must be associated (causally or non-causally) with the exposure, 
and must not be on the causal pathway between the exposure and the outcome [326].  
Proponents of the directed acyclic graph (DAG) methodology (also called causal diagrams) 
argue, however, that all these approaches, under certain circumstances may increase 
confounding rather than decrease it, due to omission of important confounders or 
inappropriate adjustment for non-confounders [327, 328]. A DAG is a graphical 
representation of the causal relationships believed to exist between the variables of interest. A 
DAG helps to identify confounders (common causes) which should be adjusted for, and 
colliders (common consequences), which should not be adjusted for. Causal diagrams are also 
a useful way to clarify and communicate qualitative beliefs about the causal assumptions 
underlying the analysis.  
In a DAG, variables are linked by arrows that represent direct causal effects (protective or 
causative) of one variable on another variable. As a cause must precede its effects, the graphs 
are always acyclic. A collider is a variable that is directly affected by at least two other 
variables in the same path (recognized when two or more arrows meet in the same path), 
where the ancestor variables may or may not themselves be correlated. Conditioning on a 
collider introduces bias (opens a “backdoor path” in the DAG terminology). After creating a 
DAG, mathematically proven rules can be applied to help decide which variables must be 
adjusted for in order to remove confounding and collider bias, to the extent that this is 
possible using the available data. Often causal pathways are not fully understood, as in the 
present thesis. In such cases, creating several causal diagrams under differing assumptions 




We selected covariates on the basis of prior research indicating that they were common causes 
of SMI and the different outcomes in paper II and III, with the limitations given by the 
available data. Selection of covariates were supported by the browser-based program 
DAGitty, version 2.3, which provides the minimum required data set to estimate unbiased 
total and direct effects [329].  
Figure 3 and Figure 4 show two examples of DAGs underlying the current thesis. These 
figures show two alternative descriptions of the possible relationship between presence of 
SMI and uptake of CVD-related diagnostic tests prior to cardiovascular death (paper III). 
These DAGs differ in the way SUD, somatic comorbidity, early life stressors and genes are 
considered to act (i.e. as confounders, mediators or unrelated variables). Red nodes indicates 
measured confounders, while blue and grey nodes indicates measured and unmeasured 
variables, respectively. Green lines indicates causal pathways and red lines biased pathways. 
No line indicates independency.  
  
Figure 3 - Directed acyclic graph (paper III) with SUD and somatic comorbidity as mediators 
 
The causal relationships displayed in Figure 3 are based on an assumption that SUD and 




between SMI and uptake of CVD-related diagnostic tests, and also that genes and early life 
stressors are unrelated to the outcome. In this situation, the minimal sufficient adjustment set 
for estimating the total effect of SMI on uptake of CVD-related diagnostic tests is age and 
sex. Estimation of unbiased direct effects under the specified causal relationship in Figure 3 is 
not possible, as it would require measurement of all covariates. 
Figure 4 shows an alternative description of the possible causal relationship in paper III, in 
which SUD [29], somatic comorbidity [69], genes [25, 330] and early life stressors [31, 33, 
34, 69] are considered possible confounders. As we lack data on genes and early life stressors, 
unbiased estimates are impossible in this scenario. 
 
Figure 4 - Directed acyclic graph (paper III) with SUD, genes, early life stressors and somatic comorbidity as 
confounders. 
 
As we did not know which of these models that best describes the true relationship between 
SMI and uptake of CVD-related diagnostic tests, we performed analyses according to both 
DAGs. However, the estimated effects differed little from one another. The same was true for 
models including (i) age and sex, versus (ii) age, sex, SUD and somatic comorbidity in paper 
II (DAGs not shown). In paper II, we selected the main model based on the overall model fit, 




observed and model-predicted values. In paper III, we chose the simplest model (i.e. 
adjustment for age and sex), as the estimates were similar, and the improvement in model fit 
negligible, when SUD and somatic comorbidities were included. 
2.7.2 Analyses of effect modification and analytical strategy 
Effect modification by sex, age and patient group was assessed by including the product of 
two variables in the regression analysis. In paper II, we found interaction between sex and 
diagnostic groups, but no linear interactions between age and diagnostic groups. We thus 
presented sex-stratified analyses in paper II. In paper III, we found no interaction with sex, 
but interaction between age above 90 year and patient group when analyzing uptake of 
specialized diagnostic tests and treatment. Because of the many endpoints presented in paper 
III, we chose not to stratify according to age, but presented results from analysis including all 
age groups. A sensitivity analysis excluding those aged 80 and above, gave unchanged 
conclusions for the main outcomes. 
In paper II, we used a three-stage analytical approach showing (i) sex-specific unadjusted 
proportions and ORs, (ii) sex- and age-adjusted ORs, and (iii) ORs adjusted for sex, age, 
modified mean score on the CCI and SUD. Due to the many endpoint applied in paper III, and 
the negligible impact of also adjusting for SUD and somatic comorbidities, we only presented 
age- and sex-adjusted results in this paper.  
In all three papers, we included extensive sensitivity analyses to strengthen our results and 
conclusions. All descriptive and statistical analyses were performed using SAS statistical 
software, version 9.4 (SAS Institute Inc., Cary, N.C.). 
2.8 Ethics 
All patient data were fully de-identified when we received the data. In Norway, studies with 
de-identified information from medical health registries do not require participant consent. 
Legal basis and exemption from professional secrecy requirements for the use of personal 
health data in research were granted by the regional committee for medical and health 
research ethics (2014/72/REK nord). Based on privacy and confidentiality considerations, we 
abstained from requesting information on possible backward-identifying variables, such as 





3.1 Summary of paper I  
The main aim of study I was to investigate all-cause and cause-specific mortality among 
patients with SCZ and/or SUD in specialized health care in Norway, compared to the general 
population. Besides presenting nationwide estimates of mortality among those with SCZ in 
Norway for the first time since the 1970s, an important motivation was to investigate the 
impact of concurrent SUD among those with SCZ on excess mortality, and vice versa. 
The study included 125,744 individuals aged 20-79 years, of which 12,318 (9.8%) died 
during follow-up. Comparing with the expected number of deaths based on the mortality of 
the general population, we found that patients in specialized health care with SCZ, SCZ-only 
or SUD (with or without SCZ) had a five-, four- and seven-fold increased all-cause mortality, 
respectively. Mortality was elevated for both genders, in all age groups and for all considered 
causes of death, with the highest SMRs observed for poisoning, suicides and respiratory 
diseases. Very high SMRs for poisoning were noted in women with SUD (with or without 
SCZ). The highest SMRs were found in the age group 20-39, mainly due to unnatural causes 
of death. The excess mortality corresponded to more than 10,000 premature deaths during a 
mean follow-up of four years (84% of all deaths in the cohort), implicating that five out of six 
patients with SCZ and/or SUD treated in specialized health care died prematurely. Four out of 
five deaths among those with SCZ-only, and 70% of deaths among those with SUD-only, 
were due to natural causes, mainly cancer and CVD (SCZ) and “other natural deaths”, 
including mental and behavioral disorders (SUD). In patients with both SCZ and SUD, only 
41% of deaths were due to natural causes. Poisoning and suicide were equally common, and 
caused the majority of deaths in males (56%) and nearly half of the deaths in females (46%).  
About 27% of the excess deaths in patients with SCZ could be attributed to SUD (or factors 
associated with SUD), with the strongest effects in men and in the youngest. Presence of SCZ 
in patients with SUD had less effect on hypothetical numbers of death, implicating that the 
main reason for the high SMRs in comorbid patients was the SUD component.  
Deaths due to poisoning and suicide in SUD patients in our sample constituted a large 
proportion of all deaths from these causes in Norway in the years 2009-2015. Using 




the complete population, to calculate expected deaths, resulted in a three-fold increase in 
SMR for poisoning in men and a doubled SMR for poisoning compared to the original model, 
showing that SMRs from unnatural causes may be substantially underestimated when using 
the general population as comparator. 
3.2 Summary of paper II  
CVD is one of the main causes of life years lost among persons with SMI, and 
underdiagnosed CVD may contribute to this. In paper II, we examined if individuals with and 
without SCZ or BD had equal likelihood of not being diagnosed with CVD prior to 
cardiovascular death. A secondary aim was to describe demographic characteristics, 
comorbidity and health care utilization in individuals with SCZ or BD and undiagnosed CVD 
prior to death. 
The study included 72,451 Norwegian citizens aged 18 years or above who died due to CVD 
in the period 2011-2016. Of these, 814 were previously diagnosed with SCZ and 673 with 
BD. The study showed that individuals with SCZ had 66% higher odds (OR 1.66; 95% CI 
1.39-1.98), women with BD 38% higher odds (OR 1.38; 95% CI 1.04-1.82), and men with 
BD the same odds (OR 0.88, 95% CI 0.63-1.24) to not be diagnosed with CVD prior to 
cardiovascular death, compared to individuals without SMI who died from CVD. The higher 
odds of undiagnosed CVD applied to all main causes of cardiovascular death. Women with 
SCZ had particularly high odds of undiagnosed CVD prior to a MI death, whereas the higher 
odds of undiagnosed CVD among women with BD was explained by undetected fatal 
cerebrovascular disease.  
Individuals with SMI who died from undiagnosed CVD died approximately ten years younger 
than individuals with undiagnosed CVD without SMI. Almost all (98%) individuals with SMI 
and undiagnosed CVD had visited primary or specialized somatic health care prior to death, 
compared to 88% among individuals without SMI.  
Compared to individuals with SMI and diagnosed CVD prior to death, individuals with SMI 
and undiagnosed CVD prior to death died younger, more often at home (SCZ only), less often 
in a nursing home, more often at places outside home and health care institutions (BD only), 




care, fewer admissions and outpatient visits in specialized somatic care prior to death, and 
more recorded SUD than individuals with SMI and diagnosed CVD.  
3.3 Summary of paper III  
As a follow-up of the findings in paper II, we investigated in paper III the prevalence of 
diagnostic testing and invasive treatment of CVD prior to cardiovascular death among 
patients with SCZ or BD, compared to patients without SCZ or BD who died from CVD. A 
secondary aim was to investigate in which treatment setting (i.e. primary or specialist health 
care) any disparities in uptake of cardiovascular care did arise. 
The study included 72,385 individuals who died of CVD in the years 2011-2016, who had 
utilized primary or specialized somatic care in the period from January 1, 2008 until death. Of 
those included, 814 were diagnosed with SCZ and 673 with BD. Compared to patients 
without SCZ or BD, patients with SCZ had similar prevalence of CVD-related diagnostic 
tests in primary care, but lower uptake of specialized diagnostic CVD examinations and 
invasive CVD treatment. The lower prevalence of CVD examinations was particularly 
pronounced for lengthy procedures or those that require physical contact with the patient 
(such as 24 hour blood pressure measurement, echocardiograms, coronary angiography and 
ultrasound of peripheral vessels). Patients with BD had similar prevalence of diagnostic CVD 
examinations in primary and specialized somatic care as patients without SMI, but lower 
prevalence of invasive CVD treatment. Among those with diagnosed CVD prior to 
cardiovascular death, prevalence of invasive cardiovascular treatment did not differ between 
those with and without SMI, with the exception of lower prevalence of vascular surgery in 
patients with BD. 
Patients with SMI also had fewer contacts with a recorded CVD diagnosis both in primary 
and specialized somatic care, and a shorter time span from first CVD-diagnosis in the 




4 Discussion of results 
4.1 Main findings 
1. Patients in specialized health care with SCZ, SCZ-only or SUD (with or without SCZ) 
had a five-, four- and seven-fold increased all-cause mortality, respectively, compared 
to the general population (paper I) 
2. Mortality was elevated for both genders, in all age groups and for all considered 
causes of death, with the highest SMRs observed for poisoning, suicides and 
respiratory diseases. Very high SMRs for poisoning were noted in women with SUD 
(paper I) 
3. The majority of deaths among those with SCZ-only or SUD-only were due to natural 
causes, while the majority of deaths among those with a dual diagnosis were due to 
external causes of death, particularly poisoning and suicide (paper I) 
4. The excess mortality corresponded to more than 10,000 premature deaths during a 
mean follow-up of four years (paper I), implying that five out of six patients with SCZ 
or SUD died prematurely (paper I) 
5. Approximately 27% of the excess deaths in patients with SCZ could be attributed to 
SUD (or factors associated with SUD), with the strongest effects in men and in the 
youngest (paper I) 
6. SMRs for poisoning and suicide in patients with SMI were substantially 
underestimated when the general population was used as comparison. This bias was 
particularly severe for patients with SUD (paper I) 
7. Persons with SCZ and women with BD were more likely, and men with BD equally 
likely, not to be diagnosed with CVD prior to cardiovascular death, compared to 
persons without SMI (paper II) 
8. The higher odds of undiagnosed CVD among persons with SCZ applied to all main 
causes of cardiovascular death, and was particularly high for women with SCZ who 
died from MI (paper II) 
9. Almost all (98%) individuals with SMI and undiagnosed CVD had visited primary or 
specialized somatic health care prior to death, compared to 88% among individuals 




10. Compared to individuals with SMI and diagnosed CVD prior to death, individuals 
with SMI and undiagnosed CVD prior to death died younger, more often at home 
(SCZ only), or outside home and health care institutions (BD only), and more often 
from IHD (SCZ only). They also had fewer health care contacts in primary care, fewer 
admissions and outpatient visits in specialized somatic care prior to death, and more 
recorded SUD than individuals with SMI and diagnosed CVD (paper II) 
11. Patients with SCZ had similar prevalence of CVD-related diagnostic tests in primary 
care prior to cardiovascular death, but lower uptake of specialized diagnostic CVD 
examinations and invasive CVD treatment, particularly lengthy procedures or those 
that require physical contact with the patient (paper III) 
12. Patients with BD had similar prevalence of diagnostic CVD examinations in primary 
and specialized somatic care as patients without SMI, but lower prevalence of invasive 
cardiovascular treatment (paper III) 
13. Prevalence of invasive cardiovascular treatment did not differ between those with and 
without SMI among those diagnosed with a relevant CVD diagnosis prior to death 
(paper III) 
14. Patients with SMI had fewer contacts with a recorded CVD diagnosis both in primary 
and specialized somatic care prior to cardiovascular death, and a shorter time span 
from first CVD-diagnosis in the observation period until cardiovascular death (paper 
III). 
4.2 Comparison with other studies  
4.2.1 Mortality among persons with SCZ 
We found SMRs of 5.1 and 4.6 in men and women with SCZ (with and without SUD), which 
were considerably higher than the 2.6-3.1 increased mortality reported in previous meta-
analyses [8, 17, 199]. Our results were also (probably) higher than the 2.3-4.5 and 1.9-4.6 
increased mortality reported in men and women with SCZ in earlier Nordic studies [12, 200, 
201, 204, 208, 331], with the exception of the 6-fold increased mortality reported in Finnish 
women with SCZ [204]. We found higher SMRs than most other Nordic studies, despite 
including prevalent cases and patients treated solely in outpatient settings, which, in isolation, 
would contribute to lower SMRs [332] (see also discussion of selection bias, page 74). 




inclusion of cases identified by secondary diagnosis only, lowered the estimates, as shown in 
the sensitivity analyses. Contrary to this, inclusion of older individuals suffering from somatic 
health problems increased the SMR in patients with SCZ in our study, also shown in the 
sensitivity analysis (see section 5.3.1 for a discussion of this). The relatively short follow-up 
(maximum 7 years), as well as the omission of patients in primary care, may also have led to 
a selection of more severe cases, oversampling patients with many health care episodes and 
patients with increased suicide risk, but this was not specific to our study. Most of the Nordic 
studies we refer to utilized data prior to 2009, which was the start of follow up in paper I (see 
Table 6, page 28). Two recent Danish studies on mortality in individuals with SCZ [195, 
202], including data for the period 1995-2008 [202] and 1995-2014 [195] reported SMRs of 
similar magnitude as we did (i.e. SMR 4.6 in both studies). The most recent study also 
documented increasing SMRs every year the last two decades for both SCZ and BD [195]. 
One likely explanation for the high SMR found in our study is thus a rising mortality gap in 
SCZ patients compared to the general population, as suggested in a previous study from 
Northern Norway [10], studies from Denmark [13], and the meta-analysis by Saha et al [8]. 
Finally, the use of a single year at the start of the study period to calculate mortality rates in 
the general population, as done in some of these studies [1, 200, 201], may have attenuated 
the SMRs in these studies, since it does not take into account increased life expectancy in the 
general population over time. 
For a discussion of cause-, age- and gender-specific mortality among persons with SCZ, see 
paper I.  
4.2.2 Mortality among persons with SCZ and/or SUD 
We found an increased all-cause and suicide mortality, and a similar cardiovascular mortality 
in patients with both SCZ and SUD, in accordance with some previous studies [130, 222-224, 
226, 254, 333], but not in line with a study reporting decreased mortality in persons with co-
occurring psychosis and cannabis use/abuse, compared to psychosis only [219]. We did not 
study mortality from cannabis use disorder separately, due to few deaths and suspicion of 
selective recording of less severe cannabis use disorder in comorbid patients (see section 




Overall, a co-occurring diagnosis of SCZ also conferred increased SMRs in SUD patients. 
However, when stratified according to type of SUD, we found similar SMRs for non-alcohol 
SUD patients with and without SCZ, in accordance with other studies [141, 216, 228, 288], 
and similar SMRs in patients with alcohol use disorder with and without SCZ, in contrast to a 
50-year follow-up study of persons with alcohol use disorder [229]. Differences in length of 
follow-up may be one explanation for the latter finding. Furthermore, when stratified 
according to gender, we found increased SMR in comorbid men, but not in comorbid women, 
in accordance with a study conducted in inpatients [231]. Thus, in our study, the increased 
SMRs in comorbid patients, both genders combined, was explained by the high proportion of 
young comorbid men with a non-alcohol SUD. The eight-to-nine-fold increased SMR in 
patients with non-alcohol SUD with and without SCZ, is similar to [334] or higher than [216, 
224] that reported elsewhere. Norway has one of the highest rates of injecting drug users 
among hard drug users [335], which may have contributed to this finding.  
We found very high SMRs for poisoning and suicide in women with SUD, which confirms 
earlier findings [15, 336], and high SMRs for respiratory diseases, probably associated with 
increased smoking prevalence in individuals with SMI [337]. The increased mortality due to 
suicide in patients with SCZ was more pronounced than reported in a systematic review [8], 
but of similar magnitude as reported in a sample with comparable age span [227].  
4.2.3 Undiagnosed CVD in persons with SMI 
The 66% higher prevalence of undiagnosed CVD prior to cardiovascular death in individuals 
with SCZ found in our study is in accordance with, but somewhat higher than, the findings in 
a parallel Danish study, where individuals with SCZ had 45% reduced odds of having been 
diagnosed with CVD at least one month prior to cardiovascular death, compared to controls 
[245]. It is also in accordance with the study by Crump et al reporting a higher proportion 
undiagnosed IHD up to one month prior to an IHD death in individuals with SCZ, compared 
to individuals without SCZ [151]. Our findings also resemble a study reporting doubled risk 
of unforeseen death in individuals with SCZ, with CVD being the most common cause [246], 
and studies reporting a decreased likelihood in individuals with SCZ of being diagnosed with 
somatic illness in the early courses of diseases [177, 253]. Our study extends these earlier 
findings by documenting that the lower odds of diagnosed CVD prior to death in individuals 




diagnosed CVD prior to death in individuals with SCZ applies to all main causes of 
cardiovascular death, with particular high odds of unrecognized CVD prior to death from MI 
in women with SCZ. Our finding of similar odds of undiagnosed CVD prior to an IHD death 
in individuals with BD is also in accordance with earlier findings [152], but the increased 
odds of undiagnosed CVD prior to a cerebrovascular death in women with BD is a novel 
finding. Earlier studies have found an increased incidence of vascular disease in women with 
BD, but not in men with BD [338, 339]. An increased risk of adverse illness course in women 
with BD has been reported [290], and may also contribute to this finding.  
4.2.4 Uptake of CVD-related diagnostic tests and invasive cardiovascular 
treatment  
We are not aware of other studies examining uptake of CVD-related diagnostic tests in a 
sample of deceased patients with and without SMI, still, our findings show similarities with 
other studies with adjacent topics. We found lower (SCZ) or similar (BD) prevalence of 24 
hour blood pressure measurement in primary care and similar (SCZ) or higher (BD) 
prevalence of diabetes testing in primary care, compared to patients without SMI. A recent 
study from Denmark [340] comparing quality of diabetes care in diabetes patients with and 
without SCZ found lower rates of blood pressure measurements, but similar rates of HbA1c 
measurements, in individuals with SCZ, in line with our findings. A study from the UK 
examining screening for cardio-metabolic risk factors in individuals with SMI found lower 
rates of blood pressure measurements, but also lower rates of HbA1c measurement in 
individuals with SMI, compared to diabetes controls [341]. A Canadian study of preventive 
CVD care in an interprofessional primary care practice with mandate to care for persons with 
barriers to health care, however, reported similar levels of blood pressure measurement and 
higher levels of diabetes screening in patients with SMI, compared to age- and sex-matched 
controls [276], indicating that tailor-made treatment for this group may improve uptake. We 
are not aware of studies comparing receipt of ECG in primary care in patients with or without 
SMI, but previous studies have documented suboptimal cardiac function monitoring (such as 
ECG) in SMI patients [342-347]. Our finding of lower levels of CVD-related health care use 
in patients with SMI is in accordance with other studies investigating both primary and 
specialized somatic care [348], and studies reporting reduced likelihood of seeing a specialist 





We found a decreased prevalence of coronary angiography prior to cardiovascular death in 
patients with SCZ and BD, compared to patients without SMI, in accordance with earlier 
studies in patients with SCZ [249, 278, 349], BD [278], or mental illness in general [249, 350-
353], particularly in older age groups [349, 350]. Our findings are also compatible with a 
study reporting lower likelihood of preventive interventions during somatic hospitalization 
among patients with SMI [354]. Little is known about receipt of echocardiography and 
ultrasound of peripheral vessels in patients with and without SMI, but patients with mental 
illness have been reported to have lower likelihood of left ventricular ejection fraction 
assessment, in which echocardiography is a common examination method [355].  
 
We found lower prevalence of invasive cardiovascular procedures in patients with SMI, in 
accordance with previous studies of receipt of cardiovascular surgery in patients with and 
without SMI [274, 356]. We found lower prevalence of revascularization in patients with SCZ 
who died from CVD, but similar uptake of revascularization in patients with and without SMI 
who were diagnosed with IHD prior to death. The latter finding is in contrast to earlier 
findings in various populations [249, 280, 281, 283, 286, 357], but consistent with a recent 
Danish study showing no difference in post-MI treatment in patients with and without SCZ 
who had undergone coronary angiography, and studies showing similar likelihood of 
revascularization in patients with IHD and BD [357] or mood disorders [283]. The finding of 
similar prevalence of revascularization in those diagnosed with IHD is also compatible with a 
study in the general Norwegian population demonstrating that lower revascularization rates 
among patients with low education were explained by differences in receipt of coronary 
angiography [358].  
 
With the exception of revascularization, receipt of invasive cardiovascular treatment in 
persons with SMI appears to be little described in the literature [359]. However, an Israeli 
study found a 50% reduced likelihood of cardiac pacemaker implantation in patients with 
SCZ [274] and a US study a reduced likelihood of receiving major surgery, including vascular 
surgery, among persons with SMI, particularly in those with SCZ [356]. These findings are in 




4.2.5 Why are persons with severe mental illness dying so young? 
Persons with SMI are at very high risk of death from external causes of death, such as 
suicides, poisoning and victimization [142, 143]. Still, natural causes account for most life 
years lost among those with SMI [4]. Persons with SMI thus mainly die of the same causes as 
others, particularly from CVD and cancer, but die younger. Such deaths may be prevented or 
postponed if identified and managed. A UK cohort study of inpatient with SCZ or BD, found 
that potentially avoidable deaths comprised 60% of all deaths in the cohort. Bringing 
mortality from avoidable causes and suicide down to general population levels would reduce 
excess mortality in persons with SMI by about 50%, but would not eliminate it [360]. 
The excess mortality in people with SMI is most likely a result of a complex interaction 
between a wide range of factors, both on the individual, health system and social level [361], 
as emphasized in the WHO's multilevel model (Table 1, page 11). Hypertension, smoking, 
raised glucose, lack of physical activity, obesity and raised cholesterol are ranked as the main 
global mortality risk factors for premature mortality, all of which are significantly increased 
in people with SMI [120, 164, 362-364], with the exception of raised hypertension in SCZ 
(see section 1.3.2). The relative contribution of the different risk factors are not well known, 
but lifestyle factors such as smoking [254, 365-368], SUD [225] and physical inactivity [254, 
368] are probably among the most important predictors of early mortality in the SMI 
population.  
Active psychosis [366], and severe cognitively impairment [369] have also been identified as 
predictors of premature mortality. Cognitive impairment, lower health literacy, impaired self-
care capacity, negative symptoms, self-stigma, depression and suspiciousness may impact the 
ability to recognize [370] and communicate somatic symptoms, and to seek timely somatic 
care [348, 371]. Psychiatric symptoms and adverse consequences related to SMI may also 
affect the ability to keep appointments, adhere to treatment plans [372], and make lifestyle 
changes [373].  
Excess mortality may also be related to adverse effects of antipsychotic medication [176]. 
Antipsychotics are associated with increased risk of weight gain, glucose intolerance, 
dyslipidemia [170], increasing the risk of type II diabetes [374], which may occur shortly 
after first-time exposure to antipsychotic medication [175]. Users of antipsychotic medication 




myocarditis and cardiomyopathy [375, 376], possibly leading to sudden cardiac death [377-
379]. On the other side, antipsychotic has been associated with reduced risk of all-cause 
mortality [380, 381], implying that the risk of adverse CVD-related effects must thus be 
balanced against the effect of decreased overall mortality.  
 
Lower uptake of potentially effective treatment, and lower quality of care, also contribute to 
excess mortality among those with SMI. A number of studies in a variety of settings have 
documented suboptimal screening/monitoring of CVD risk factors [156, 247, 248, 268], lower 
rates of cardiovascular prescriptions [250, 255-259, 271] and invasive cardiovascular 
treatment [11, 249, 277, 278] among those with SMI. The current literature also confırms 
disparities in cancer screening [382], COPD treatment [383], osteoporosis treatment [384], 
pre-dialysis renal care [385], and end-of-life care [386, 387] among those with SMI. 
Plausible mechanisms at the provider level explaining this disparity include complexity of 
care, time constraints and poor communication with patient or primary care health workers 
[388]. Also, a tendency to focus on mental rather than somatic health, as well as 
misattributing of physical symptoms to mental illness may contribute [388-390]. Discomfort 
with or stigmatizing attitudes towards patients with SMI among health care providers have 
been reported [391, 392], particularly regarding SCZ [393, 394] and those with comorbid 
SUD [395], and may unintendedly influence medical decision-making. In a study of quality of 
somatic treatment among older persons with SCZ, higher adequacy of somatic treatment was 
associated with lower rates of depression, fewer positive symptoms and more negative 
symptoms [396]. In another study of providers’ decision making, a history of SCZ was found 
to negatively affect primary care provider’s expectations of treatment adherence and ability to 
understand educational materials [397]. 
 
Unclear responsibility with regard to physical health examination in patients with SMI [370], 
as well as the separation between primary and secondary health care and between somatic and 
psychiatric health care, probably contribute to underdiagnosis and undertreatment [398]. 
Navigating between psychiatric, primary and specialized somatic health care systems may 
constitute a particular challenge to those with SMI. Both individuals with SMI and mental 




improved prevention and treatment for physical problems among persons with SMI [398, 
399]. 
 
Finally, as emphasized in the comprehensive WHO multilevel model, the social and 
environmental circumstances in which people live their lives are essential to the 
understanding of the excess mortality among persons with SMI. Besides severity of illness, 
the very high risk of unnatural death among those with SMI is probably best understood in 
this context. Poorer socioeconomic conditions [400], unemployment, homelessness and lack 
of social support, which are all more common in those with SMI, contribute to disparities in 
health, including excess mortality [203, 401-404] and call for a wider set of interventions than 
those directed at the individual or health system level alone. 
4.2.6 Mechanisms explaining underdiagnosis of CVD and suboptimal 
cardiovascular health care use in individuals with SMI  
Many of the same mechanisms proposed as explanations for excess mortality, may also 
explain why people with SMI are at increased risk of underdiagnosis and undertreatment of 
CVD. In addition, there are some specific factors related to the association between SMI and 
CVD that need mentioning. 
We found that undiagnosed CVD was more common in the youngest. Individuals with SMI 
are at increased risk of dying at ages when health care providers may not usually suspect 
CVD. Current risk prediction algorithms for CVD have been shown to underestimate the risk 
of CVD in individuals with SCZ, particularly in younger men [405], and may likely lead to 
lower detection rates in individuals with SCZ compared to others. There is also a possibility 
that younger patients are prescribed higher doses of antipsychotic medicine due to more 
severe symptoms at an early stage in the disease course, and hence are at higher risk of 
adverse cardiac effects such as arrhythmias, deviations in blood pressure, heart failure, 
myocarditis, and sudden death [377, 378, 380, 406-408].  
Previous studies have found impaired glucose tolerance and insulin resistance in patients with 
first episode psychosis [409], and a genetic overlap in risk factors for SMI and MetS [330, 
410] and SCZ and CVD [25, 411], suggesting that individuals with SMI are more susceptible 
to CVD. These common risk factors may imply a more malign course of CVD in persons with 




examining post MI-survival, which found unexplained cardiovascular mortality among those 
with SCZ after thorough adjustment for demographic, clinical and behavioral factors [284, 
412], implying that SCZ may be an independent risk factor for CVD mortality. Another study 
reported that CVD in persons with SCZ appeared to be less related to weight, compared to 
controls, where intrinsic metabolic differences associated with SCZ was proposed as one 
possible explanation [413]. Increased pain tolerance [414] and increased risk of silent CVD 
[415] not associated with traditional cardiovascular risk factors [416, 417], have also been 
reported in individuals with SCZ, likely affecting timely health care seeking and diagnosis.  
In spite of younger age, people with SMI have more comorbidities, including higher rates of 
smoking, obesity and SUD [418], higher risk for postoperative complications [419, 420] and 
mortality following cardiac treatment [284]. Disparities in invasive CVD treatment may thus 
reflect clinicians' uncertainty and judgments about treatment risks and compliance with 
postoperative care. Lack of consent, or lack of capacity to give informed consent, may also be 
an issue, as noted in a recent study investigating decisions about cardiac examination and 
treatment, where patients with SCZ tended to be more likely to decline both examination and 





5 Discussion of methods 
Systematic errors (bias), random errors and confounding are threats to the internal validity of 
epidemiological studies. Random error reflects a problem of precision and can be reduced by 
increasing the sample size. Bias reflects flaws in study design, analyses, interpretation or 
dissemination of results, whereas confounding distorts the measurement of effects due to 
extraneous causal factors. Bias and confounding are major limitations in observational 
studies, and are discussed in more detail below.  
5.1 Observational studies: Pros and cons 
The aim of analytical epidemiological studies is to identify and evaluate causes or risk factors 
for diseases or health-related events. There are two main categories of such studies; 
interventional (i.e. randomized controlled study (RCT)) and observational studies, each with 
its own strengths and weaknesses. RCTs ranks highest in the evidence hierarchy due to two 
defining properties: (i) random allocation of the exposure (intervention), which reduces the 
probability of confounding, and (ii) blinding of participants and investigators, which 
minimizes bias caused by the placebo effect. 
Due to strict eligibility criteria, RCTs often have low external validity (generalizability). An 
RCT may also be unethical to conduct (e.g. randomization to a harmful exposures or drugs 
that has known benefits but uncertain side effects). Other weaknesses include inability to 
study rare or long-term outcomes. 
Strengths in the RCT design reflect limitations of observational research, and vice versa, and 
show the complementary roles of the two approaches. Observational studies are by definition 
studies that observe without intervening. Strengths in this approach include less restrictive 
eligibility criteria (reflecting real-world case mix, with higher external validity), longer 
follow-up, lower costs and greater timeliness. Observational studies are thus often used to 
study problems that are not addressable in an RCT, such as effectiveness in real world 
settings, long-term or rare side effects of treatment, or effects of harmful exposures or 
exposure that should not be modified for ethical reasons. The biggest obstacle in observation 
studies is confounding (which can produce unpredictable results), and systematic bias due to 
selection or information bias. However, a well-conducted observation study can provide an 




at the analysis stage. Other weaknesses in observational studies include access only to 
predefined variables, and noise associated with variations/changes in coding practices. 
Despite the limitations of observation studies, many accepted medical causal relationships 
have been documented in such studies (e.g. the relationship between smoking and lung 
cancer). Also, two much cited meta-analyses comparing RCT versus high-quality 
observational cohort studies both reported similar estimates of effect in the two approaches 
[421, 422]. Ioannadis et al [423] found discrepancies in 16% of all studied topics, but only 8% 
of topics covered by prospective studies, while MacLehose et al [424] found small 
discrepancies in high-quality studies, but large discrepancies in low-quality studies, which 
had a tendency to report more extreme effect sizes. A well-known example of departure from 
such findings are studies on the relationship between postmenopausal estrogen and the risk of 
coronary heart disease, in which the RCT found higher, and the observational studies lower, 
risk of heart disease [425]. Hernan et al later showed that the discrepancy could largely be 
explained by differences in the distribution of time since menopause and length of follow-up 
[425]. 
5.2 Strengths 
The major strength of the studies included in this thesis is the use of unselected and complete 
nationwide registry data of recent date, in a setting with free access to health services and no 
bias associated with selective self-reporting. The inclusion of outpatients and patients treated 
solely in somatic hospitals (paper I), as well as the inclusion of patients treated in primary 
care (paper II and III) enabled more generalizable risk estimates than reported in many 
previous studies. The unconventional study design in papers II and III enabled comparisons of 
people with and without SMI with assumed equal need of health care. Adding to the strengths 
is also the exploration of bias incorporated in estimates of SMRs when the exposure is 
common and the general population is used as reference. Furthermore, in all three papers, we 
included extensive sensitivity analyses to strengthen our results and conclusions. 
Finally, the CDR is found to provide high quality data on the underlying cause of death [307], 
and the validity of a SMI diagnosis in hospital case registries is found good compared to 





Bias results from systematic errors in the design or conduct of a study, flaws in the method of 
selecting study participants, flaws in the procedures for gathering relevant exposure or 
outcome information, or in the interpretation, reporting or publication of results. Bias thus 
relates to the process, not the results per se, requiring careful evaluation of design, methods 
and procedures. Bias is broadly of two types, i.e. selection bias and misclassification bias, 
both are discussed more in detail in the following sections.  
5.3.1 Selection bias 
Selection bias is a distortion that results from the procedures used to select individuals into 
the study [316]. Of particular relevance for the studies included in the current thesis is the 
potential biases resulting from inclusion of prevalent cases (also called cross-sectional bias). 
In studies of long-lasting diseases (e.g. SMI or SUD) that include prevalent cases, a late look 
at those affected in young age will miss early fatal cases, but also mild cases and those who 
recovered (left truncation). Incidence-prevalence bias can be avoided by only including 
incident cases, but the relatively short history of the NPR and the KUHR database made this 
impossible. However, in paper I we had an intention of including as many as possible of the 
true SCZ population treated in specialized care in Norway, as well as capturing deaths from 
diseases that occur late in life, such as CVD and cancer. Also, studies of incident exposures 
may implicate right censoring (i.e. the study ends before the event has occurred) and may 
therefore be unable to assess the long-term effects of the exposure [428]. 
We lacked data for primary care in paper I, and thus presumably included only the most 
severely ill. We also included people with a diagnosis of SMI/SUD registered solely in 
somatic care, who were 10-20 years older than their counterparts diagnosed in psychiatric 
settings. Patients with SMI who only utilized specialized somatic care constituted 6%, 22% 
and 1% of patients with SCZ-only, SUD-only and SCZ+SUD, respectively, but 24%, 45% 
and 5% of all deaths in the subgroups. If these somatic diseases were unrelated to the mental 
disorder, we may have introduced bias by enriching the sample with persons at particularly 
high risk of mortality. A sensitivity analysis, excluding patients identified solely in somatic 
care, showed that the SMRs were reduced from 4.5 to 3.8 (-16%) in men with SCZ-only and 




with SUD-only (SMRs decreased from 6.4 to 5.7 (-11%) in men and from 7.4 to 6.3 (-15%) in 
women), while results for the dually diagnosed were less affected.  
On the other hand, excess mortality in patients with SCZ or SUD is known to be highest the 
first years after diagnosis [1, 429, 430]. The older group identified in somatic health care only 
may thus be a group of healthy survivors who coped well with their mental illness, but were 
entering an age where the physical comorbidities associated with SMI had reached a severe 
stage. Whether inclusion of patients with SCZ or SMI treated solely in somatic care should be 
considered a question of external validity or selection bias depends on whether the somatic 
diseases that led to inclusion is related to, or independent of, the mental illness.  
Survivor bias may also be present in the dually diagnosed (paper I), as individuals would have 
to live long enough to get a second diagnosis, and in study II and III, where the participants 
would have to live long enough to develop CVD. 
5.3.2 Misclassification bias 
Misclassification bias (also called information bias) results from a systematic tendency to 
classify an individual, a value or an attribute to an erroneous category [324], leading to 
different accuracy of information between comparison groups [324]. Misclassification that 
depends on the actual values of other variables in the analysis is labeled differential 
misclassification, while misclassification that does not depend on the actual values of other 
variables is labeled non-differential [314]. Differential misclassification introduces bias in an 
unpredictable direction (either overestimation or underestimation). Non-differential 
misclassification gives in most situations results biased towards the null-hypothesis, but can 
sometimes produce bias away from the null if the misclassification depends on the errors in 
classifying other variables, or if the exposure or disease variable has more than two levels 
[314]. Two potential sources of information bias in the current thesis are discussed below, 






5.3.2.1 Medical surveillance bias 
Medical surveillance bias (also called detection bias) refers to the situation where known 
exposure to one factor leads to a closer surveillance of another feature relevant for the study, 
increasing the probability of detection of this other factor. In study I, a known diagnosis of 
SCZ may have led to closer surveillance of SUD due to the known higher risk of comorbidity. 
Less severe SUD, undiagnosed in those without SCZ, may thus have been diagnosed in those 
with SCZ. It may be that the same mechanism also apply to the BD group in paper II and III, 
as higher health care utilization probably leads to more diagnoses. 
In observational studies, the best strategy for avoiding medical surveillance bias is to 
implement systematic, standardized, and periodic data collection procedures for everyone 
regardless of exposure status. This is, however, no option when using real world registry data. 
5.3.2.2 Misclassification of diagnostic groups in administrative data 
5.3.2.2.1 Misclassification of SMI in administrative data 
Norwegian validity studies have found high agreement between clinical diagnoses in the NPR 
and research based diagnosis for SCZ [426, 427], fair agreement for schizoaffective disorder 
[427] and good [427] or moderate agreement for BD [431]. One Norwegian study reported a 
considerable underdiagnosis of BD in administrative data, mainly in currently depressed 
patients [431]. Good validity of SCZ diagnoses [432] and lower validity of schizoaffective 
disorder diagnoses [433] has also been reported in other countries. 
 
SMI diagnoses in the KUHR database has not been validated, but Statistics Norway estimated 
that 0.3% of the ICPC-2 diagnoses in the KUHR database in 2015 were incorrect [434]. Also, 
primary care diagnoses have been found to be valid in GP registries in other countries, 
particularly for chronic diseases [435]. A possible misclassification, however, arise from the 
inclusion of affective disorder in primary care (ICPC-2 code P73) in the BD group. The 
ambiguity in this diagnosis may have led to an inclusion of individuals with severe depression 
but not BD. In order to get a rough estimate of this possible misclassification, we examined 
the concordance in diagnosis among those with a BD diagnosis registered in the primary care 
and a concurrent affective diagnosis registered in specialized health care (paper III). Of these, 
21% had a different affective disorder than BD registered in the specialist health service. We 




non-BD affective disorders recorded in specialized care (results not shown), and also similar 
results when excluding patients with a BD diagnosis from primary care only (paper III). 
 
Diagnostic instability of SMI diagnoses may also be a concern in administrative data. A 
cohort study of patients with first episode psychosis, found that most patients (89%) 
diagnosed with SCZ at baseline maintained the diagnosis after ten years, while 32% of 
patients with first episode psychosis who initially received a non-SCZ diagnosis had a SCZ 
diagnosis by year 10 [436]. The problem of instability of diagnoses, together with the 
relatively short observation periods, may have affected the classification of diagnostic groups 
in the current studies, but probably most in study I, which had a higher proportion of younger 
patients. We tried, however, to minimalize this potential problem by defining start of follow-
up based on a broader set of diagnoses in study I (see page 51). 
5.3.2.2.2 Misclassification of SUD in administrative data 
We found a seven-year prevalence of SUD in schizophrenic patients of 25%, which is equal 
to the prevalence of SUD reported in a recent Norwegian study [165], but considerably lower 
than reported in other studies [115, 437]. SUD diagnoses in the NPR have not been subject to 
formal validity checks, but a Norwegian hospital based validation study found SUD diagnoses 
to be fairly good, although only 31% classified with SUD by expert opinion were identified in 
administrative data [426]. In another Nordic study, SUD was underreporting for nearly 50% 
of individuals with SCZ in the Danish Psychiatric Register [438]. A possible underreporting 
of SUD in specialized care may have led to misclassification bias in study I, possibly 
overestimating SMRs both in patients with SCZ-only and in patients with both SCZ and SUD. 
In the study by Hjorthøj et al, however, identifying patients with SUD from hospital data only 
did not change results appreciably [223].  
Ignoring the temporal relationship between SCZ and SUD (paper I), is another source of 
potential misclassification of patients with SUD. A post hoc analysis revealed, however, that 
a majority of comorbid patients had both diagnosed within a year.  
5.3.2.2.3 Misclassification of CVD in administrative data 
Recent meta-analyses investigating the validity of CVD diagnoses in administrative data, 
found valid diagnostic codes for MI and acute stroke [439, 440]. Heart failure diagnoses 




cases were not captured [441]. Previous Norwegian studies also found valid information 
regarding stroke [442] and intracranial hemorrhage [443] in the NPR. The validity of 
cardiovascular diagnoses in general [444, 445], atrial fibrillation and atrial flutter [446], 
intracerebral hemorrhage [447] have been found to be high in other Nordic registries, while 
the validity of heart failure [448] and peripheral arterial disease diagnoses has been 
questioned [449].  
The validity of cardiovascular diagnoses in the KUHR database is unknown. Although it is 
possible to enter at least three diagnoses per GP contact, 85% of these encounters had only 
one recorded diagnosis. In paper II, there is a possibility that only the SMI diagnosis was 
recorded, even if CVD may have been a topic during the consultation. However, among 
individuals with SMI, only 17% of the primary health care encounters included a SMI 
diagnosis, so it seems reasonable to assume that any recognized CVD would be recorded at 
some point during the at least three-year long observation period. Furthermore, a sensitivity 
analysis with recorded CVD in specialized health care only as dependent variable (paper II) 
gave similar results as the main model. And, as already mentioned, diagnoses in GP registries 
have been found valid in other countries, particularly for chronic diseases [435].  
Lack of information concerning history of CVD prior to the study period, may have led to 
misclassification of undiagnosed CVD in paper II due to stable, long-term and currently 
untreated CVDs. As individuals with SMI have higher fatality rate from CVD [18, 284, 450], 
stable, long-term and currently untreated CVDs may be less likely among persons with SMI 
compared to others. Our findings thus probably underestimate the real difference between 
individuals with and without SMI.  
5.3.2.2.4 Validity of CVD-related procedures in administrative data 
An investigation of medical coding practices in specialized health care in Norway found that 
the recording of medical procedures were more precise than the recording of diagnoses, but 
that non-surgical procedures were underreported [451]. Although this investigation was 
limited to pneumonia and hip replacement surgery, these findings probably have transfer 
value to other patient groups in Norway. The level of screening/monitoring of CVD risk 
factors in paper III may thus be underestimated in all patients, but probably most in patients 





5.3.2.3 Misclassification of underlying cause of death  
Determining cause of death is subject to uncertainty, and the reliability of cause of death 
classification has long been a cause for concern [452]. Autopsy is regarded as the most 
accurate mean of determining the cause of death, but is infrequently undertaken in Norway. 
More than 90% of cases in the CDR are based on information in the death certificate, in some 
cases supplemented by information from other sources. Sources of error include uncertainties 
about the cause of death itself, illogical structure of reported causes of death, and incorrect or 
inadequate coding of the diagnosis. Classification and coding of underlying cause of death 
can be particularly challenging when several causes of death are reported and multiple 
sequences are possible (such as in multi-morbid patients). Another problem is the frequent 
use of intermediate, immediate, unspecified, or otherwise inapplicable causes of death, 
collectively termed “garbage codes” [453], such as heart failure, ill-defined cancer site, 
senility, ill-defined external causes of injuries, and septicemia.  
In a meta-analysis of discrepancies between clinical diagnoses and autopsy findings, 
including studies conducted during 1970-2000, the authors concluded that at least one-third of 
death certificates were likely to be erroneous and that half of the autopsies contained findings 
that were not suspected prior to death [454]. Developments in diagnostic practices and 
procedures in the last decades, helping to ensure correct diagnoses before death, may, 
however, have improved mortality statistics. Only a few recent validation studies of the CDR 
have been conducted. A Norwegian population-based study examining 1,140 autopsies 
conducted in the years 1964-2005 found very good agreement between autopsy findings and 
mortality statistics in the CDR for both stroke and coronary heart disease [455]. Misclassified 
cases remained inside the circulatory system in approximately half of the cases, while the 
remaining cases were randomly distributed over the entire spectrum of diseases, reducing the 
risk of systematic errors. A Norwegian study published in 2005, investigating the impact of 
autopsies on death statistics, however, found substantial (17%) underreporting of 
cardiovascular deaths, particularly in the young and old, and in women [456]. Autopsy studies 
often include cases where the clinical uncertainty of underlying cause of death were 
particularly high, implicating that findings from such studies may not be directly transferable 
to other cases.  
Another Norwegian study comparing mortality statistics to information in medical records of 




of death differed in 18% of the cases, for 12% also with respect to ICD-10 chapter. A 
significant reduction of diagnoses such as sepsis, cardiac arrest, unspecified pneumonia, renal 
failure and fractures without specific cause was noted. Because of the balancing effect of 
exchanges between disease chapters, only minor changes in overall mortality statistics were 
observed. 
The validity of cause of death in elderly patients has been questioned due to multi-morbidity 
and general frailty [458]. This potential error may be of less relevance in study I, which 
included only those aged 20 to 79. Excluding those aged 80 and above in study III gave, 
however, similar estimates for the main endpoints and qualitatively the same conclusions as 
the main models, as shown in the sensitivity analysis. 
5.3.2.3.1 Are cardiovascular deaths at particular risk of misclassification? 
Misclassification of cardiovascular deaths arises both from not recognizing actual death from 
CVD, and from labeling non-cardiovascular deaths cardiovascular. These types of errors are 
captured in the concepts of specificity, sensitivity and predictive value. The quality in cause 
of death assignments with respect to CVD is known to be worse than for cancer [459], and is 
characterized by sensitivity and specificity lower than 85% [460]. A meta-analysis of 
discrepancies between clinical diagnoses and autopsy findings reported that IHD/MI, 
pulmonary embolism and pneumonia often were misclassified and often were confused with 
each other in [454]. Another study reported that incorrect causal sequences on death 
certificates regarding CVD had increased in the US in recent years [461].  
The literature shows inconsistent findings as to whether CVD deaths are over-reported [462] 
[463], underreported [459, 464-466] or reliably reported [455, 467]. Systematic reviews 
suggest that stroke deaths correspond to true stroke deaths [439], whereas the accuracy of MI 
as underlying cause of death may be suboptimal [440]. A Norwegian population based 
autopsy study examining the accuracy of IHD and cerebrovascular disease as causes of death 
found, however, a satisfactory quality in the mortality statistics in the city of Bergen [455]. In 
this study, the sensitivity and positive predictive value of fatal cerebrovascular disease were 
0.75 and 0.86, respectively, and 0.87 and 0.85, respectively, for IHD deaths. Cohen’s Kappa 
coefficients were 0.78 for cerebrovascular disease and 0.80 for IHD. About half of the 
mismatches remained inside the circulatory system, while the remaining cases were randomly 




The validity of MI as underlying cause of death was also good in Danish [467] and Finnish 
[468] studies. We found similar results when we included all deaths with CVD as underlying 
or contributing cause of death, as shown in the sensitivity analyses (studies II-III).  
Table 12 shows selected CVD codes used as underlying cause of death, specified according to 
patient group (paper III). These codes were proposed by Lozani et al as markers of lower 
quality cardiovascular mortality categories [469]. Overall, we found similar (SCZ) or lower 
(BD) proportions of ill-defined cardiovascular causes of death among those SMI compared to 
those without SMI. The largest discrepancy was found for cardiac arrest, which was reported 
as underlying cause of death in 2.4% of persons with BD, compared to 1.4% among those 
without SMI.  
Table 12 - Percentage of ill-defined cardiovascular causes of death in patients with and without schizophrenia 
(SCZ) or bipolar disorder (BD) in the years 2011-2016. 
Underlying cause of death SCZ BD No SMI 
I50 Heart failure 11.2% 10.4% 11.6% 
I51.6 Cardiovascular disease, unspecified 1.6% 1.2% 1.3% 
I70.9 Generalized and unspecified atherosclerosis 0.6% 0.1% 1.1% 
I46 Cardiac arrest 1.5% 2.4% 1.4% 
I51.9 Heart disease, unspecified 1.0% 0.9% 0.8% 
I49.0 Ventricular fibrillation and flutter 0.0% 0.0% 0.1% 
I51.4 Myocarditis, unspecified 0.2% 0.3% 0.1% 
I47.2 Ventricular tachycardia 0.1% 0.0% 0.0% 
I51.5 Myocardial degeneration 0.1% 0.0% 0.0% 
Any of the above 16.3% 15.3% 16.3% 
  
To summarize, it seems reasonable to assume that the presence of misclassification of 
cardiovascular deaths is of similar magnitude among those with or without SMI/SUD (i.e. 
non-differential misclassification). Hence, the actually observed cause specific SMR (study I) 
probably underestimates the true effect. However, when comparing sub-diagnosis within the 
CVD chapter caution may be necessary. Here differential misclassification might be present, 
with an unpredictable direction of bias.  
5.3.2.3.2 Are individuals with SMI or SUD at particular risk of misclassified death? 
Young age of death, increased risk of sudden deaths [377, 378, 380, 406-408], more deaths 
outside health care institutions, poisoning, suicides and substance use may increase the 
likelihood of misclassified death among those with SMI or SUD. An Australian autopsy study 




autopsy, which the authors speculated could be attributed to sudden cardiac death [470]. 
Longer postmortem time before discovery in individuals with SCZ compared to others has 
also been reported [471], possibly affecting the reliability of assumed causes of death. On the 
other side, a Norwegian study reported that autopsies conducted after deaths that occurred 
outside hospitals had increased in the period 2007-2011, with CVD, external causes and 
alcoholism as the most common underlying cause of death [472].  
Younger persons with multi-morbidity (such as patients with SMI or SUD), could be 
underrepresented in studies II and III due to competing causes of death [456]. We found, 
however, very few persons with a diagnosis of SMI or SUD recorded as underlying cause of 
death and CVD as contributing cause of death in these samples, and similar results when we 
included all deaths with CVD as underlying or contributing cause of death, as shown in the 
sensitivity analysis. Also, young age at death was a positive predictor of medical autopsy in 
another Norwegian study [455].  
The use of ill-defined causes of death, the so called “garbage codes“ [453], is another source 
of error in mortality statistics. In paper I, ill-defined causes of death accounted for 10% of 
deaths in SCZ-only, 9% of deaths in SUD-only and 7% of deaths in patients with both SCZ 
and SUD. To investigate whether there were indications of systematic differences in the 
quality of mortality statistics between individuals with or without SMI, we compared the 
percentage of deaths assigned to selected ill-defined causes of death among patients with SMI 
in study I to that reported previously for the Norwegian population (Table 13). The 
comparison showed lower frequency of such diagnoses among those with SCZ or SUD 
compared to the general population, although some reservations have to be made since the 




Table 13 - Percentage of selected ill-defined causes of death in the general population and in psychiatric sub-
populations in Norway 
Underlying cause of death Gen pop SCZ  SUD 
 (1996-2010)
a  (2009-2015)b (2009-2015)b 
I50 Heart failure 3.9 1.0 0.7 
R99 Other ill-defined and unspecific causes of death 1.6 1.8 1.4 
R96 Other sudden death, cause unknown 1.4 1.0 1.0 
C80 Malignant neoplasm, without specification of site 1.2 0.8 0.5 
R54 Senility 1.1 0.1 0.0 
I51 Complications and ill-defined descriptions of heart disease 1.0 0.8 0.7 
I70 Atherosclerosis 0.8 0.3 0.3 
X59 Exposure to unspecified factor 0.7 0.6 0.6 
N19 Unspecified kidney failure 0.6 0.5 0.2 
A41 Other sepsis 0.6 1.0 1.0 
Any of the above 12.9 7.8 6.4 
a Source: http://www.fhi.no/dokumenter/8192560710.pdf 
b Source: The Norwegian Patient Registry and The Norwegian Cause of Death Registry  
 
 
Suicides and accidents also present a challenge in the classification of manner of death, which 
is relevant for mortality statistics regarding people with SMI or SUD. Some studies suggest 
that the “injury death of undetermined intent” diagnosis may reduce the reported suicide rate 
by up to 10% [473]. However, in a study of the validity of suicide statistics in relation to 
undetermined deaths, including 29 European countries, Norway scored highest on the quality 
indicator for suicide statistics [473]. Also, in a study examining the reliability of the national 
suicide statistics in the Nordic countries, 81% (Sweden), 88% (Norway) and 90% (Denmark) 
of deaths registered as suicide in the official mortality statistics were confirmed by expert 
classification [474]. Uncertainty was highest for suicides due to poisoning, but reclassification 
did not change the overall official suicide statistics of the three Scandinavian countries. 
The presence of SUD also present a challenge in mortality statistics, and SUD related deaths 
may be underestimated when only underlying cause of death is counted, particularly alcohol 
related deaths [218]. A Swedish study found that mortality statistics missed one third of drug 
related deaths [475], while a study from the US found valid information regarding deaths 






In section 2.7.1 (page 54) we discussed the possibility of distorted estimates due to 
confounding by common genetic susceptibility for SMI and CVD, early life stressors and 
childhood SES. Based on assumptions of similar causal relationships in study I, we believe 
that the estimates in study I may be confounded by the same factors, as illustrated in Figure 5. 
 
Figure 5 - Directed acyclic graph (paper I) with unmeasured confounders. 
 
The DAG displayed in Figure 5 suggests two alternative minimal adjustment sets for 
estimation of the direct effect of SCZ on excess mortality. The minimal adjustment set 
requiring the smallest number of variables would include measurements of CVD, health care 
seeking/access, other physical diseases, quality of care, risk behavior, unhealthy life style, in 
addition to sex and age, as well as an unlikely assumption of no unmeasured confounding 





5.5 Other limitations 
The relatively short duration of the NPR and the KUHR database is a limitation. In study I, 
this precluded analyses of incident cases, as well as analysis of secular trends in SMRs. In 
paper II and III, this may have led to misclassification of undiagnosed CVD due to stable, 
long-term and currently untreated CVDs. 
The lack of information on other variables relevant to the studies is another limitation. In 
study I, we lacked information about SUD prescriptions, which would have enabled 
identification of more SUD cases. We also lacked data regarding untreated persons with 
SCZ/SUD and patients treated solely in primary care. Access to such data would have made 
the results more generalizable. In paper II, we lacked information on antipsychotic 
prescriptions, which made us unable to study the association between antipsychotic 
medication and sudden cardiac death. In paper III, we lacked complete information on 
procedures conducted at radiology departments (such as computed tomographic angiography 
and ultrasound of peripheral vessels), and information on prehospital procedures during 
transportation to hospital (such as ECG or thrombolysis), which reduced the precision in the 
measurement of performed diagnostic tests and treatment. We also lacked information on 
known risk factors for CVD (such as smoking), severity of CVD (such as ST-segment 
elevation MI and extent of coronary disease) and travel time to hospital. Equal severity of 
CVD could, however, be approximated by the fact that they all died from the same causes of 
death. Finally, we lacked information concerning cardiovascular prescriptions, which made us 
unable to study pharmacological prevention and treatment of CVD in paper III. 
5.6 Generalizability 
Study I included only patients in specialized health care, probably implying higher mortality 
than would be found among patients with SCZ and/or SUD in the general population. The 
generalizability of these findings is therefore to specialized care settings with similar health 
care systems and socioeconomic features.  
Paper II and III included all patients who died from CVD, as well as all patients with SCZ or 
BD treated in any health care setting in Norway. The findings are thus assumed to be 
representative of individuals with severe CVD in countries with publicly funded and readily 





In this thesis, utilizing nationwide Norwegian data to investigate mortality among patients 
with SCZ and/or SUD, and the impact of SMI on detection and treatment of CVD, we 
demonstrated that patients with SCZ and/or SUD who receives specialized health care in 
Norway have a four- to seven-fold increased mortality compared to the general population. 
Particular high mortality was observed for poisoning, suicides and respiratory diseases. The 
excess mortality corresponded to more than 10,000 premature deaths during a mean of four 
years of follow-up, implicating that five out of six patients with SCZ and/or SUD died 
prematurely, and mostly from natural causes such as CVD and cancer. About 27% of the 
excess deaths in patients with SCZ could be attributed to SUD (or factors associated with 
SUD), with the strongest effects in men and in the youngest.  
Despite the increased risk for CVD among those with SCZ or BD, and the fact that almost all 
individuals with SMI utilized primary or somatic specialist health care during the study 
period, we found a considerable underdiagnosis of CVD prior to cardiovascular death in 
individuals with SCZ. This was also the case for women with BD, but not men with BD. The 
higher likelihood of undiagnosed CVD applied to all main types of cardiovascular death, and 
was most frequent in the youngest in all diagnostic groups.  
We also demonstrated lower prevalence of specialized cardiovascular examinations and 
invasive interventions prior to cardiovascular death in patients with SCZ and BD. Individuals 
with these conditions may thus not receive adequate levels of medically indicated 
cardiovascular treatment. We found no difference in utilization of cardio-metabolic diagnostic 
tests in primary care, and similar prevalence of invasive cardiovascular treatment among 
those with and without SMI who were diagnosed with CVD prior to cardiovascular death. 
These findings suggests that underdiagnosis and underutilization of specialized cardiovascular 
examinations, more than poor access to primary care or restraints due to contraindications or 
perceived noncompliance with postoperative care, are among the most important obstacles to 
equitable cardiovascular health care among those with SMI.  
6.1 Implications 
The many disease-specific, lifestyle-specific, health care-specific and socio-environmental 




call for complex intervention strategies addressing aspects of prevention, detection, follow-up 
and treatment at all levels of primary and specialist health care.  
Evidence from the literature [361, 477-479], supported by the findings in our study, show that 
current actions and interventions have been far from able to counter the increased risks 
persons with SMI are exposed to. Some studies nevertheless allow some optimism. Increasing 
evidence demonstrates effectiveness of lifestyle and pharmacological interventions regarding 
weight loss and prevention of weight gain in people with SCZ [480-487], at least in the short 
run [485]. A systematic review found that exercise improved cardiorespiratory fitness among 
persons with SMI, with better outcomes observed following high intensity and high frequency 
interventions supervised by qualified personnel [488]. Pharmacological treatment may also 
reduce tobacco smoking in persons with SCZ or BD [487], and improvement of weight, blood 
pressure and glucose monitoring among users of antipsychotic medication was demonstrated 
following guideline implementation [248]. Studies have also suggested greater uptake of 
prevention services by people with SCZ after being given general health advice [489], and 
acceptability of participation in CVD risk assessment among individuals with SCZ [490]. A 
US study also found a positive association between better performance on process-based 
quality measures (e.g. psychosocial treatment, psychotherapy, continuity of care) and reduced 
1- and 2- year mortality in patients with SMI and concurrent SUD [491], as well as a positive 
association between higher frequency of health care contacts and reduced mortality in the 
comorbid.  
Interventions targeting health behavior (such as smoking, SUD and cardiorespiratory fitness) 
and metabolic risk factors (such as diabetes and hypertension) in persons with SMI are thus 
both necessary and possible actions to improve health outcomes. The limited evidence of 
long-term effectiveness of interventions addressing somatic risk factors in individual SMI 
and/or SUD [361, 477-479] suggests, however, that changes also at interpersonal, 
organizational, societal and policy levels probably are needed [478]. Such structural 
approaches could involve changing patterns of health service delivery, organizational models 
and financing systems. Screening for physical disease within psychiatric settings warrants 
further research. Also, physical activity as an integrated part of standard treatment of persons 
with SMI should be further investigated and pursued. Successful implementation in the SMI 
population may require personalized or tailored interventions, longer duration, more frequent 




Our studies further support and highlight the need for strengthened efforts to reduce 
underdiagnosis and undertreatment of somatic disease among those with SMI. A proactive, 
structured and tailored approach for correct diagnosis and treatment of somatic diseases is 
needed, underlined by the fact that these patients may have a more malignant disease course, 
with higher morbidity in the younger age groups and shorter time to recognize symptoms. 
Strengthened efforts are also needed to secure equitable access to secondary prophylactic 
treatment [18, 257]. There is also a need to define more accurately the responsibility for 
maintaining follow-up and treatment of somatic risk factors in patients with SMI. 
Investigations as to whether other organization models for primary, somatic and mental health 
services succeed better in promoting physical health among persons with SMI are also 
needed. Studies from the Veteran Affairs health care system [493, 494] and others [276], 
indicate that integrated, coordinated or collaborative health care may be beneficial in reducing 
inequities in health outcomes for people with SMI. Although previous studies have shown 
mixed results with regard to the effectiveness of financial incentives in improving quality of 
care [495, 496], we suggest that further investigations should be carried out to study whether 
the introduction of specific financial incentives for somatic health screening/monitoring in 
patients with SMI in primary and specialized health could help reducing underdiagnosis and 
undertreatment in these populations. Also, the high proportion of deaths directly linked to 
poisoning in SUD patients urgently calls for a more effective societal prevention of SUD-
related unnatural deaths.  
An approach that includes both individual focused and system focused interventions [478] is 
probably needed, involving both service users, primary and integrated specialist health care.  
  
6.2 Suggestions for further work 
Some unresolved issues in paper I-III could be further investigated. These include the 
following topics: 
 We were unable to conclude whether the lower prevalence of specialized diagnostic 
tests in persons with SCZ and women with BD were due to lacking referrals from 




Barriers to, and facilitators of, access to specialized examinations for people with SMI 
could be investigated in further studies. 
 We observed differences with regard to health care seeking, undiagnosed CVD and 
health care outcomes between men and women with BD, which could be further 
investigated in other studies and populations.  
 Few mortality studies among persons with SMI have included cases both in primary 
and specialized health care and in disability registries. Such studies could enhance the 
generalizability of findings regarding mortality in the SMI population. 
In a broader perspective, further research is strongly needed that addresses possible structural 
changes that can be made with the specific aim to improve the health outcomes of the high-
risk subgroup with SMI. The different risk profiles in younger and older persons points to the 
need for such efforts to be age-differentiated, with particular emphasis on the younger age 
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Abstract
Individuals with schizophrenia or substance use disorder have a substantially increased
mortality compared to the general population. Despite a high and probably increasing preva-
lence of comorbid substance use disorder in people with schizophrenia, the mortality in the
comorbid group has been less studied and with contrasting results. We performed a nation-
wide open cohort study from 2009 to 2015, including all Norwegians aged 20–79 with
schizophrenia and/or substance use disorder registered in any specialized health care set-
ting in Norway, a total of 125,744 individuals. There were 12,318 deaths in the cohort, and
total, sex-, age- and cause-specific standardized mortality ratios (SMRs) were calculated,
comparing the number of deaths in patients with schizophrenia, schizophrenia only, sub-
stance use disorder only or a co-occurring diagnosis of schizophrenia and substance use
disorder to the number expected if the patients had the age-, sex- and calendar-year specific
death rates of the general population. The SMRs were 4.9 (95% CI 4.7–5.1) for all schizo-
phrenia patients, 4.4 (95% CI 4.2–4.6) in patients with schizophrenia without substance use
disorder, 6.6 (95% CI 6.5–6.8) in patients with substance use disorder only, and 7.4 (95% CI
7.0–8.2) in patients with both schizophrenia and substance use disorder. The SMRs were
elevated in both genders, in all age groups and for all considered causes of death, and most
so in the youngest. Approximately 27% of the excess mortality in all patients with schizo-
phrenia was due to the raised mortality in the subgroup with comorbid SUD. The increased
mortality in patients with schizophrenia and/or substance use disorder corresponded to
more than 10,000 premature deaths, which constituted 84% of all deaths in the cohort. The
persistent mortality gap highlights the importance of securing systematic screening and
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Introduction
Individuals with schizophrenia have a two- to three-fold increased mortality compared to the
general population [1–3] and a 10-20-year reduction in average life span [2, 4–6]. Individuals
with substance use disorder (SUD) have an even higher risk of premature death, ranging from
a four-fold increased mortality among persons with alcohol use disorder (AUD) [7–10] to a
four to-15-fold increased mortality among opioid users [11–13]. A concurrent diagnosis of
schizophrenia spectrum disorder (SCZ) and SUD (henceforth referred to as SCZ+SUD) is
associated with a variety of detrimental outcomes, among these increased somatic morbidity
[14–19], increased risk of fatal overdoses, violent behavior [20–23] and victimization [24, 25].
Despite these vulnerabilities and a high [26, 27], and probably increasing [28], prevalence of
comorbid SUD in SCZ patients, the mortality in the comorbid group has been less studied and
with contrasting results. Studies of SCZ individuals with co-morbid SUD have found both
increased [29–34] and decreased [35] all-cause mortality, increased suicide mortality [36, 37],
but no difference in cardiovascular mortality [38] compared to SCZ individuals without SUD.
Studies of SUD individuals report both higher [39, 40], similar [12, 13, 40–43], and lower [44]
mortality in individuals also diagnosed with a psychotic disorder, compared to individuals
with SUD-only, depending on type of SUD and gender [40]. Only a few studies with complete
national coverage have investigated all cause [30, 33, 34, 40] or cause-specific mortality [33,
34] in patients with SCZ-only, SUD-only or co-morbid SCZ and SUD, and neither of these
reported results for different age groups or mortality from unnatural causes of death.
The aims of the present study were to (i) investigate standardized mortality ratios for all
cause mortality (SMRs) in patients with SCZ, SCZ-only, SUD-only and SCZ+SUD, diagnosed
in Norwegian psychiatric or somatic specialist health care, (ii) describe how much of the excess
mortality that could be attributed to a concurrent diagnosis of SCZ and SUD, and (iii) investi-
gate age-, sex-, and cause-specific SMRs in patients with SCZ-only, SUD-only or SCZ+SUD.
We hypothesized that mortality in patients with SCZ and/or SUD would be increased com-
pared to the general population for all main causes of death, and that patients with a concur-
rent diagnosis of SCZ and SUD would have particularly high SMRs.
Materials and methods
Study population
The study population included all in- and outpatients diagnosed with SCZ and/or SUD in the
Norwegian specialized health care system during 2009–2015, who were 20–79 years old when
they had their first consultation in the time bracket. Patients with SCZ and/or SUD were iden-
tified through the Norwegian Patient Registry (NPR), which is a mandatory national registry
covering all patients receiving specialist health care (i.e. government-owned hospitals and out-
patient clinics, publicly financed substance use treatment facilities and private health clinics
with governmental reimbursement). Since 2009 the coverage in the NPR is almost 100% [45,
46]. The exception is private mental health clinics with governmental reimbursement, where
the proportion of the episodes that were reported to the NPR increased from 76% in 2009 [47]
to 97% in 2015 [48], but only 0.2% of patients in the present study were treated solely in these
clinics. Patients were excluded if an invalid ID number (n = 6,178), a diagnosis of intellectual
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disability (ICD-10 codes F70-F79) (n = 1,632), or inconsistent data regarding age, gender or
emigration date (n = 666) were recorded.
Diagnostic categories
Diagnostic codes in the NPR follow the International Classification of Diseases and Related
Health Problems, 10th Revision (ICD-10) [49]. Patients were included in the SCZ group if a
diagnosis of schizophrenia-related disorders (F20-F29) was recorded in the NPR during 2009–
2015. The SUD group included patients with a diagnosis of mental and behavioral disorders
due to use of psychoactive substances (F10-F19, excluding tobacco (F17)), and patients with at
least one somatic diagnosis strongly indicating alcohol abuse (see list of ICD-10 codes in S1
Table). Patients identified by somatic diagnoses only constituted 4.1% of the SUD group. A
total of 275 patients treated in substance use treatment facilities, with a diagnosis of SCZ, but
no registered diagnosis of SUD (excluding pathological gambling (F63.0)), were included in
the SCZ+SUD group. In subgroup analyses, we differentiated between patients with a non-
alcohol SUD (F11-F16, F18-F19, Z50.3, Z71.5 and Z72.2), and patients with AUD only. Hard
drug use disorder was deemed present if the patient was diagnosed with disorders due to use
of opioids (F11), cocaine (F14), other stimulants (mostly amphetamines, F15), hallucinogens
(F16), volatile solvents (F18), and multiple drug use and use of other psychoactive substances
(F19).
Information on deaths
The Cause of Death Registry (CDR), which includes 98% of all deaths in Norway [50], pro-
vided data on the underlying cause of death, based on death certificates issued by physicians.
The National Population Registry provided information about year of birth and date of death
or emigration. Accurate linkage regarding mortality of the patients was obtained using the
unique 11 digit personal ID number included in all the registries. Causes of death were coded
according to ICD-10 [49] and divided into natural causes (A00-R99), unnatural causes
(V01-Y98) and missing cause of death. Natural causes of death were further divided into car-
diovascular (I00-I99), respiratory (J00-J99), cancer (C00-C97) and other natural causes.
Unnatural causes of death were divided into poisoning (X40-X49), suicide (X60-X84 and
Y87.0) and other unnatural causes.
The reference population included all residents in Norway aged 20–79 during 2009–2015.
Annual number of deaths in gender-stratified five-year age groups for the reference population
were obtained from the Norwegian Institute of Public Health [51], and annual population fig-
ures in the age groups 20–79 in the years 2009–2015 were obtained from Statistics Norway
[52].
Follow-up
The study cohort was followed from the admission date of the index episode (their first consul-
tation during 2009–2015). Patients already hospitalized before January 1, 2009, were followed
from this date (n = 2,633). To account for diagnostic instability in SCZ patients, we defined an
extended diagnostic spectrum covering schizophrenia (F20-F29), affective disorders
(F30-F39), and personality disorder (F60). If a diagnosis of SCZ was ever recorded, the index
episode was defined as the first episode with a diagnosis within the extended diagnostic spec-
trum. Follow-up ended on December 31, 2015, on the date of emigration from Norway, on
December 31 in the year of the 79th birthday, or on the date of death, whichever came first.
Standardized mortality ratios in schizophrenia and/or substance use disorder
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Statistical analysis
For comparison with the mortality of the general population of Norway, SMRs with corre-
sponding 95% confidence intervals were calculated for patients with SCZ, SCZ-only, SUD-
only, and SCZ+SUD. SMR reflects the relative mortality of the patient group compared to that
of the general population and is computed as the observed number of deaths divided by the
expected number of deaths. The expected number of deaths was calculated as the total number
of person-years at risk in each sex-, age group- and calendar year band, multiplied by the cor-
responding age- (5-year age groups), sex- and calendar-year specific (2009–2015) death rate in
the general population. Age was defined as attained age at the end of each calendar year, as we
did not have access to exact birth dates. Person-years at risk contributed by persons who
moved from one age band to the next during follow-up was assigned to the respective sex-, age
group- and calendar year bands, using the “lexis” method [53]. The number of excess deaths
was calculated as the difference between observed and expected deaths.
Biased SMRs may be a major problem when the prevalence of exposure in the general pop-
ulation is high [54]. In contrast to SCZ, unnatural deaths in the SUD subgroup constitute a
large proportion of unnatural deaths in the general population, implicating risk of biased
SMRs for unnatural causes of death in this subgroup. We consequently investigated the impact
on SMRs for poisoning, suicide and all-cause mortality in patients with SUD (SUD-only and
SCZ+SUD combined), using an unexposed comparison group, rather than the general popula-
tion, for calculation of the expected number of deaths. This unexposed comparison group con-
stituted the Norwegian population excluding subjects with recorded SUD in specialized health
care and corresponding deaths from the relevant age-/gender group in the reference popula-
tion. The mortality rates in this unexposed population was calculated and applied when com-
puting the expected number of deaths.
We also investigated the impact on SMRs of the temporal ordering of SCZ and SUD diag-
noses in comorbid patients, and of varying inclusion criteria in a series of pre-specified sensi-
tivity analyses (i) excluding patients treated solely in somatic hospitals during follow-up (e.g.
older individuals with presumably stable mental illness suffering from somatic health prob-
lems), (ii) excluding patients diagnosed with SCZ as a secondary diagnosis only, and (iii)
including only patients diagnosed with narrow schizophrenia (F20) in the SCZ group.
The analyses were conducted using SAS statistical software, version 9.4 (SAS Institute Inc.,
Cary, N.C.)
Ethics
All patient data were fully de-identified when accessed by the investigators. In Norway, studies
with de-identified information from medical health registries do not require participant con-
sent. Legal basis and exemption from professional secrecy requirements for the use of personal
health data in research was granted by the regional committee for medical and health research
ethics (2014/72/REK nord).
Results
Characteristics of the study population
A total of 125,744 individuals were included in the study during 2009–2015. They were
aged 20–79 at start of follow-up. Of these, 27,859 (22.2%) were registered with a diagnosis
of SCZ, 20,537 (16.3%) with SCZ-only, 97,885 (77.8%) with SUD-only, and 7,322 (5.8%)
with SCZ+SUD (Table 1). Men were overrepresented in the SUD groups (66.6% in SUD-only
Standardized mortality ratios in schizophrenia and/or substance use disorder
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and 70.1% in SCZ+SUD). In patients with SUD, AUD was most common in patients with
SUD-only (66.4%), whereas non-alcohol SUD was most common in comorbid patients
(76.5%).
Table 1. Characteristics of the study population. Patients aged 20–79 with schizophrenia spectrum disorder (SCZ) and/or substance use disorder (SUD).
SCZ-only SUD-only SCZ+SUD
Men
Patients, n (%) 10,509 65,175 5,126
Personyears, sum 48,776 250,350 26,873
Personyears, mean (SD) 4.6 (2.3) 3.8 (2.2) 5.2 (2.0)
Age at start of follow-up, mean (SD) 43.4 (15.2) 43.5 (15.7) 35.2 (12.0)
No. of patients with substance use disorder, n (%)
Alcohol use disorder - 44,198 (67.8) 2,230 (43.5)
Alcohol use disorder only - 33,917 (52.0) 980 (19.1)
Non-alcohol substance use disorder - 31,258 (48.0) 3,984 (77.7)
Cannabis use disorder - 13,688 (21.0) 1,805 (35.2)
Hard drug use disorders - 23,073 (35.4) 3,202 (62.5)
Non-alcohol substance use disorder only - 20,977 (32.2) 2,734 (53.3)
Unknown substance use disorder - 0 (0.0) 162 (3.2)
No. of health care episodes per person-year, median (IQR)
No. of admissions, mental care 0.2 (0.0–0.4) 0.0 (0.0–0.0) 0.3 (0.2–0.6)
No. of outpatient visits, mental care 5.6 (1.1–16.5) 0.0 (0.0–2.0) 7.3 (1.9–19.0)
No. of admissions, medical care 0.0 (0.0–0.2) 0.2 (0.0–0.4) 0.1 (0.0–0.3)
No. of outpatient visits, medical care 0.6 (0.0–1.9) 1.5 (0.5–4.2) 0.9 (0.3–2.0)
No. of admissions, SUD treatment - 0.0 (0.0–0.2) 0.0 (0.0–0.1)
No. of outpatient visits, SUD treatment - 0.2 (0.0–3.9) 0.0 (0.0–1.8)
Women
Patients, n (%) 10,028 32,710 2,196
Personyears, sum 45,970 126,174 11,946
Personyears, mean (SD) 4.6 (2.3) 3.9 (2.2) 5.4 (1.9)
Age at start of follow-up, mean (SD) 47.9 (16.1) 42.5 (16.2) 39.1 (14.0)
No. of patients with substance use disorder, n (%)
Alcohol use disorder - 20,800 (63.6) 965 (43.9)
Alcohol use disorder only - 15,471 (47.3) 442 (20.1)
Non-alcohol substance use disorder - 17,239 (52.7) 1,641 (74.7)
Cannabis use disorder - 4,573 (14.0) 433 (19.7)
Hard drug use disorders - 11,834 (36.2) 1,247 (56.8)
Non-alcohol substance use disorder only - 11,910 (36.4) 1,118 (50.9)
Unknown substance use disorder - 0 (0.0) 113 (5.1)
No. of health care episodes per person-year, median (IQR)
No. of admissions, mental care 0.2 (0.0–0.4) 0.0 (0.0–0.2) 0.4 (0.2–0.7)
No. of outpatient visits, mental care 5.8 (1.2–17.0) 0.8 (0.0–6.1) 8.4 (2.5–21.6)
No. of admissions, medical care 0.1 (0.0–0.3) 0.2 (0.0–0.5) 0.2 (0.0–0.5)
No. of outpatient visits, medical care 1.0 (0.2–3.1) 2.4 (0.9–6.0) 1.5 (0.6–3.3)
No. of admissions, SUD treatment - 0.0 (0.0–0.0) 0.0 (0.0–0.0)
No. of outpatient visits, SUD treatment - 0.0 (0.0–3.7) 0.0 (0.0–1.6)
Abbreviations: SCZ, schizophrenia spectrum disorder; SUD, substance use disorder; SCZ+SUD, concurrent diagnoses of schizophrenia and substance use disorder; SD,
standard deviation; IQR, interquartile range.
https://doi.org/10.1371/journal.pone.0202028.t001
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All-cause mortality
Of the 125,744 individuals included, 12,318 (9.8%) died during follow-up (Table 2). Mean age
at death was highest in patients with SCZ-only (62.0 years) and lowest in patients with SCZ
+SUD (47.3 years), and particularly low in comorbid men (45.3 years). Comparing with the
expected number of deaths based on the mortality of the general population, we found a SMR
of 4.9 (95% CI 4.7–5.1) in SCZ patients (with or without SUD), and SMRs of 4.4 (95% CI 4.2–
4.6), 6.6 (95% CI 6.5–6.7) and 7.4 (95% CI 6.9–8.1) in patients with SCZ-only, SUD-only, and
SCZ+SUD, respectively, corresponding to 10,328 excess deaths (of which 18% were in SCZ
patients). In men, the SMRs for patients with SCZ (with or without SUD), SCZ-only, SUD-
only, and SCZ+SUD were 5.1 (95% CI 4.8–5.4), 4.5 (95% CI 4.2–4.8), 6.4 (95% CI 6.2–6.5) and
7.6 (95% CI 6.9–8.4), respectively. In women, the corresponding figures were 4.6 (95% CI 4.3–
4.9), 4.3 (95% CI 4.0–4.6), 7.4 (95% CI 7.1–7.6) and 7.0 (95% CI 6.0–8.2). All-cause mortality
was elevated for both genders and in all age groups (Fig 1), but the SMRs were consistently
Table 2. Number of deaths (overall and in different age groups) and mean age of death, according to sex. Patients aged 20–79 with schizophrenia spectrum disorder
(SCZ) and/or substance use disorder (SUD).
SCZ-only SUD-only SCZ+SUD
Men
Deaths, n 972 7,334 423
Age at death 20–39, n (%) 90 (9.3) 847 (11.5) 170 (40.2)
Age at death 40–59, n (%) 295 (30.3) 2,445 (33.3) 171 (40.4)
Age at death 60–79, n (%) 587 (60.4) 4,042 (55.1) 82 (19.4)
Age at death, mean (SD) 60.3 (13.6) 58.6 (13.7) 45.3 (14.2)
Women
Deaths, n 832 2,592 165
Age at death 20–39, n (%) 42 (5.0) 256 (9.9) 34 (20.6)
Age at death 40–59, n (%) 198 (23.8) 928 (35.8) 75 (45.5)
Age at death 60–79, n (%) 592 (71.2) 1,408 (54.3) 56 (33.9)
Age at death, mean (SD) 64.0 (12.3) 59.0 (13.6) 52.5 (14.2)
Abbreviations: SCZ, schizophrenia spectrum disorder; SUD, substance use disorder; SCZ+SUD, concurrent diagnoses of schizophrenia and substance use disorder; SD,
standard deviation.
https://doi.org/10.1371/journal.pone.0202028.t002
Fig 1. All-cause age, gender, and calendar-year standardized mortality ratios according to gender and age among
patients with schizophrenia and/or substance use disorders.
https://doi.org/10.1371/journal.pone.0202028.g001
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higher in the youngest age groups. Women aged 20–39 years with SUD had particularly high
SMRs; 15 in the SUD-only group and 18 in the SCZ+SUD group.
Sensitivity analyses (i) excluding patients treated solely in somatic hospitals during follow-
up, or (ii) patients with a secondary diagnosis of SCZ only indicated decreased SMRs for SCZ-
only (both models) and SUD-only (model ii), whereas application of a narrow definition of
SCZ (F20) (model iii) resulted in moderately increased SMRs for SCZ-only (S2 Table).
Impact of a concurrent diagnosis of SCZ and SUD
Overall, comorbid patients had higher all-cause SMRs than patients with SCZ-only or SUD-
only. However, when stratified according to sex and type of SUD (Table 3), SMRs were similar
in SUD patients with or without comorbid SCZ, except in comorbid men with a non-alcohol
SUD who had higher SMR than men with non-alcohol SUD-only. Comorbid patients aged
20–39, 40–59 and 60–69 had 107%, 57% and 6% higher numbers of deaths compared to what
could be expected if the same age-specific SMRs as patients with SCZ-only had applied,
whereas application of age-specific SMRs for SUD-only in the comorbid had smaller impact
on hypothetical numbers of death. Thus, the major reason for the high SMRs in comorbid
patients was the SUD component. In this total Norwegian patient population, approximately
27% of the excess number of deaths in all patients with SCZ was due to the raised mortality in
the subgroup with comorbid SUD. This effect was strongest in men and in the youngest.
Supplementary analyses examining the temporal ordering of SCZ and SUD diagnoses in
comorbid patients showed that SCZ and SUD were mostly co-occurring: 39% had both diag-
noses within three months, 55% within one year and 70% within two years. One in four
comorbid patients had a SUD diagnosis more than three months prior to the SCZ diagnosis,
whereas 36% had a SCZ diagnosis more than three months prior to the SUD diagnosis. The
SMRs tended to be higher when the SUD diagnosis preceded the SCZ diagnosis, and were
highest when the first diagnosis of SCZ and SUD during follow-up were recorded within a
short time interval (S3 Table).
Cause specific mortality
We found elevated mortality from all considered causes of death in all subgroups (Table 4). In
both men and women, the highest SMRs were observed for poisoning, suicides and respiratory
Table 3. All-cause age, gender, and calendar-year standardized mortality ratios among patients aged 20–79 with substance use disorders only (SUD-only) or con-
current SUD and schizophrenia related disorders (SCZ+SUD), according to type of SUD.
SUD-only SCZ+SUD
Obs SMRa (95% CI) Obs SMRa (95% CI)
Men 7,334 6.4 (6.2–6.5) 423 7.6 (6.9–8.3)
AUD-only 5,109 5.9 (5.7–6.0) 120 5.4 (4.5–6.4)
Non-alcohol SUD 2,225 8.0 (7.7–8.3) 295 9.4 (8.4–10.5)
Unknown SUD 0 8 4.0 (2.0–8.0)
Women 2,592 7.4 (7.1–7.7) 165 7.0 (6.0–8.2)
AUD-only 1,520 7.0 (6.6–7.3) 47 6.4 (4.8–8.5)
Non-alcohol SUD 1,072 8.0 (7.5–8.5) 111 7.4 (6.1–8.9)
Unknown SUD 0 7 6.9 (3.3–14.4)
Abbreviations: SUD, substance use disorder; SCZ+SUD, concurrent diagnoses of schizophrenia and substance use disorder; Obs, observed deaths; SMR, standardized
mortality ratio; 95% CI, 95% confidence interval; AUD, Alcohol Use Disorder.
a The standard population used for the sex- and calendar year specific age standardization was the annual population of Norway aged 20–79 in the years 2009–2015.
https://doi.org/10.1371/journal.pone.0202028.t003
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diseases. Women had higher SMRs for unnatural death than men in all age groups, and higher
SMRs for suicides. SMRs for natural causes of death did not differ much with age neither for
men nor for women. For unnatural causes of death, SMRs in people with SCZ-only were stable
across age groups, except in women aged 20–39, who had elevated SMRs compared to other
age groups. In patients with SUD, SMRs in the age group 20–59 were elevated compared to
age 60–79, except in comorbid women who had a 30-fold increased SMR across all age groups.
Table 4. Cause-specific age, gender, and calendar-year standardized mortality ratios among men and women aged 20–79 with schizophrenia-related disorders
(SCZ) and/or substance use disorders (SUD).
SCZ-only SUD-only SCZ+SUD
Obs SMRa 95% CI Obs SMRa 95% CI Obs SMRa 95% CI
Men
Natural causes 775 4.2 (3.9–4.5) 5,293 5.4 (5.3–5.6) 182 4.6 (4.0–5.3)
Age 20–39 17 3.3 (2.1–5.3) 141 5.5 (4.6–6.4) 24 5.7 (3.8–8.5)
Age 40–59 211 4.7 (4.1–5.3) 1,555 6.9 (6.6–7.2) 86 5.1 (4.1–6.3)
Age 60–79 547 4.1 (3.8–4.5) 3,597 5.0 (4.8–5.2) 72 3.9 (3.1–5.0)
Subtype
Cardiovascular 200 3.9 (3.4–4.5) 1,252 4.7 (4.4–4.9) 35 3.3 (2.4–4.6)
Respiratory 123 8.5 (7.1–10.1) 617 8.0 (7.4–8.7) 30 13.1 (9.1–18.7)
Cancer 197 2.6 (2.3–3.0) 1,180 2.9 (2.7–3.1) 30 1.9 (1.3–2.7)
Other 255 6.1 (5.4–6.9) 2,244 10.2 (9.8–10.7) 87 8.3 (6.7–10.3)
Unnatural causes 186 6.9 (5.9–7.9) 1,837 13.3 (12.7–13.9) 228 16.3 (14.3–18.5)
Age 20–39 72 7.8 (6.2–9.8) 684 14.1 (13.1–15.2) 140 17.4 (14.8–20.6)
Age 40–59 76 6.4 (5.1–8.0) 807 14.2 (13.3–15.3) 81 16.0 (12.9–19.9)
Age 60–79 38 6.4 (4.6–8.7) 346 10.4 (9.4–11.6) 7 7.6 (3.6–16.0)
Subtype
Poisoning 30 4.6 (3.2–6.5) 903 27.5 (25.8–29.3) 115 29.0 (24.2–34.9)
Suicide 115 11.6 (9.7–13.9) 499 9.9 (9.0–10.8) 87 16.0 (13.0–19.8)
Other 41 3.8 (2.8–5.2) 435 7.9 (7.2–8.7) 26 5.6 (3.8–8.3)
Missing 11 1.6 (0.9–2.8) 204 5.4 (4.7–6.2) 13 5.5 (3.2–9.5)
Women
Natural causes 703 3.9 (3.6–4.2) 1,921 6.0 (5.8–6.3) 90 4.4 (3.6–5.4)
Age 20–39 8 3.0 (1.5–6.0) 46 5.2 (3.9–7.0) 8 7.9 (4.0–15.8)
Age 40–59 146 4.2 (3.6–4.9) 608 7.4 (6.8–8.0) 40 5.2 (3.8–7.0)
Age 60–79 549 3.9 (3.6–4.2) 1,267 5.6 (5.3–5.9) 42 3.6 (2.6–4.8)
Subtype
Cardiovascular 150 4.3 (3.7–5.1) 306 5.4 (4.8–6.1) 17 5.1 (3.2–8.2)
Respiratory 126 7.1 (6.0–8.4) 292 10.0 (8.9–11.2) 22 13.4 (8.9–20.4)
Cancer 239 2.7 (2.4–3.1) 451 2.8 (2.5–3.0) 19 1.7 (1.1–2.7)
Other 188 4.7 (4.1–5.5) 872 12.6 (11.8–13.4) 32 7.2 (5.1–10.1)
Unnatural causes 113 9.9 (8.2–11.9) 629 23.2 (21.4–25.0) 74 30.9 (24.6–38.9)
Age 20–39 29 15.7 (10.9–22.6) 201 26.7 (23.2–30.6) 26 32.4 (22.1–47.7)
Age 40–59 47 9.7 (7.3–12.9) 305 25.8 (23.1–28.9) 35 29.9 (21.5–41.7)
Age 60–79 37 7.8 (5.7–10.8) 123 15.8 (13.2–18.8) 13 30.9 (18.0–53.3)
Subtype
Poisoning 11 5.1 (2.8–9.2) 263 44.7 (39.6–50.4) 25 43.5 (29.4–64.4)
Suicide 77 19.0 (15.2–23.8) 248 22.7 (20.0–25.7) 38 36.7 (26.7–50.4)
Other 25 4.8 (3.2–7.1) 118 11.4 (9.5–13.7) 11 14.1 (7.8–25.4)
Missing 16 5.0 (3.1–8.2) 42 6.7 (5.0–9.1) 1 nr nr
Abbreviations: Obs, observed deaths; SMR, standardized mortality ratio; 95% CI, 95% confidence interval; nr, Not reportable because of small samples (no. of
deaths < 5) within the data category.
a The standard population used for the sex- and calendar year specific age standardization was the annual population of Norway aged 20–79 in the years 2009–2015.
https://doi.org/10.1371/journal.pone.0202028.t004
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Overall, 73% of excess number of deaths were from natural causes. In SCZ-only and SUD-
only, natural causes accounted for 82% and 73% of all deaths, respectively, with cancer and
cardiovascular disease being the most common causes. In the SCZ+SUD group, unnatural
causes accounted for 54% of all deaths. Women with SUD-only had higher SMRs than men
with SUD-only for nearly all considered causes of death. Women with SUD (with or without
SCZ) had particularly high SMRs (approximately 45) for poisoning.
Deaths due to poisoning and suicide in SUD patients in our sample constituted a large pro-
portion of all deaths from these causes in Norway in the years 2009–2015 (52% and 22%,
respectively). In a supplementary analysis we assessed the bias in SMRs for poisoning and sui-
cide for patients with SUD (SUD-only and SCZ+SUD combined) using an unexposed com-
parison group (e.g. no diagnosis of SUD in specialized health care), rather than the general
population, to calculate expected deaths. This resulted in a three-fold increase in SMR for poi-
soning in men and a doubled SMR for poisoning in women (from 27.7 to 82.9 in men, and
from 44.6 to 98.5 in women), whereas SMRs for suicides increased from 10.5 to 13.7 in men
and from 23.9 to 33.8 in women. The SMRs for all-cause mortality were also affected
(increased from 6.4 to 7.3 in men, and from 7.3 to 7.9 in women).
Discussion
Our study shows that patients in specialized health care with SCZ, SCZ-only or SUD (with or
without SCZ) had a five-, four- and seven-fold increased total mortality, respectively, com-
pared to the general population. Mortality was elevated for both genders, in all age groups and
for all considered causes of death, with the highest SMRs observed for poisoning, suicides and
respiratory diseases. Very high SMRs for poisoning were noted in women with SUD (with or
without SCZ). The highest SMRs were found in the age group 20–39, mainly due to unnatural
causes of death.
The excess mortality corresponded to more than 10 000 premature deaths (84% of all deaths
in the cohort). About 27% of the excess deaths in SCZ patients could be attributed to SUD (or fac-
tors associated with SUD). The nearly five-fold increased mortality in SCZ (with and without
SUD) was substantially higher than reported in meta-analyses [1, 55], and also higher than
reported in a recent Nordic study [56]. The omission of patients in primary care, and the relatively
short follow-up, may have led to a selection of more severe cases, oversampling patients with
many health care episodes and patients with increased suicide risk. Inclusion of older individuals
suffering from somatic health problems, such as cardiovascular and respiratory diseases, is
another explanation of the elevated SMR in SCZ patients, as shown in the sensitivity analysis. Dif-
ferences in case finding criteria might also have contributed, also shown in the sensitivity analyses,
whereas survivor bias resulting from inclusion of prevalent cases would have the opposite effect.
Also, catchment of SCZ might be higher in Norway compared to countries without universal
health care. Another contributing explanation might be the rising mortality gap in schizophrenia
patients compared to the general population reported in recent studies [1, 57, 58], partly explained
by decreased mortality from cardiovascular disease in the general population [59, 60].
The increased all cause and suicide mortality, as well as the similar cardiovascular mortality
in comorbid patients, is in accordance with some previous studies [29–34, 38], but not in line
with a study reporting decreased mortality in persons with co-occurring psychosis and canna-
bis use/abuse, compared to psychosis only [35]. In the present study, mortality from cannabis
use disorder was not studied separately, due to few deaths and suspicion of selective recording
of less severe cases in comorbid patients.
Overall, a co-occurring diagnosis of SCZ also conferred increased SMRs in SUD patients.
However, when stratified according to type of SUD, we found similar SMRs for non-alcohol
Standardized mortality ratios in schizophrenia and/or substance use disorder
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SUD patients with and without SCZ, in accordance with other studies [12, 13, 41, 42], and simi-
lar SMRs in AUD patients with and without SCZ, in contrast to a 50-year follow-up study of
AUD persons [39]. Differences in length of follow-up may be one explanation for the latter find-
ing. Furthermore, when stratified according to gender, we found increased SMR in comorbid
men, but not in comorbid women, in accordance with a study conducted in inpatients [40].
Thus, in our study, the increased SMRs in comorbid patients, both genders combined, was
explained by the high proportion of young comorbid men with a non-alcohol SUD. The eight-
to-nine-fold increased SMR in patients with non-alcohol SUD with and without SCZ, is similar
to [61] or higher than [12, 31] reported elsewhere. Norway has one of the highest rates of inject-
ing drug users among hard drug users [62], which may have contributed to this finding.
The very high all cause SMRs found among young patients were similar to [63] or higher
than [31, 64] reported earlier. Previous studies have found excess mortality to be highest the
year following a first diagnosis of severe mental illness, due to increased mortality from unnat-
ural causes of death [2, 65]. Besides low expected death rates in the youngest in the general
population, the inverse relationship between the SMR and age may thus partly be explained by
the inclusion of presumably more incident cases in the youngest and more prevalent cases
among the oldest in our study, and may have been amplified by survivor bias, treatment-com-
pliant patients in our sample and lower suicide rates with increasing age in SCZ patients [66].
Comorbid women did not, however, experience a decrease in SMR with increasing age, but
had very high mortality across all age groups. We found very high SMRs for poisoning and sui-
cide in women with SUD, which confirms earlier findings [60, 67], and high SMRs for respira-
tory diseases, probably associated with increased smoking prevalence in individuals with
severe mental disorders [68]. The increased mortality due to suicide in patients with SCZ was
more pronounced than reported in a systematic review [1], but of similar magnitude as
reported in a sample with comparable age span [37].
The excess mortality in patients with severe mental illness has been ascribed to a wide range
of factors, both at the individual level, health system level and at the societal level [69]. Expla-
nations include lifestyle factors [38, 70] (such as smoking, substance use, physical inactivity
and unhealthy diet), poorer socioeconomic conditions [71], suboptimal use of or access to
medical care [72], and metabolic side effects of high dosages of antipsychotic medication [73],
as well as higher levels of suicides, poisoning, violent behavior [20–23] and victimization [24,
25]. It is thus a huge challenge to address the complex needs of patients with severe mental ill-
ness in combination with SUD, both with regard to general improvement of outcome as well
as prevention of premature mortality. Despite the well known high association between SUD
and SCZ there is no evidence supporting one specific treatment strategy for patients with dual
diagnoses [69, 74, 75]. Likewise, there is little evidence for successful interventions addressing
somatic risk factors in patients with severe mental disorders [70, 76], although evidence-based
interventions for smoking cessation and weight reduction in persons with severe mental illness
exist [69]. The universal health care system in Norway, designed to prevent socioeconomic dif-
ferences in health care, has unfortunately not been able to address these issues. Generally, a
population approach for prevention is considered the key avenue for non-communicable dis-
eases, e.g. cardiovascular diseases and cancer [77]. The patients here studied clearly constitute
a high-risk group, but there is limited knowledge of effective intervention and treatment strate-
gies to use with these vulnerable patients [4]. An approach that includes both individual
focused and system focused interventions is probably needed, involving both primary and
integrated specialist health care. Further research is needed to pinpoint effective system
focused interventions specifically aiming at reaching the high-risk subgroup with mental ill-
ness. The extremely high mortality risk in young patients highlights the need for such efforts
to be implemented in the younger age groups.
Standardized mortality ratios in schizophrenia and/or substance use disorder
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Strengths and limitations
The major strength of this study is the use of unselected and complete nationwide registry data
of recent date, covering all specialist health care settings, and with no bias associated with
selective self-reporting. The inclusion of outpatients and patients treated solely in somatic hos-
pitals also enabled more generalizable risk estimates. The CDR is found to provide high quality
data on the underlying cause of death [78]. Also, the validity of a schizophrenia diagnosis in
hospital case registries is good when compared to diagnoses based on structured research
interviews [79, 80]. Furthermore, in Norway, treatment of psychosis is mainly a specialist task,
with free admission to hospital treatment and a maximum annual cost of 2205 NOK (approxi-
mately 235 €) for outpatient treatment, implying high coverage for SCZ in the NPR.
The relatively short follow-up is a limitation, which also precluded analysis of secular trends
in SMRs. Another important limitation is the lack of control for unmeasured individual risk
factors associated with mortality. However, studies adjusting for such factors [30, 38, 81] still
revealed an increased mortality after adjustment. The SMRs in the current study may be prone
both to under- and overestimation. We found underestimated SMRs for unnatural causes of
death in SUD patients when the general population, rather than an unexposed population, was
used as reference. Survivor bias in comorbid patients may also have resulted in underestima-
tion, as patients would have to live long enough to receive both diagnoses. On the other hand,
underreporting of less severe SUD in specialized care may have led to overestimated SMRs in
all groups, although a higher detection rate of less severe SUD in comorbid patients (Berkson’s
bias) may be suspected. SCZ and SUD were identified independently of time, ignoring the pos-
sibility that the two diagnoses were not co-occurring. However, supplementary analyses
showed that a majority of comorbid patients had both diagnosed within a year. We were not
able to differentiate between patients with a primary psychotic disorder that co-occurs with
SUD and patients with substance-induced psychosis, although we found indications that
patients with a SUD diagnosis preceding SCZ had worse outcomes. We found a 26% preva-
lence of SUD in SCZ patients during a mean follow-up of four years, which is similar to a pre-
vious Norwegian study [27] SUD diagnoses in the NPR have not been subject to formal
validity checks [80], but a Norwegian validation study found hospital diagnosis of SUD to be
fairly valid, although only 31% classified with SUD by expert opinion was identified in admin-
istrative data [79] Another Nordic study found nearly 50% underreporting of SUD in individ-
uals with schizophrenia in the Danish Psychiatric Register [82]. However, a sensitivity analysis
identifying SUD patients from hospital data only did not change results appreciably in the
study by Hjorthøj et al [30]. We had no information concerning frequency and level of past
and current substance abuse, nor information concerning prescriptions for treatment of SUD.
Finally, this study included only patients in specialized health care, possibly implying higher
mortality than would be found among patients with SCZ and/or SUD in the general popula-
tion. The generalizability of these findings is therefore to specialized care settings with similar
health care systems and socioeconomic features.
Conclusion
Our study demonstrates that patients with SCZ and/or SUD who receives specialized health
care have a substantially elevated risk of premature mortality compared to the general popula-
tion for both natural and unnatural causes of death. The high mortality in these vulnerable
patients, and the differences in causes of death between the subgroups in our study, call for
complex intervention strategies addressing several aspects of prevention, follow-up and treat-
ment at all levels of primary and specialist health care. Young patients and women with SUD
(with or without SCZ) have for unnatural causes particularly high mortality compared to the
Standardized mortality ratios in schizophrenia and/or substance use disorder
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general population. The high proportion of deaths directly linked to poisoning in SUD patients
urgently calls for a more effective societal prevention of SUD-related unnatural deaths.
Disclaimer
Data from the Norwegian Patient Registry have been used in this publication. The interpreta-
tion and reporting of these data are the sole responsibility of the authors, and no endorsement
by the Norwegian Patient Registry is intended nor should be inferred.
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S1 Table. List of somatic diagnosis indicating alcohol abuse or drug abuse. 
ICD-10 code Description 
E24.4 Alcohol-induced pseudo-Cushing syndrome 
E52 Niacin deficiency [pellagra] 
G31.2 Degeneration of nervous system due to alcohol 
G62.1 Alcoholic polyneuropathy 
G72.1 Alcoholic myopathy 
I42.6 Alcoholic cardiomyopathy 
K29.2 Alcoholic gastritis 
K70 Alcoholic liver disease 
K86.0 Alcohol-induced chronic pancreatitis 
O35.4 Maternal care for (suspected) damage to fetus from alcohol 
O35.5 Maternal care for (suspected) damage to fetus by drugs 
Z50.2 Alcohol rehabilitation 
Z50.3 Drug rehabilitation 
Z71.4 Alcohol abuse counselling and surveillance 
Z71.5 Drug abuse counselling and surveillance 
Z72.1 Alcohol use 




S2 Table. Sensitivity-analysis for all-cause age, gender, and calendar-year standardized mortality ratios among men and women aged 20-79 with schizophrenia-
related disorders (SCZ) and/or substance use disorders (SUD). 
    SCZ-only  SUD-only  SCZ+SUD 
    Obs SMR (95 % CI)  Obs SMR (95 % CI)  Obs SMR (95 % CI) 
Men              
 Original model 972 4.5 (4.2-4.8)  7,334 6.4 (6.2-6.5)  423 7.6 (6.9-8.3) 
 (i) Excluding patients in somatic hospitals 678 3.8 (3.5-4.1)  3,419 5.7 (5.5-5.9)  324 7.8 (7.0-8.7) 
 (ii) Primary diagnosis only a 669 3.8 (3.5-4.1)  7,412 6.4 (6.3-6.6)  346 7.3 (6.6-8.2) 
 (iii)  SCZ defined as F20 only 670 5.2 (4.8-5.6)  7,530 6.4 (6.3-6.6)  227 7.9 (7.0-9.0) 
              
Women            
 Original model 832 4.3 (4.0-4.6)  2,592 7.4 (7.1-7.7)  165 7.0 (6.0-8.2) 
 (i) Excluding patients in somatic hospitals 591 3.6 (3.3-4.0)  1,226 6.2 (5.9-6.5)  105 6.5 (5.4-7.9) 
 (ii) Primary diagnosis only a 570 3.6 (3.3-3.9)  2,620 7.4 (7.1-7.7)  137 6.6 (5.6-7.9) 
 (iii)  SCZ defined as F20 only 469 5.0 (4.6-5.5)  2,680 7.3 (7.0-7.6)  77 9.3 (7.4-11.6) 
              
Abbreviations: Obs, observed deaths; SMR, standardized mortality ratio; 95 % CI, 95 % confidence interval; AUD, Alcohol Use Disorder.  




S3 Table. All-cause age, gender, and calendar-year standardized mortality ratios among patients aged 20-79 with schizophrenia-related disorders (SCZ) and a 
concurrent substance use disorder (SUD), according to the temporal ordering of SCZ and SUD diagnosis 
 1 month  3 months  6 months 
 Obs SMR (95 % CI)  Obs SMR (95 % CI)  Obs SMR (95 % CI) 
SCZ preceding SUD diagnosis  189  5.5  (4.8-6.4)  161  5.2  (4.4-6.1)  146  5.3  (4.5-6.2) 
SUD preceding SCZ diagnosis  167  8.4  (7.2-9.8)  145  7.9  (6.7-9.3)  121  7.6  (6.4-9.1) 
Both diagnosis within specified time frame 217  9.8  (8.6-11.2)  267  9.9  (8.8-11.1)  306  8.3  (8.3-10.4) 







Undiagnosed cardiovascular disease prior to
cardiovascular death in individuals with
severe mental illness
Heiberg IH, Jacobsen BK, Balteskard L, Bramness JG, Næss Ø,
Ystrom E, Reichborn-Kjennerud T, Hultman CM, Nesvag R, Høye A.
Undiagnosed cardiovascular disease prior to cardiovascular death in
individuals with severe mental illness.
Objective: To examine whether individuals with schizophrenia (SCZ) or
bipolar disorder (BD) had equal likelihood of not being diagnosed with
cardiovascular disease (CVD) prior to cardiovascular death, compared
to individuals without SCZ or BD.
Methods: Multivariate logistic regression analysis including nationwide
data of 72 451 cardiovascular deaths in the years 2011–2016. Of these,
814 had a SCZ diagnosis and 673 a BD diagnosis in primary or
specialist health care.
Results: Individuals with SCZ were 66% more likely (OR: 1.66; 95%
CI: 1.39–1.98), women with BD were 38% more likely (adjusted OR:
1.38; 95% CI: 1.04–1.82), and men with BD were equally likely (OR:
0.88, 95% CI: 0.63–1.24) not to be diagnosed with CVD prior to
cardiovascular death, compared to individuals without SMI. Almost all
(98%) individuals with SMI and undiagnosed CVD had visited primary
or specialized somatic health care prior to death, compared to 88%
among the other individuals who died of CVD.
Conclusion: Individuals with SCZ and women with BD are more likely
to die due to undiagnosed CVD, despite increased risk of CVD and
many contacts with primary and specialized somatic care. Strengthened
efforts to prevent, recognize, and treat CVD in individuals with SMI
from young age are needed.
I. H. Heiberg1 ,
B. K. Jacobsen1,2,3,
L. Balteskard1, J. G. Bramness4,5,
Ø. Næss6,7, E. Ystrom8,9,10,
T. Reichborn-Kjennerud6,8,
C. M. Hultman11,12,
R. Nesvag5,13, A. Høye1,5,14
Significant outcomes
• In this nationwide study, we found a considerable under diagnosis of cardiovascular disease (CVD)
prior to cardiovascular death in individuals with schizophrenia (SCZ). Similar relationships were found
for women, but not men, with bipolar disorder (BD).
• The higher likelihood of undiagnosed CVD applied to all main types of cardiovascular death and was
particularly pronounced in the youngest.
• Almost all individuals with SMI and undiagnosed CVD prior to cardiovascular death were in contact
with primary or specialized somatic health care in the observation period before death, demonstrating
that opportunities for identification and management of CVD risk factors exist.
Limitations
• Information on antipsychotic medications and history of CVD prior to the study period was lacking.
• As for other studies based on health registries, the diagnostic quality has not been established for all dis-
ease categories.
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Introduction
Individuals with schizophrenia (SCZ) or bipolar
disorder [BD; henceforth referred to as severe men-
tal illness (SMI)] have impaired cardiovascular
health (1, 2). A higher incidence of cardiovascular
disease (CVD) in individuals with SMI has been
documented (3, 4), as well as increased mortality
from CVD compared to the general population (5,
6). Cardiovascular mortality has been reduced by
50% in the general population since 2000 (7), but
remain high among individuals with SMI (8, 9). A
recent study found that Norwegians with SCZ
treated in specialized health care in the period
2009–2015 had a fourfold to fivefold increased risk
of cardiovascular death compared to the general
population (10), which is substantially higher than
the doubled risk reported in earlier studies (11, 12).
Excess cardiovascular mortality in individuals
with SMI is often attributed to socioeconomic dis-
advantage (13), lifestyle factors such as unhealthy
diet, physical inactivity, smoking, and alcohol
abuse (14), and metabolic side-effects of antipsy-
chotic medication (15). It is also a substantial over-
lap between genetic risk for SMI and genetic risk
for type I diabetes, hypertension, cardiac dysrhyth-
mia, and non-rheumatic heart disease (16), indicat-
ing additional frailty for CVD in individuals with
SMI. There is, however, a rising concern that sub-
optimal health care, including underdiagnosis and
treatment delay of CVD, may also contribute to
the elevated cardiovascular mortality among indi-
viduals with SMI (17, 18). Meta-analytic studies
have reported inferior preventive care regarding
CVD risk factors in patients with SMI, compared
to others (19–21). Large population-based cohort
studies have reported lower or similar rates of
recorded CVDs such as atrial fibrillation, hyper-
tension, and ischemic heart disease (IHD) in indi-
viduals with SMI, compared to others (1, 22–24),
in spite of increased risk of CVD. Lower prescrip-
tions rates for cardiovascular medication in indi-
viduals with SMI compared to others have also
been reported (25–27), possibly implying under-
diagnosis and under-treatment of CVD in these
individuals. Furthermore, in a survey of mental
health service users, 39% reported not having dis-
cussed CVD risk factors with healthcare profes-
sionals the previous year (28).
While evidence regarding the prevalence of undi-
agnosed CVD in individuals with SMI is accumu-
lating, mortality from undiagnosed CVD in
individuals with SMI is less studied. Exceptions
include two nationwide Swedish studies, where the
proportion of individuals who died from IHD
undiagnosed 1 month prior to an IHD death was
higher in individuals with SCZ compared to others
(23), but not significantly different between indi-
viduals with or without BD (29). Importantly,
when restricting the analysis to people who were
previously diagnosed with IHD, SCZ was only
modestly associated with higher IHD mortality,
which indicates that premature cardiovascular
deaths in individuals with SMI may be prevented if
CVDs were identified and treated (30–32). To clar-
ify reasons for premature cardiovascular deaths in
individuals with SMI, it is important to investigate
to what extent these individuals are in contact with
and treated in primary or specialized somatic
health care prior to cardiovascular death. SCZ and
BD often have an early onset and a chronic course,
which makes it more likely to assume that the pres-
ence of SMI may have affected the detection and
treatment of CVD in the years, possibly decades,
leading up to a cardiovascular death. We chose not
to merge SCZ and BD into one SMI group, as they
often differ with regard to symptom expression,
socioeconomic background of patients, and health-
care utilization. Previous studies (23, 29, 33) did
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not differentiate between sexes, although sex is
associated with severity of both SMI (34–36) and
CVD (37), and healthcare utilization (38, 39). We
therefore present sex-specific analyses, to facilitate
identification of groups at particularly risk of fatal
undiagnosed CVD.
Aims of the study
We examined whether individuals with and without
schizophrenia or bipolar disorder had equal likeli-
hood of not being diagnosed with cardiovascular
disease prior to cardiovascular death. Secondary
aims were to describe sex-specific differences
between individuals with schizophrenia and bipolar
disorder, and to describe demographic characteris-
tics, comorbidity, and healthcare utilization in
individuals with schizophrenia or bipolar disorder




We obtained mortality data for the period 2011–
2016 from the Norwegian Cause of Death Regis-
try (CDR), and diagnostic data on individuals
with SMI and/or CVD and information on use
of primary and specialized health care from the
Norwegian Directorate of Health’s system for
control and payment of health reimbursements in
primary care (the KUHR database) and the Nor-
wegian Patient Registry (NPR) for the period
2008–2016.
Nearly all healthcare services in Norway are
publicly funded, which ensures representative and
almost complete data in national health registries.
The CDR provides 98% complete information on
causes of death based on standardized certificates
completed by the physician who examined the
deceased (40). The CDR also receives notifications
of autopsy findings and may request supplemen-
tary information from physicians, healthcare insti-
tutions, and clinical registries such as the Medical
Birth Registry and the Cancer Registry. In approx-
imately half of all cases, the underlying cause of
death is determined using automated classification
software (16, 17), which process data according to
the rules of ICD-10, whereas the remaining cases
are set by professional coders (supervised by physi-
cians), based on the death certificate and any sup-
plementary information.
The KUHR database contains information on
consultations in primary care (i.e., visits at general
practitioners’ (GP) offices, home visits by GPs, and
emergency room visits). As GPs are funded mainly
on a fee-for-service basis, the completeness of
reported contacts in the KUHR database is consid-
ered to be almost 100%. The NPR contains infor-
mation on all contacts in specialized health care in
Norway (i.e., government-owned hospitals and
out-patient clinics, publicly financed substance use
treatment facilities, and private health clinics with
governmental reimbursement). Since 2008, the cov-
erage in the NPR has been almost 100%, except for
substance use treatment facilities which were
included from 2009, and private somatic health
clinics with governmental reimbursement, in which
approximately 85% of all contacts were reported in
the study period (41, 42).
Diagnostic codes in the CDR and the NPR fol-
low the International Classification of Diseases
and Related Health Problems, 10th Revision
(ICD-10), whereas diagnostic codes for primary
care contacts in the KUHR database follow the
International Classification of Primary Care 2nd
Edition (ICPC-2). Accurate linkage across data
sources was obtained using an encrypted personal
identification number included in all registries.
Subject inclusion criteria and diagnostic categories
Deceased individuals aged 18 years or older were
included if a diagnosis of CVD (ICD-10 codes I00–
I82) was recorded as underlying cause of death in
the death certificate. The study included deaths in
the years 2011–2016, securing at least 3 years of
observation time in the NPR and the KUHR
database prior to death (as information concerning
healthcare utilization during 2008–2016 was
included).
Cardiovascular causes of death were subdivided
into IHD (I20–I25), other forms of heart disease
(OHD, I30–I52) and cerebrovascular diseases
(I60–I69). IHD was further subdivided into
myocardial infarction (MI, ICD-10 codes I21–I22
and I25.2), and OHD was further subdivided into
heart failure (ICD-10, codes I09.9, I11.0, I13.0,
I13.2, I25.5, I42.0, I42.5–I42.9, I43, and I50) and
arrhythmia (ICD-10, codes I44.1–I44.3, I45.6,
I45.9, and I47–I49). Foreign citizens and individu-
als registered as having died abroad were excluded
(N = 132).
Individuals were included in the SMI group if a
diagnosis of SCZ (ICD-10 code F20 or ICPC-2
code P72) or BD (ICD-10 codes F30–F31 or
ICPC-2 code P73) was recorded in the NPR or the
KUHR database during the years 2008–2016, or in
the death certificate. Individuals diagnosed with




A diagnosis of CVD was considered present if
ICD-10-codes I00–I82 or G45, or corresponding
ICPC-2 diagnoses (codes K70–K71, K74–K80,
K82–K84, K86–K87, and K89–K94) were
recorded in the NPR or the KUHR database in
the period from inclusion (January 1, 2008) and up
to 1 month prior to death. Diagnoses of CVD
recorded only within the last month prior to death
were not counted to avoid including CVDs sec-
ondary to other fatal diseases.
Analysis and statistical methods
Sex, age, and use of primary and specialized
somatic care (the latter including all contacts in
government-owned hospitals, out-patient clinics,
and private health clinics with governmental reim-
bursement with a somatic diagnosis), and comor-
bidity up to 1 month prior to death were used to
assess group comparability. Mean score on the
Charlson comorbidity index (CCI) (43) was used
to describe somatic comorbidity recorded in pri-
mary or specialized somatic care, and was modified
to exclude CVD (i.e., MI, heart failure, peripheral
vascular disease, and cerebrovascular disease),
applying weights from Quan et al. (44). Continu-
ous variables, with the exception of CCI, were pre-
sented as medians with the 25 and 75 percentile
and compared using the Kruskal–Wallis test. Chi-
square tests were used to compare proportions.
Significant results were followed by post hoc tests
with Bonferroni correction for multiple compar-
isons to assess whether there were any differences
between the three groups (45). A two-tailed
P-value < 0.05 was considered statistically signifi-
cant.
We applied the following analytic strategy:
First, the proportion of people who had not been
diagnosed with CVD prior to cardiovascular
death was computed and compared across the
three groups. Second, crude sex-specific odds
ratios (ORs) for not being diagnosed with CVD
prior to cardiovascular death were calculated
using logistic regression and reported with corre-
sponding 95% confidence intervals (CI). Third,
we adjusted for age at death adding a linear vari-
able with six categories (age 18–49, 50–59, 60–69,
70–79, 80–89, and 90 years or above). No linear
interactions between age and diagnostic groups
were found. Sex- and age-stratified ORs were also
calculated, applying age-groups 18–59, 60–79, and
80 years or above. Finally, we included in the
model the modified mean score on the CCI and
recorded substance use disorders (SUD, see diag-
nostic codes in Table S1). Subgroup analyses were
conducted for individuals with IHD, MI, OHD,
or cerebrovascular disease as underlying cause of
death. To test the consistency of study findings,
we also conducted additional analysis to assess
the impact of (i) excluding individuals with
dementia (see codes in Table S1), (ii) excluding
cases with causes of death that should not be con-
sidered underlying causes of death (46), (iii)
including CVD diagnosis during the last month
prior to death, (iv) applying CVD recorded in spe-
cialized somatic care only as dependent variable,
(v) including cases with CVD as contributing
cause of death, and (vi) adjustment for observa-
tion time. All analyses were performed using SAS
statistical software, version 9.4 (SAS Institute
Inc., Cary, NC, USA).
Ethics
All patient data were fully de-identified when
accessed by the investigators. In Norway, studies
with de-identified information from medical health
registries do not require participant consent. Legal
basis and exemption from professional secrecy
requirements for the use of personal health data in
research were granted by the Regional Committee
for Medical and Health Research Ethics (2014/72/
REK nord).
Results
Characteristics of the study population
A total of 72 451 Norwegian citizens aged 18 years
or older who died due to CVD in the period 2011–
2016 were included in the study (Table 1). Of
these, 814 (1.1%) were registered with SCZ and
673 (0.9%) with BD. During the study period,
most individuals with SCZ (55%) had their SCZ
diagnosis recorded in primary care only, while
35% had a SCZ diagnosis recorded in both pri-
mary and specialized health care, 8% in specialized
health care only, and 3% in the CDR only (results
not shown in the tables). Among individuals with
BD, 37% had a BD diagnosis in primary care only,
47% both in primary and specialized health care,
15% in specialized health care only, and 1% in the
CDR only.
Women were in majority in all three groups
(SCZ, BD, and no SMI; Table 1). Men and women
with SMI died 9 and 7 years younger, respectively,
than men and women without SMI. Nearly 75%
of individuals without SMI died at ages 80 years
or above, whereas less than half of individuals with
SMI who died of CVD reached this age. IHD was
the most common cause of cardiovascular death
and accounted for nearly 40% of all deaths in the
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three groups. No significant differences in causes
of cardiovascular deaths were noted across groups.
Men with SCZ had lower frequency of GP visits
and specialized somatic out-patient visits, but simi-
lar frequency of emergency room visits and
somatic admissions, compared to men without
SMI, whereas women with SCZ had higher fre-
quency of emergency room visits, lower frequency
of specialized somatic out-patient visits, but similar
frequency of GP visits and somatic hospital admis-
sions compared to women without SMI (Table 2).
Individuals with BD had higher frequency of both
primary and specialized somatic care compared to
individuals with SCZ, and also higher frequency of
GP visits, emergency room visits, and somatic hos-
pital admissions compared to individuals without
SMI. Individuals with SMI had higher frequency
of SUD compared to individuals without SMI,
and women with SMI also higher prevalence of
diagnosed chronic obstructive pulmonary disease
(COPD) and dementia compared to women with-
out SMI (Table 2).
Undiagnosed CVD prior to cardiovascular death
Twenty-three per cent of individuals with SCZ who
died from CVD had not been diagnosed with CVD
in primary or specialized somatic health care prior
to death, compared to 17% in individuals with BD
and 11% in individuals without SMI (P < 0.0001).
The highest proportion of undiagnosed CVD prior
to cardiovascular death was found in individuals
who died at ages 18–59, of whom 60% of individu-
als with SCZ, 37% of individuals with BD, and
44% of individuals without SMI were undiagnosed
with CVD prior to death (Fig. 1).
Most individuals with diagnosed CVD prior to
death had their CVD diagnosis recorded both in
primary and specialized somatic care, but individu-
als with SCZ least so (74% in individuals with
SCZ, compared to 79% in individuals with BD
and 80% in individuals without SMI, P = 0.012,
results not shown in the tables). A slightly higher
proportion of individuals with SCZ had their CVD
diagnosis recorded only in specialized somatic
health care prior to death (11% in individuals with
SCZ, compared to 9% of individuals with BD, and
6% of individuals without SMI, P = 0.050, results
not shown in tables).
Unadjusted analyses showed that individuals
with SCZ or BD had 132% and 56% higher odds,
respectively, of not being diagnosed with CVD
prior to cardiovascular death, compared to indi-
viduals without SMI (OR 2.32; 95% CI: 1.97–2.74
Table 1. Cardiovascular deaths among individuals with schizophrenia, bipolar disorder, or no severe mental illness who died at ages 18 years or above, according to sex, age,
and cause of death
Schizophrenia Bipolar disorder No severe mental illness P-value Post hoc comparisons
Men
Deaths, n 384 291 33 015
Age at death, mean (SD) 70.9 (14.3) 70.9 (13.0) 79.8 (12.1) <0.0001 SCZ, BD < No SMI
Age 18–59 at death, n (%) 80 (20.8) 57 (19.6) 2330 (7.1) <0.0001 No SMI < SCZ, BD
Age 60–79 at death, n (%) 181 (47.1) 154 (52.9) 10 853 (32.9) <0.0001 No SMI < SCZ, BD
Age ≥ 80 at death, n (%) 123 (32.0) 80 (27.5) 19 832 (60.1) <0.0001 SCZ, BD < No SMI
Underlying cause of death, n (%)
I20–I25 Ischemic heart diseases 175 (45.6) 117 (40.2) 13 969 (42.3) 0.311 –
Myocardial infarction 102 (26.6) 65 (22.3) 8510 (25.8) 0.381 –
I30–I52 Other forms of heart disease 100 (26.0) 68 (23.4) 8422 (25.5) 0.676 –
Heart failure 45 (11.7) 28 (9.6) 3863 (11.7) 0.542 –
Arrhythmia 23 (6.0) 8 (2.7) 1988 (6.0) 0.064 –
I60–I69 Cerebrovascular diseases 70 (18.2) 71 (24.4) 6825 (20.7) 0.128 –
Other cardiovascular diseases† 39 (10.2) 35 (12.0) 3799 (11.5) 0.689 –
Women
Deaths, n 430 382 37 949
Age at death, mean (SD) 80.5 (13.3) 79.3 (12.6) 86.7 (9.5) <0.0001 BD < SCZ < No SMI
Age 18–59 at death, n (%) 42 (9.8) 26 (6.8) 761 (2.0) <0.0001 No SMI < BD < SCZ
Age 60–79 at death, n (%) 117 (27.2) 132 (34.6) 5446 (14.4) <0.0001 No SMI < SCZ < BD
Age ≥ 80 at death, n (%) 271 (63.0) 224 (58.6) 31 742 (83.6) <0.0001 SCZ, BD < NO SMI
Underlying cause of death, n (%)
I20–I25 Ischemic heart diseases 152 (35.3) 135 (35.3) 11 883 (31.3) 0.064 –
Myocardial infarction 92 (21.4) 87 (22.8) 7532 (19.8) 0.310 –
I30–I52 Other forms of heart disease 123 (28.6) 101 (26.4) 12 004 (31.6) 0.040 –
Heart failure 60 (14.0) 58 (15.2) 5797 (15.3) 0.768 –
Arrhythmia 25 (5.8) 14 (3.7) 3162 (8.3) 0.001 BD < No SMI
I60–I69 Cerebrovascular diseases 114 (26.5) 96 (25.1) 9696 (25.6) 0.852 –
Other cardiovascular diseases† 41 (9.5) 50 (13.1) 4366 (11.5) 0.286 –
BD, bipolar disorder; SCZ, schizophrenia; SD, standard deviation; SMI, severe mental illness.
†Other cardiovascular diseases: ICD-10 codes I00–I15, I26–I28, and I70–I82.
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in individuals with SCZ and OR: 1.56; 95% CI:
1.27–1.92 in individuals with BD, results not
shown in tables). After adjustment for age at death
and comorbidities, we found that individuals with
SCZ were 66% more likely (OR: 1.66; 95% CI:
1.39–1.98), women with BD were 38% more likely
(OR: 1.38; 95% CI: 1.04–1.82), and men with BD
were equally likely (OR: 0.88, 95% CI: 0.63–1.24)
not to be diagnosed with CVD prior to cardiovas-
cular death, compared to individuals without SMI
(Fig. 2). Recorded SUD and higher medical
comorbidity were negatively associated with the
odds of undiagnosed CVD (results not shown), but
inclusion of these covariates did not alter results
notably compared to the age-adjusted models
(Table 3).
Subgroup analyses according to cause of death
with adjustment for age at death and comorbidities
showed that individuals with SCZ had higher odds
of not being diagnosed with CVD prior to death
for all main causes of cardiovascular death
(Table 3). Women with SCZ had particularly high
odds of undiagnosed CVD prior to a MI death.
Individuals with BD had similar odds of undiag-
nosed CVD prior to cardiovascular death as indi-
viduals without SMI, except that women with BD
who died from cerebrovascular disease had higher
odds of undiagnosed CVD (Table 3).
The sensitivity analyses (Figure S1) confirmed
the main results; SCZ (in both men and women)
and BD in women were associated with increased
odds of not being diagnosed with CVD prior to
Table 2. Healthcare utilization and comorbidity in individuals with schizophrenia, bipolar disorder, or no severe mental illness who died from CVD at ages 18 years or above,
according to sex
Schizophrenia Bipolar disorder No severe mental illness P-value Post hoc comparisons
Men 384 291 33 015
Patients according to healthcare sector, n (%)
General practitioner 366 (95.3) 290 (99.7) 32 058 (97.1) 0.004 SCZ, No SMI < BD
Emergency room 283 (73.7) 240 (82.5) 23 570 (71.4) 0.000 SCZ, No SMI < BD
Specialized somatic care 337 (87.8) 278 (95.5) 30 880 (93.5) <0.0001 SCZ < BD, No SMI
Specialized mental care 248 (64.6) 200 (68.7) 2840 (8.6) <0.0001 No SMI < SCZ, BD
No healthcare use 5 (1.3) 0 (0.0) 478 (1.4) 0.115 –
No. of healthcare contacts per person-year, median (25/75 percentile)
GP visits 6.3 (3.0–12.3) 9.6 (5.6–15.2) 7.6 (3.9–13.3) <0.0001 SCZ < No SMI < BD
Emergency room visits 0.5 (0.3–1.0) 0.7 (0.3–1.5) 0.5 (0.3–0.9) <0.0001 SCZ, No SMI < BD
Somatic admissions 0.5 (0.2–1.0) 0.7 (0.3–1.2) 0.6 (0.3–1.1) 0.001 SCZ, No SMI < BD
Somatic out-patient visits 1.0 (0.3–2.3) 2.1 (0.8–3.6) 2.0 (0.8–3.9) <0.0001 SCZ < BD, No SMI
Patients with selected comorbidities, n (%)
Diabetes 90 (23.4) 74 (25.4) 7551 (22.9) 0.568 –
COPD 65 (16.9) 65 (22.3) 5775 (17.5) 0.092 –
Substance use disorder 55 (14.3) 72 (24.7) 1846 (5.6) <0.0001 No SMI < SCZ < BD
Dementia 77 (20.1) 66 (22.7) 5901 (17.9) 0.058 –
Modified CCI, mean (SD) 1.11 (1.8) 1.35 (1.8) 1.24 (1.7) 0.017 SCZ < BD, No SMI
No CC groups, n (%) 217 (56.5) 129 (44.3) 15 996 (48.5) 0.003 BD, No SMI < SCZ
≥2 CC groups, n (%) 71 (18.5) 69 (23.7) 7042 (21.3) 0.243 –
Women 430 382 37 949
Patients according to healthcare sector, n (%)
General practitioner 405 (94.2) 375 (98.2) 36 221 (95.4) 0.175 –
Emergency room 338 (88.0) 302 (79.1) 27 983 (84.8) 0.005 –
Specialized somatic care 399 (92.8) 368 (96.3) 35 898 (94.6) 0.082 –
Specialized mental care 251 (58.4) 240 (62.8) 3134 (8.3) <0.0001 No SMI < SCZ, BD
No healthcare use 5 (1.2) 1 (0.3) 579 (1.5) 0.110 –
No. of healthcare contacts per person-year, median (25/75 percentile)
GP visits 6.4 (2.9–12.5) 9.3 (5.0–16.3) 7.1 (3.6–12.4) <0.0001 SCZ, No SMI < BD
Emergency room visits 0.5 (0.3–1.1) 0.6 (0.3–1.1) 0.5 (0.3–0.9) <0.0001 No SMI < SCZ, BD
Somatic admissions 0.5 (0.3–0.9) 0.7 (0.3–1.2) 0.5 (0.3–1.0) 0.000 SCZ, No SMI < BD
Somatic out-patient visits 1.2 (0.5–2.3) 1.5 (0.7–3.1) 1.5 (0.6–2.9) <0.0001 SCZ < No SMI < BD
Patients with selected comorbidities, n (%)
Diabetes 92 (21.4) 82 (21.5) 6902 (18.2) 0.061 –
COPD 78 (18.1) 78 (20.4) 4805 (12.7) <0.0001 No SMI < SCZ, BD
Substance use disorder 17 (4.0) 45 (11.8) 748 (2.0) <0.0001 No SMI < SCZ < BD
Dementia 158 (36.7) 123 (32.2) 10 006 (26.4) <0.0001 No SMI < SCZ, BD
Modified CCI, mean (SD) 1.25 (1.6) 1.37 (1.6) 1.08 (1.5) <0.0001 No SMI < BD
No CC groups, n (%) 204 (47.4) 154 (40.3) 19 518 (51.4) <0.0001 BD < No SMI
≥2 CC groups, n (%) 80 (18.6) 82 (21.5) 6227 (16.4) 0.016 No SMI < BD
BD, bipolar disorder; CC groups, Charlson Comorbidity groups; COPD, chronic obstructive pulmonary disease; GP, general practitioner; Modified CCI, Charlson comorbidity index
modified to exclude CVD (e.g., myocardial infarction, heart failure, peripheral vascular disease, and cerebrovascular disease); SCZ, schizophrenia; SD, standard deviation; SMI,
severe mental illness.
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CVD death, whereas no association was found for
BD in men.
Characteristics of individuals with undiagnosed CVD
Individuals with SMI who died from undiag-
nosed CVD died approximately 10 years younger
than individuals with undiagnosed CVD without
SMI (Table S2). Individuals with SMI and undi-
agnosed CVD had lower likelihood of dying in a
nursing home, and individuals with SCZ and
undiagnosed CVD had a higher likelihood of
death at home, compared to individuals without
SMI. No differences with regard to cause of
death were found between the three groups (re-
sults not shown).
Almost all (98%) individuals with SMI and
undiagnosed CVD had visited primary or special-
ized somatic health care prior to death, compared
to 88% among individuals without SMI (results
not shown in tables). Eighty-eight per cent of
individuals with SCZ and 97% of individuals with
BD had visits in primary care in the observation
period, compared to 78% of individuals without
SMI, and a majority of individuals with SMI had
also been in contact with specialized somatic
health care prior to death (73% of individuals with
SCZ, and 84% in individuals with BD, compared
to 70% of individuals without SMI). Having no
healthcare contacts up to 1 month prior to death
was uncommon in individuals with SMI (5% and
1% in individuals with SCZ or BD, respectively),
while this was the case for 12% of individuals with-
out SMI. Individuals with BD and undiagnosed
CVD prior to death had more GP contacts and
more admissions in specialized somatic care, com-
pared to individuals without SMI who died from
undiagnosed CVD, and individuals with SMI more
emergency room visits (Table S2).
Compared to individuals with SMI and diag-
nosed CVD prior to death, individuals with SMI
and undiagnosed CVD prior to death died
Fig. 1. Proportion of individuals with
schizophrenia, bipolar disorder, and no
severe mental illness (no SMI) who
were undiagnosed with cardiovascular
disease up to one month prior to
cardiovascular death, according to




younger, more often at home (SCZ only), less
often in a nursing home, more often at places out-
side home and healthcare institutions (BD only),
and more often from IHD (SCZ only) (Table S2).
They also had fewer healthcare contacts in primary
care, fewer admissions and out-patient visits in
specialized somatic care prior to death, and more
recorded SUD than individuals with SMI and
diagnosed CVD.
Discussion
In this study based on the entire Norwegian popu-
lation, we found that men and women with SCZ
and women with BD were more likely to be undi-
agnosed with CVD prior to cardiovascular death,
even though most had been in contact with pri-
mary or specialized somatic care prior to death.
The higher odds of undiagnosed CVD applied to
all main causes of cardiovascular death and was
most pronounced in the youngest.
The higher level of undiagnosed CVD prior to
cardiovascular death in individuals with SCZ is in
accordance with earlier studies reporting doubled
risk of unforeseen death in individuals with SCZ,
CVD being the most common cause (33), and also
in accordance with studies reporting a decreased
likelihood in individuals with SCZ of being diag-
nosed with somatic illness in the early courses of
diseases (24, 47). It is also in accordance with a
Swedish registry study, in which the proportion of
individuals who died from IHD undiagnosed up to
1 month prior to an IHD death was higher in indi-
viduals with SCZ, compared to individuals without
SCZ (23). Our study extends these earlier findings
by documenting that the higher likelihood of undi-
agnosed CVD prior to death in individuals with
SCZ may be related to the low age at death, and
by documenting that the higher likelihood of undi-
agnosed CVD prior to death in individuals with
SCZ applies to all main causes of cardiovascular
death and is particularly pronounced for deaths
from MI in women with SCZ. Our finding of simi-
lar odds of undiagnosed CVD prior to an IHD
death in individuals with BD is also in accordance
with earlier findings (29), but the increased odds of
undiagnosed CVD prior to a cerebrovascular
death in women with BD is a novel finding. Earlier
studies have found an increased incidence of vascu-
lar disease in women with BD, but not in men with
BD (48, 49). An increased risk of adverse illness
course in women with BD has been reported (34)
and may also contribute to this finding. We also
observed higher levels of somatic out-patient visits
in men with BD, including a higher level of somatic
out-patient visits with a CVD diagnosis
(P = 0.001, results not shown), indicating
increased healthcare seeking and/or increased
referral rates to specialized somatic care in men
with BD, compared to women with BD. The find-
ing may not be a stable finding, however, and
should be replicated in independent studies.
We do not assume that cardiovascular deaths
always can be prevented, as they may result from
sudden and unpredictable events such as MI and
stroke. Nevertheless, differences between groups
found for the same causes of death in our study
suggest that other mechanisms are also at work,
Fig. 2. Adjusted odds ratios with 95%
upper (UCL) and lower (UCL)
confidence limits for not being
diagnosed with cardiovascular disease
prior to cardiovascular death in
individuals with schizophrenia or
bipolar disorder, according to sex and
age-group.
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both at individual, provider, and system level. Cur-
rent risk prediction algorithms for CVD have been
shown to underestimate the risk in individuals with
SCZ, particularly in younger men (50), and may
likely lead to lower detection rates in individuals
with SCZ compared to others. Also, unclear
responsibility with regard to physical health exami-
nation in patients with SMI (51), complexity of
care and misinterpretation of physical complaints
as psychosomatic symptoms (52), as well as
separation between primary and secondary health
care and between somatic and psychiatric health
care, may contribute to underdiagnosis. General
stigma toward people with SMI (53), particularly
those with comorbid SUD, has also been reported
(54), although our results showed a negative asso-
ciation between recorded SUD and undiagnosed
CVD. Given the overlap in genetic risk factors for
SMI and CVD (16), it could be that individuals
with SMI are more susceptible to CVD. Genetic
risk for a severe outcome would under other cir-
cumstances imply an increased alertness in clini-
cians. Under these assumptions, reduced access to
screening and treatment would have a dispropor-
tionate effect in the SMI population.
The ability to recognize somatic symptoms and
seek timely somatic care may be impaired in indi-
viduals with SMI due to negative symptoms, cog-
nitive impairment, and social isolation. Increased
pain tolerance (55), as well as increased risk of
silent CVD (56) not associated with traditional
cardiovascular risk factors (57), has also been
reported in individuals with SCZ, possibly affect-
ing healthcare seeking. Reduced or delayed health-
care seeking has been reported earlier for older
non-affective psychotic patients, especially regard-
ing CVD (58).
In our study, undiagnosed CVD was associated
with young age at death. Individuals with SCZ
have increased the prevalence of risk factors for
early cardiovascular mortality (59) and are at
increased risk of dying at ages when healthcare
providers may not usually suspect CVD. There is
also a possibility that younger patients are pre-
scribed higher doses of antipsychotic medicine due
to more severe symptoms at an early stage in the
disease course and hence are at higher risk of
adverse cardiac effects such as arrhythmias, devia-
tions in blood pressure, heart failure, myocarditis,
and sudden death (60–65). Both typical and atypi-
cal antipsychotic medication have been associated
with sudden cardiac death (66, 67), through mech-
anisms such as QTc interval lengthening (68), pos-
sibly leading to fatal arrhythmias, and myocarditis
and cardiomyopathy associated with clozapine use
(69). The possibility of more lethal, or faster pro-
gressing, CVD in individuals with SMI may also
influence the odds for not having CVD diagnosed
prior to cardiovascular death.
Strengths and limitations
The main strength of this study is the use of unse-
lected, complete nationwide data on all individuals
who died of CVD during a 6-year period, includ-
ing complete diagnostic data from both primary
Table 3. Subgroup analyses showing odds ratios with 95% confidence intervals for
not being diagnosed with CVD prior to cardiovascular death, according to sex,







OR (95% CI)§ OR (95% CI)§ OR (95% CI)§
Both genders
Ischemic heart disease
Schizophrenia 2.40 (1.87–3.07) 1.64 (1.26–2.12) 1.70 (1.30–2.22)
Bipolar disorder 1.23 (0.88–1.73) 0.84 (0.59–1.19) 0.92 (0.64–1.31)
Myocardial infarction
Schizophrenia 2.49 (1.83–3.39) 1.85 (1.33–2.56) 1.99 (1.42–2.78)
Bipolar disorder 1.37 (0.92–2.05) 1.05 (0.69–1.60) 1.14 (0.74–1.74)
Other forms of heart disease (I30–I52)
Schizophrenia 2.69 (1.91–3.79) 1.82 (1.27–2.61) 1.85 (1.28–2.67)
Bipolar disorder 1.67 (1.06–2.65) 1.00 (0.62–1.61) 1.08 (0.67–1.76)
Cerebrovascular
Schizophrenia 1.77 (1.23–2.54) 1.43 (0.99–2.06) 1.47 (1.01–2.13)
Bipolar disorder 1.74 (1.19–2.54) 1.38 (0.93–2.03) 1.45 (0.98–2.15)
Men
Ischemic heart disease
Schizophrenia 2.40 (1.72–3.34) 1.42 (0.99–2.03) 1.47 (1.02–2.11)
Bipolar disorder 1.24 (0.76–2.00) 0.70 (0.42–1.16) 0.78 (0.47–1.31)
Myocardial infarction
Schizophrenia 2.00 (1.30–3.09) 1.40 (0.87–2.23) 1.48 (0.92–2.38)
Bipolar disorder 1.65 (0.93–2.90) 1.09 (0.60–2.00) 1.20 (0.65–2.21)
Other forms of heart disease (I30–I52)
Schizophrenia 3.20 (1.95–5.26) 1.73 (0.99–3.02) 1.73 (0.98–3.06)
Bipolar disorder 1.95 (0.96–3.96) 0.90 (0.43–1.90) 0.98 (0.46–2.09)
Cerebrovascular
Schizophrenia 2.78 (1.62–4.78) 1.80 (1.02–3.16) 1.75 (0.99–3.09)
Bipolar disorder 1.32 (0.67–2.58) 0.91 (0.45–1.81) 0.96 (0.47–1.92)
Women
Ischemic heart disease
Schizophrenia 2.41 (1.67–3.50) 1.85 (1.26–2.72) 1.91 (1.29–2.83)
Bipolar disorder 1.26 (0.78–2.03) 0.94 (0.58–1.53) 0.99 (0.61–1.62)
Myocardial infarction
Schizophrenia 3.19 (2.06–4.93) 2.47 (1.57–3.89) 2.68 (1.68–4.27)
Bipolar disorder 1.20 (0.68–2.14) 0.97 (0.54–1.74) 1.03 (0.57–1.86)
Other forms of heart disease (I30–I52)
Schizophrenia 2.34 (1.46–3.76) 1.82 (1.12–2.96) 1.85 (1.13–3.03)
Bipolar disorder 1.50 (0.82–2.76) 1.06 (0.57–1.96) 1.14 (0.61–2.14)
Cerebrovascular
Schizophrenia 1.30 (0.80–2.11) 1.13 (0.69–1.85) 1.23 (0.75–2.03)
Bipolar disorder 2.04 (1.28–3.24) 1.68 (1.05–2.71) 1.77 (1.09–2.87)
CI, confidence interval; OR, odds ratio; SUD, substance use disorder.
†Adjusted for age-group at death (categories 18–49, 50–59, 60–69, 70–79, 80–89,
and 90 and above).
‡Adjusted for age-group at death (see note †), SUD, and comorbidities (modified
Charlson Index).
§Bold figures: Significant association at P-value < 0.05.
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and specialized health care, and individuals with-
out any healthcare contacts in the observation per-
iod prior to death. However, some limitations
need attention. First, we had no information con-
cerning history of CVD prior to the study period.
Stable, long-term and currently untreated CVDs
may thus have led to misclassification of undiag-
nosed CVD in this study. As individuals with SMI
have higher lethality from CVD (70–72), our find-
ings probably underestimate the real difference
between individuals with and without SMI. It
could be, however, that people with SMI to a lar-
ger extent live with, for example, untreated valve
insufficiency, which is not treated due to con-
traindications to major surgery (such as smoking),
although newer, less invasive techniques may have
reduced this potential disparity. We did not have
information on prescription of cardiovascular
medication, but it is unlikely that such prescrip-
tions would not be accompanied by a CVD diag-
nosis in primary care.
Second, we lacked information on antipsychotic
prescriptions, which made us unable to study the
association between antipsychotic medication and
sudden cardiac death. We observed, however, a
similar (SCZ) or lower (BD) likelihood of fatal
arrhythmias in individuals with SMI, compared to
individuals without SMI.
Third, we had no information on the severity of
CVD. However, as the study included only
deceased individuals, control for differences in
medical need may be approximated by the fact that
they all died from the same underlying causes of
death. Also, studies of undiagnosed MI in the gen-
eral population (73) and in individuals with SMI
(71) have reported similar demographic character-
istics, similar coronary risk profiles, and similar
mortality among persons with diagnosed and pre-
viously undiagnosed MI.
Fourth, the validity of diagnoses is a concern
when using administrative registry data. Previous
studies have found high agreement between DSM-
IV diagnosis and clinical diagnoses of SMI in the
NPR (74), and valid information regarding stroke
(75). Also, in other Nordic registries, the validity
of cardiovascular diagnoses in general (76, 77),
atrial fibrillation and atrial flutter (78), and intrac-
erebral hemorrhage (79) have been found to be
high, whereas the validity of heart failure diag-
noses (80) and peripheral arterial disease diagnoses
(81) may be questionable. The accuracy of diag-
noses in the KUHR database has not yet been
established. According to Statistics Norway, about
0.3% of main diagnoses set by the GP in the
KUHR database in 2015 were assumed to have an
incorrect diagnostic code (82), and the validity of
diagnostic coding in general practice registries in
other countries has been found good, particularly
for chronic diseases (83). We included persons with
a diagnosis of affective disorder (ICPC-2 code P73)
in the BD group, which may have led to an inclu-
sion of individuals with severe depression but not
BD.
The CDR is found to provide high-quality infor-
mation on causes of death (84). Autopsy is consid-
ered as the gold standard for determination of
causes of death, but is infrequently undertaken in
Norway. During the period 2008–2013, the pro-
portion of autopsies in Norway remained stable at
7.5%, equally distributed between medical and
forensic autopsies (85). A Norwegian study from
2011 reported very good agreement between
autopsy findings and mortality statistics for both
stroke and coronary heart disease in the CDR (86).
An earlier Norwegian study investigating to what
extent underlying cause of death based on the
death certificate was changed when taking into
account autopsy results, found a substantial (17%)
underreporting of cardiovascular deaths, particu-
larly in the young and old, and in women (87). The
decision to perform an autopsy is, however, not
made at random, and findings from such studies
may therefore not be directly transferable to other
cases. The most common error is that immediate
or intermediate causes of death are registered as
the underlying cause of death (88). We found,
however, similar results when we included all
deaths with CVD as underlying or contributing
cause of death, as shown in the sensitivity analysis.
We had no data on sudden death (ICD-10 code
R98), possibly implying underestimated cardiovas-
cular deaths. However, only about 2% of underly-
ing causes of death in Norway in the years 2011–
2016 were assigned to unknown or unspecified
causes (R96–R99) (7). Longer postmortem time
before discovery in individuals with SCZ com-
pared to others has also been reported (89), possi-
bly affecting the reliability of cause of death codes
in individuals with SCZ.
Fifth, although it is possible to enter at least
three diagnoses per primary care contact, 85% of
these encounters had only one recorded diagnosis,
both in individuals with and without SMI. There is
therefore a possibility that only the SMI diagnosis
was recorded, even if CVD may have been the sub-
ject of the consultation. However, among individu-
als with SMI, only 17% of the primary healthcare
encounters included a SMI diagnosis, so it seems
reasonable to assume that any recognized CVD
would be recorded at some point in the observa-
tion period. Also, analysis with recorded CVD in
specialized health care only as dependent variable
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gave similar results, as shown in the sensitivity
analysis.
Furthermore, individuals with SMI have a sub-
stantially increased risk of premature death from
suicides and accidents, particularly in the youngest
age-groups (10, 90). As persons with SMI included
in our study must have lived long enough to
develop CVD, this may have introduced survivor
bias. Substance abuse and low socioeconomic sta-
tus, which are associated with increased risk of
accidental death, and also increased CVD risk,
were, however, not associated with increased risk
of undiagnosed IHD (23, 29) or increased risk of
unforeseen death (33) in earlier studies.
Finally, the findings are representative of indi-
viduals with severe CVD in countries with publicly
funded and readily available health services for
both somatic and mental disorders.
Clinical implications
Persons with SMI constitute a subgroup at partic-
ularly high risk of early and severe CVD (50). In
our study, almost all individuals with SMI with
undiagnosed CVD prior to cardiovascular death
utilized primary or specialized somatic care in the
observation period preceding death, showing that
opportunities for identification and management
of cardiovascular disease exist. Hence, a diagnosis
of SCZ or BD should act as a trigger for enhanced
screening for CVD among the youngest patients,
and antipsychotic medicine in younger patient
groups should be carefully selected in order to min-
imize cardiovascular risk. Furthermore, there is a
need to define more accurately the responsibility
for maintaining follow-up and treatment of CVD
risk factors and early CVD in patients with SMI.
Albeit death from undiagnosed CVD cannot
always be prevented, the results from our study
indicate that improved health care at a structural
level should be specifically directed toward
younger patients. Improved recognition, monitor-
ing, and treatment of individual CVD risk factors
should be stressed. Further research is strongly
needed, to investigate age-differentiated risk fac-
tors and interventions both at the system level and
at the individual level.
Acknowledgements
This study was supported by a research grant from the North-




1. Kilbourne AM, Morden NE, Austin K et al. Excess heart-
disease-related mortality in a national study of patients
with mental disorders: identifying modifiable risk factors.
Gen Hosp Psychiatry 2009;31:555–563.
2. Foguet-Boreu Q, Fernandez San Martin MI, Flores Mateo
G et al. Cardiovascular risk assessment in patients with a
severe mental illness: a systematic review and meta-analy-
sis. BMC Psychiatry, 2016;16:141.
3. Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the
risk of cardiovascular diseases: a meta-analysis of thir-
teen cohort studies. J Psychiatr Res 2013;47:1549–
1556.
4. Prieto ML, Cuellar-Barboza AB, Bobo WV et al. Risk of
myocardial infarction and stroke in bipolar disorder: a sys-
tematic review and exploratory meta-analysis. Acta Psy-
chiatr Scand 2014;130:342–353.
5. Westman J, H€allgren J, Wahlbeck K, Erlinge D, Alfreds-
son L, Osby U. Cardiovascular mortality in bipolar disor-
der: a population-based cohort study in Sweden. BMJ
Open 2013;3:e002373.
6. Hjorthøj C, St€urup AE, McGrath JJ, Nordentoft M. Years
of potential life lost and life expectancy in schizophrenia: a
systematic review and meta-analysis. Lancet Psychiatry
2017;4:295–301.
7. Norwegian Institute of Public Health. Dødsarsaker,
nøkkeltall (LHF)  per 100 000, standardisert [Causes of
death, key figures (LHF) – per 100,000, standardized].
2018 [January 15, 2019]; Available from: http://www.
norgeshelsa.no/norgeshelsa/
8. Laursen TM, Nordentoft M. Heart disease treatment and
mortality in schizophrenia and bipolar disorder – changes
in the Danish population between 1994 and 2006. J Psychi-
atr Res 2011;45:29–35.
9. €Osby U, Westman J, H€allgren J, Gissler M. Mortality
trends in cardiovascular causes in schizophrenia, bipolar
and unipolar mood disorder in Sweden 1987–2010. Eur J
Public Health 2016;26:867–871.
10. Heiberg IH, Jacobsen BK, Nesvag R et al. Total and cause-
specific standardized mortality ratios in patients with
schizophrenia and/or substance use disorder. PLoS One
2018;13:e0202028.
11. Hansen V, Jacobsen BK, Arnesen E. Cause-specific mortal-
ity in psychiatric patients after deinstitutionalisation. Br J
Psychiatry 2001;179:438–443.
12. Høye A, Jacobsen BK, Hansen V. Increasing mortality in
schizophrenia: are women at particular risk? A follow-up
of 1111 patients admitted during 1980–2006 in Northern
Norway. Schizophr Res 2011;132:228–232.
13. Manrique-Garcia E, Sidorchuk A, Hallqvist J, Moradi T.
Socioeconomic position and incidence of acute myocardial
infarction: a meta-analysis. J Epidemiol Community
Health 2011;65:301–309.
14. von Hausswolff-Juhlin Y, Bjartveit M, Lindstr€om E, Jones
P. Schizophrenia and physical health problems. Acta Psy-
chiatr Scand Suppl 2009;000:15–21.
15. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH,
Annamalai A. Antipsychotic-induced weight gain in first-
episode psychosis patients: a meta-analysis of differential
effects of antipsychotic medications. Early Interv Psychia-
try 2016;10:193–202.
16. Wang K, Gaitsch H, Poon H, Cox NJ, Rzhetsky A. Classifi-
cation of common human diseases derived from shared




17. Druss BG, Bradford WD, Rosenheck RA, Radford MJ,
Krumholz HM. Quality of medical care and excess mortal-
ity in older patients with mental disorders. Arch Gen Psy-
chiatry 2001;58:565–572.
18. Mitchell AJ, Lord O. Do deficits in cardiac care influence
high mortality rates in schizophrenia? A systematic review
and pooled analysis. J Psychopharmacol 2010;24(4
Suppl):69–80.
19. Lord O, Malone D, Mitchell AJ. Receipt of preventive
medical care and medical screening for patients with men-
tal illness: a comparative analysis. Gen Hosp Psychiatry
2010;32:519–543.
20. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De
Hert M. Guideline concordant monitoring of metabolic
risk in people treated with antipsychotic medication: sys-
tematic review and meta-analysis of screening practices.
Psychol Med 2012;42:125–147.
21. Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S.
Hypertension risk and clinical care in patients with bipolar
disorder or schizophrenia; a systematic review and meta-
analysis. J Affect Disord 2017;225:665–670.
22. Gabilondo A, Alonso-Moran E, Nu~no-Solinis R, Orueta JF,
Iruin A. Comorbidities with chronic physical conditions
and gender profiles of illness in schizophrenia. Results
from PREST, a new health dataset. J Psychosom Res,
2017;93:102–109.
23. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comor-
bidities and mortality in persons with schizophrenia: a
Swedish national cohort study. Am J Psychiatry
2013;170:324–333.
24. MuNk-Jørgensen P, Mors O, Mortensen PB, Ewald H. The
schizophrenic patient in the somatic hospital. Acta Psychi-
atr Scand Suppl 2000;102:96–99.
25. Lahti M, Tiihonen J, Wildgust H et al. Cardiovascular
morbidity, mortality and pharmacotherapy in
patients with schizophrenia. Psychol Med 2012;42:
2275–2285.
26. Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse
C. Cardiovascular drug use and mortality in patients with
schizophrenia or bipolar disorder: a Danish population-
based study. Psychol Med 2014;44:1625–1637.
27. Skrede S, Tvete IF, Tanum L, Steen VM, Bramness JG.
Incident users of antipsychotic agents and future use of
cholesterol-lowering drugs: an observational, pharma-
coepidemiologic study. J Clin Psychiatry 2015;76:e111–
e116.
28. Pitman AL, Osborn DP, Wright CA, Nazareth I, King MB.
Cardiovascular screening of people with severe mental ill-
ness in England: views of service users and providers. Psy-
chiatr Serv 2011;62:1338–1345.
29. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comor-
bidities and mortality in bipolar disorder: a Swedish
national cohort study. JAMA Psychiatry 2013;70:931–
939.
30. World Health Organization. Prevention of cardiovascular
disease: guidelines for assessment and management of
total cardiovascular risk. Geneva, Switzerland: World
Health Organization, 2007.
31. Cohn JN, Hoke L, Whitwam W et al. Screening for early
detection of cardiovascular disease in asymptomatic indi-
viduals. Am Heart J 2003;146:679–685.
32. Newby DE, Adamson PD, Berry C et al. Coronary CT
angiography and 5-year risk of myocardial infarction. N
Engl J Med 2018;379:924–933.
33. Copeland LA, Zeber JE, Rosenheck RA, Miller AL.
Unforeseen inpatient mortality among veterans with
schizophrenia. Med Care 2006;44:110–116.
34. Erol A, Winham SJ, McElroy SL et al. Sex differences in
the risk of rapid cycling and other indicators of adverse ill-
ness course in patients with bipolar I and II disorder.
Bipolar Disord 2015;17:670–676.
35. Petkari E, Mayoral F, Moreno-Kustner B. Gender matters
in schizophrenia-spectrum disorders: results from a health-
care users epidemiological study in Malaga, Spain. Compr
Psychiatry 2017;72:136–143.
36. Abel KM, Drake R, Goldstein JM. Sex differences in
schizophrenia. Int Rev Psychiatry 2010;22:417–428.
37. Phan HT, Blizzard CL, Reeves MJ et al. Sex differences in
long-term mortality after stroke in the INSTRUCT
(INternational STRoke oUtComes sTudy): a meta-analy-
sis of individual participant data. Circ Cardiovasc Qual
Outcomes 2017;10:e003436.
38. Campi TR Jr, George S, Villacıs D, Ward-Peterson M,
Barengo NC, Zevallos JC. Effect of charted mental illness
on reperfusion therapy in hospitalized patients with an
acute myocardial infarction in Florida. Medicine (Balti-
more) 2017;96:e7788.
39. Kontopantelis E, Olier I, Planner C et al. Primary care
consultation rates among people with and without severe
mental illness: a UK cohort study using the Clinical Prac-
tice Research Datalink. BMJ Open 2015;5:e008650.
40. Pedersen AG, Ellingsen CL. Data quality in the causes of
death registry. Tidsskr Nor Laegeforen 2015;135:768–770.
41. Helsedirektoratet [The Norwegian Directorate of Health].
Aktivitetsdata for avtalespesialister 2009 [Data on activities




42. L€utzen J, Fuglset AS, Dahlstrøm I. Aktivitetsdata for
avtalespesialister 2015 [Data on activities by specialists in
private practice 2015]. Oslo: Helsedirektoratet [The Nor-
wegian Directorate of Health], 2015.
43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new
method of classifying prognostic comorbidity in longitudi-
nal studies: development and validation. J Chronic Dis
1987;40:373–383.
44. Quan H, Li B, Couris CM et al. Updating and validating
the Charlson comorbidity index and score for risk adjust-
ment in hospital discharge abstracts using data from 6
countries. Am J Epidemiol 2011;173:676–682.
45. Elliott AC, Hynan LS. A SAS macro implementation of a
multiple comparison post hoc test for a Kruskal–Wallis anal-
ysis. Comput Methods Programs Biomed 2011;102:75–80.
46. GBD 2013 Mortality and Causes of Death Collaborators.
Global, regional, and national age-sex specific all-cause
and cause-specific mortality for 240 causes of death, 1990–
2013: a systematic analysis for the Global Burden of Dis-
ease Study 2013. Lancet, 2015;385:117–171.
47. Oud MJ, Meyboom-de Jong B. Somatic diseases in patients
with schizophrenia in general practice: their prevalence
and health care. BMC Fam Pract, 2009;10:32.
48. Fiedorowicz JG, He J, Merikangas KR. The association
between mood and anxiety disorders with vascular dis-
eases and risk factors in a nationally representative sam-
ple. J Psychosom Res 2011;70:145–154.
49. Swain NR, Lim CC, Levinson D et al. Associations between
DSM-IV mental disorders and subsequent non-fatal, self-
reported stroke. J Psychosom Res 2015;79:130–136.
50. McLean G, Martin JL, Martin DJ, Guthrie B, Mercer SW,
Smith DJ. Standard cardiovascular disease risk algorithms
underestimate the risk of cardiovascular disease in
schizophrenia: evidence from a national primary care
database. Schizophr Res 2014;159:176–181.
569
Severe mental illness and fatal undiagnosed CVD
51. De Hert M, Cohen D, Bobes J et al. Physical illness in
patients with severe mental disorders. II. Barriers to care,
monitoring and treatment guidelines, plus recommenda-
tions at the system and individual level. World Psychiatry,
2011;10:138–151.
52. Jones S, Howard L, Thornicroft G. ‘Diagnostic overshad-
owing’: worse physical health care for people with mental
illness. Acta Psychiatr Scand 2008;118:169–171.
53. Harangozo J, Reneses B, Brohan E et al. Stigma and dis-
crimination against people with schizophrenia related to
medical services. Int J Soc Psychiatry 2014;60:359–366.
54. Schomerus G, Lucht M, Holzinger A, Matschinger H,
Carta MG, Angermeyer MC. The stigma of alcohol depen-
dence compared with other mental disorders: a review of
population studies. Alcohol Alcohol 2011;46:105–112.
55. Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaugh-
ran F, Correll CU. Decreased pain sensitivity among peo-
ple with schizophrenia: a meta-analysis of experimental
pain induction studies. Pain 2015;156:2121–2131.
56. Nielsen J, Juel J, Alzuhairi KS et al. Unrecognised
myocardial infarction in patients with schizophrenia. Acta
Neuropsychiatr 2015;27:106–112.
57. Weir-McCall JR, Fitzgerald K, Papagiorcopulo CJ et al.
Prevalence of unrecognized myocardial infarction in a
low-intermediate risk asymptomatic cohort and its rela-
tion to systemic atherosclerosis. Eur Heart J Cardiovasc
Imaging 2017;18:657–662.
58. Swildens W, Termorshuizen F, de Ridder A, Smeets H,
Engelhard IM. Somatic care with a psychotic disorder.
lower somatic health care utilization of patients with a
psychotic disorder compared to other patient groups and
to controls without a psychiatric diagnosis. Adm Policy
Ment Health, 2016;43:650–662.
59. Chung KH, Chen PH, Kuo CJ, Tsai SY, Huang SH, Wu
WC. Risk factors for early circulatory mortality in patients
with schizophrenia. Psychiatry Res 2018;267:7–11.
60. Straus SM, Bleumink GS, Dieleman JP et al. Antipsy-
chotics and the risk of sudden cardiac death. Arch Intern
Med 2004;164:1293–1297.
61. Ray WA, Chung CP, Murray KT, Hall K, Stein CM.
Atypical antipsychotic drugs and the risk of sudden car-
diac death. N Engl J Med 2009;360:225–235.
62. Ifteni P, Correll CU, Burtea V, Kane JM, Manu P. Sudden
unexpected death in schizophrenia: autopsy findings in
psychiatric inpatients. Schizophr Res 2014;155:72–76.
63. Hou PY, Hung GC, Jhong JR, Tsai SY, Chen CC, Kuo CJ.
Risk factors for sudden cardiac death among patients with
schizophrenia. Schizophr Res 2015;168:395–401.
64. Khasawneh FT, Shankar GS. Minimizing cardiovascular
adverse effects of atypical antipsychotic drugs in patients
with schizophrenia. Cardiol Res Pract 2014;2014:273060.
65. Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al.
Antipsychotic treatment and mortality in schizophrenia.
Schizophr Bull 2015;41:656–663.
66. Honkola J, Hookana E, Malinen S et al. Psychotropic
medications and the risk of sudden cardiac death dur-
ing an acute coronary event. Eur Heart J
2012;33:745–751.
67. Li KJ, Greenstein AP, Delisi LE. Sudden death in
schizophrenia. Curr Opin Psychiatry 2018;31:169–175.
68. Zhai D, Lang Y, Dong G et al. QTc interval lengthening in
first-episode schizophrenia (FES) patients in the earliest
stages of antipsychotic treatment. Schizophr Res
2017;179:70–74.
69. Khan AA, Ashraf A, Baker D et al. Clozapine and inci-
dence of myocarditis and sudden death – Long term Aus-
tralian experience. Int J Cardiol 2017;238:136–139.
70. Kugathasan P, Laursen TM, Grøntved S, Jensen SE,
Aagaard J, Nielsen RE. Increased long-term mortality
after myocardial infarction in patients with schizophrenia.
Schizophr Res 2018;199:103–108.
71. Boden R, Molin E, Jernberg T, Kieler H, Lindahl B, Sund-
str€om J. Higher mortality after myocardial infarction in
patients with severe mental illness: a nationwide cohort
study. J Intern Med 2015;277:727–736.
72. Prior A, Laursen TM, Larsen KK et al. Post-stroke mor-
tality, stroke severity, and preadmission antipsychotic
medicine use–a population-based cohort study. PLoS One
2014;9:e84103.
73. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized
myocardial infarction. Ann Intern Med 2001;135:801–811.
74. Nesvag R, J€onsson EG, Bakken IJ et al. The quality of sev-
ere mental disorder diagnoses in a national health registry
as compared to research diagnoses based on structured
interview. BMC Psychiatry 2017;17:93.
75. Varmdal T, Bakken IJ, Janszky I et al. Comparison of the
validity of stroke diagnoses in a medical quality register
and an administrative health register. Scand J Public
Health 2016;44:143–149.
76. Sundbøll J, Adelborg K, Munch T et al. Positive predictive
value of cardiovascular diagnoses in the Danish National
Patient Registry: a validation study. BMJ Open 2016;6:
e012832.
77. Pajunen P, Koukkunen H, Ketonen M et al. The validity of
the Finnish Hospital Discharge Register and Causes of
Death Register data on coronary heart disease. Eur J Car-
diovasc Prev Rehabil 2005;12:132–137.
78. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Sch-
midt EB, Joensen AM. Validity of the diagnoses atrial fib-
rillation and atrial flutter in a Danish patient registry.
Scand Cardiovasc J 2012;46:149–153.
79. Hald SM, Kring Sloth C, Hey SM et al. Intracerebral hem-
orrhage: positive predictive value of diagnosis codes in
two nationwide Danish registries. Clin Epidemiol
2018;10:941–948.
80. Delekta J, Hansen SM, AlZuhairi KS, Bork CS, Joensen
AM. The validity of the diagnosis of heart failure (I50.0–
I50.9) in the Danish National Patient Register. Dan Med
J, 2018;65:A5470.
81. Lasota AN, Overvad K, Eriksen HH, Tjønneland A, Sch-
midt EB, Grønholdt MM. Validity of peripheral arterial
disease diagnoses in the danish national patient registry.
Eur J Vasc Endovasc Surg 2017;53:679–685.
82. Statistics Norway. Allmennlegetjenesten, 2015 [Public
Health Services, 2015], 2015 [June 24th, 2018]; Available
from: https://www.ssb.no/helse/statistikker/fastlegetj/aar/
2016-06-08?fane=om
83. Khan NF, Harrison SE, Rose PW. Validity of diagnostic
coding within the General Practice Research Database:
a systematic review. Br J Gen Pract 2010;60:e128–
e136.
84. Phillips DE, Lozano R, Naghavi M et al. A composite met-
ric for assessing data on mortality and causes of death: the
vital statistics performance index. Popul Health Metr
2014;12:14.
85. Folkehelseinstituttet [The Norwegian Institute of Public
Health]. Legemeldinger om dødsfall er grunnlaget for
dødsarsaksstatistikken [Medical reports on deaths are the
basis for the cause of death statistics]. 2015, 25.03.2015
[cited 2019 January 22, 2019]; Available from: https://
www.fhi.no/hn/helseregistre-og-registre/dodsarsaksregiste
ret/legemeldinger-om-dodsfall/.
86. Gulsvik AK, Gulsvik A, Svendsen E, Mæhle BO, Thelle
DS, Wyller TB. Diagnostic validity of fatal cerebral
570
Heiberg et al.
strokes and coronary deaths in mortality statistics: an
autopsy study. Eur J Epidemiol 2011;26:221–228.
87. Alfsen GC, Mæhlen J. Obduksjonens betydning for reg-
istrering av dødsarsak [The value of autopsies for deter-
mining the cause of death]. Tidsskr Nor Laegeforen
2012;132:147–151.
88. Eriksson A, Stenlund H, Ahlm K et al. Accuracy of death
certificates of cardiovascular disease in a community
intervention in Sweden. Scand J Public Health
2013;41:883–889.
89. Nilsson LL, Logdberg B. Dead and forgotten–postmortem
time before discovery as indicator of social isolation and
inadequate mental healthcare in schizophrenia. Schizophr
Res 2008;102:337–339.
90. Nordentoft M, Madsen T, Fedyszyn I. Suicidal behavior
and mortality in first-episode psychosis. J Nerv Ment Dis
2015;203:387–392.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Results of sensitivity analyses.
Table S1. List of diagnoses describing psychiatric comorbidity.
Table S2. Characteristics of deaths, health care utilization and
comorbidity in the subgroups with undiagnosed and diagnosed
CVD prior to cardiovascular death.
571











Dementia F00  Dementia in Alzheimer disease 
 F01  Vascular dementia 
 F02  Dementia in other diseases classified elsewhere 
 F03  Unspecified dementia 
 F05.1  Delirium superimposed on dementia 
 G30  Alzheimer disease 
 G31.1  Senile degeneration of brain, not elsewhere classified 




F10-16, F18-F19 Mental and behavioral disorders due to use of psychoactive substances, 
except tobacco (F17) 
 E24.4  Alcohol-induced pseudo-Cushing syndrome 
 E52  Niacin deficiency [pellagra] 
 G31.2  Degeneration of nervous system due to alcohol 
 G62.1  Alcoholic polyneuropathy 
 G72.1  Alcoholic myopathy 
 I42.6  Alcoholic cardiomyopathy 
 K29.2  Alcoholic gastritis 
 K70  Alcoholic liver disease 
 K86.0  Alcohol-induced chronic pancreatitis 
 O35.4  Maternal care for (suspected) damage to fetus from alcohol 
 O35.5  Maternal care for (suspected) damage to fetus by drugs 
 Z50.2  Alcohol rehabilitation 
 Z50.3  Drug rehabilitation 
 Z71.4  Alcohol abuse counselling and surveillance 
 Z71.5  Drug abuse counselling and surveillance 
 Z72.1  Alcohol use 
 Z72.2  Drug use 
  P15 Chronic alcohol abuse  
  P16 Acute alcohol abuse 
  P18 Medication abuse  





Table S2. Characteristics of deaths, health care utilization and comorbidity in the subgroups with undiagnosed 
and diagnosed CVD prior to cardiovascular death. 
    Schizophrenia Bipolar disorder No severe mental 
illness 
p-value Post hoc 
comparisons 
Individuals with undiagnosed CVD prior to CVD death 
 Deaths, n 186  112  8,020    
 Age at death, mean (SD) 66.1 (17.0) 68.5 (14.7) 76.8 (16.4) <.0001 SCZ, BD < No SMI 
  Age 18-59 at death, n (%) 73 (39.2) 31 (27.7) 1,351 (16.8) <.0001 No SMI < BD < SCZ 
  Age 60-79 at death, n (%) 61 (32.8) 50 (44.6) 2,475 (30.9) 0.007 No SMI < BD 
  Age ≥ 80 at death, n (%) 52 (28.0) 31 (27.7) 4,194 (52.3) <.0001 SCZ, BD < No SMI 
 Place of death, n (%)         
  Home 63 (33.9) 32 (28.6) 1,833 (22.9) 0.001 No SMI < SCZ 
  Hospital 46 (24.7) 41 (36.6) 2,378 (29.7) 0.093 - 
  Nursing home 54 (29.0) 26 (23.2) 3,051 (38.0) 0.000 SCZ, BD < no SMI 
  Other or unknown 23 (12.4) 13 (11.6) 758 (9.5) 0.309 - 
 Patients according to health care sector, n (%)       
  GP or emergency room 164 (88.2) 109 (97.3) 6,313 (78.7) <.0001 No SMI < SCZ, BD 
  Specialized somatic care 135 (72.6) 94 (83.9) 5,589 (69.7) 0.004 No SMI < BD 
  No health care use 9 (4.8) 1 (0.9) 986 (12.3) <.0001 SCZ, BD < No SMI 
 Health care utilization per person-year, median (IQR)       
  GP visits  3.7 (0.9-7.5) 7.3 (3.1-13.5) 1.7 (0.2-4.7) <.0001 No SMI < SCZ < BD 
  Emergency room visits 0.2 (0.0-0.5) 0.2 (0.0-0.6) 0.0 (0.0-0.3) <.0001 No SMI < SCZ, BD 
  Somatic admissions 0.0 (0.0-0.23) 0.2 (0.0-0.5) 0.0 (0.0-0.20) <.0001 No SMI < SCZ < BD 
  Somatic outpatient visits 0.3 (0.0-1.2) 0.8 (0.2-2.1) 0.4 (0.0-1.3) 0.001 SCZ, No SMI < BD 
Individuals with diagnosed CVD prior to CVD death 
 Deaths, n 628  561  62,944    
 Age at death, mean (SD) 78.9 (12.4) 77.1 (12.7) 84.3 (10.2) <.0001 BD < SCZ < No SMI 
  Age 18-59 at death, n (%) 49 (7.8) 52 (9.3) 1,740 (2.8) <.0001 No SMI < SCZ, BD 
  Age 60-79 at death, n (%) 237 (37.7) 236 (42.1) 13,824 (22.0) <.0001 No SMI < SCZ, BD 
  Age ≥ 80 at death, n (%) 342 (54.5) 273 (48.7) 47,380 (75.3) <.0001 SCZ, BD < No SMI 
 Place of death, n (%)         
  Home 110 (17.5) 136 (24.2) 9,821 (15.6) <.0001 SCZ, No SMI < BD 
  Hospital 173 (27.5) 176 (31.4) 21,825 (34.7) 0.000 SCZ < No SMI 
  Nursing home 319 (50.8) 228 (40.6) 29,006 (46.1) 0.002 BD < SCZ, No SMI 
  Other or unknown 26 (4.1) 21 (3.7) 2,292 (3.6) 0.797 - 
 Patients according to health care sector, n (%)       
  GP or emergency room 607 (96.7) 556 (99.1) 61,966 (98.4) 0.001 SCZ < BD, No SMI 
  Specialized somatic care 601 (95.7) 552 (98.4) 61,189 (97.2) 0.017 SCZ < BD 
  No health care use 1 (0.2) 0 (0.0) 71 (0.1) 0.685 - 
 Health care utilization per person-year, median (IQR)       
  GP visits  6.9 (3.1-13.6) 9.7 (5.5-16.0) 7.7 (4.1-13.2) <.0001 SCZ < No SMI < BD 
  Emergency room visits 0.4 (0.1-1.0) 0.5 (0.2-1.1) 0.3 (0.1-0.7) <.0001 NO SMI < SCZ < BD 
  Somatic admissions 0.5 (0.3-1.0) 0.6 (0.3-1.1) 0.5 (0.2-1.0) <.0001 SCZ, No SMI < BD 
  Somatic outpatient visits 1.2 (0.5-2.5) 1.8 (0.8-3.6) 1.7 (0.7-3.4) <.0001 SCZ < BD, No SMI 
Abbreviations: CVD, Cardiovascular disease; SCZ, Schizophrenia; BD, Bipolar disorder; SMI, Severe mental illness; GP, 








Figure S1. Results of sensitivity analyses. Adjusted Odds Ratios (OR) with 95% upper (UCL) and lower (UCL) 
Confidence Limits for not being diagnosed with cardiovascular disease (CVD) prior to cardiovascular death in 
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Objective: To examine whether patients with schizophrenia (SCZ) or bipolar disorder (BD) 
had lower prevalence of diagnostic testing and treatment of cardiovascular disease (CVD) in 
primary or specialized health care.  
Methods: A nationwide study of 72,385 individuals who died from CVD, of whom 814 and 
673, respectively, were previously diagnosed with SCZ or BD. Log-binomial regression was 
applied to study the impact of SMI on uptake of diagnostic tests (e.g. blood pressure, glucose 
or HbA1c measurements, electrocardiography, echocardiography, coronary angiography, 
ultrasound of peripheral vessels) and invasive cardiovascular treatment (i.e. revascularization, 
arrhythmia treatment and vascular surgery).  
Results: Patients with SCZ or BP had similar prevalence of cardio-metabolic diagnostic tests 
in primary care as patients without SMI, but patients with SCZ had lower prevalence of 
specialized CVD examinations (PR 0.78; 95% CI 0.73-0.85). Overall, subjects with SMI had 
lower prevalence of invasive cardiovascular treatment (PR 0.58 (95% CI 0.49-0.70) for SCZ 
and 0.78 (95% CI 0.66-0.92) for BD), but the prevalence of invasive cardiovascular treatment 
did not differ between those with and without SMI when CVD was diagnosed prior to death. 
Conclusion: Access to specialized cardiovascular examinations and treatment are the main 
barriers to equality in cardiovascular treatment for those with SMI. 
 
 
Keywords: Schizophrenia, Bipolar Disorder, Cardiovascular Diseases, Health Services 
 
Significant Outcomes 
 Patients with SCZ had lower prevalence of specialized CVD examinations, and 
patients with SCZ and BD lower prevalence of invasive cardiovascular treatment prior 
to cardiovascular death, implicating need of strengthened efforts to prevent, detect and 
treat CVD in these individuals.  
 The prevalence of invasive cardiovascular treatment did not differ between those with 
and without SMI when CVD was diagnosed prior to death. 
 Underutilization of specialized diagnostic tests rather than reduced access to primary 
care or disparate invasive treatment of acknowledged CVD may be the most important 
driver of disparities in the SMI population.  
 
Limitations 
 The level of screening/monitoring of CVD risk factors may be underestimated as we 
lacked precise information regarding the purpose and content of some common 
diagnostic tests included in broad batteries of biomarkers, some of which, but not all, 
measure CVD risk factors. 






Equal access to health care for equal medical need is a core value in countries with universal 
health care. Although individuals with schizophrenia (SCZ) or bipolar disorder (BD) 
(henceforth referred to as severe mental illness, SMI) have higher prevalence of risk factors 
for cardiovascular disease (CVD)[1], and higher cardiovascular morbidity [2] and mortality 
[3, 4], inequalities in access to or uptake of health services for prevention and treatment of 
CVD have repeatedly been reported in these individuals [5-9]. Current guidelines for 
management of psychosis recommend regular assessments of smoking, diet, physical activity, 
weight, waist circumference, blood pressure, fasting blood glucose, glycated hemoglobin 
(HbA1c) and fasting lipids [10].  
Meta-analyses mainly based on studies from the US, report inferior preventive care of 
CVD in individuals with SMI regarding metabolic monitoring [5, 6], blood pressure 
monitoring [5], hypertension treatment [7] and cardiovascular prescriptions [8], and also 
lower likelihood of invasive coronary procedures such as coronary angiography, percutaneous 
coronary intervention (PCI) and coronary artery bypass graft (CABG) [9]. Lower likelihood 
of cardiovascular risk factor monitoring [11], cardiovascular prescriptions [12-16], and acute 
treatment of CVD [17-19] have also been reported in comparative studies from countries with 
universal health care, including the UK [11, 13, 16], Denmark [14, 17], Finland [12], Norway 
[15], Canada [19] and Taiwan [18]. Some recent studies, however, report similar access to 
treatment following acute myocardial infarction (MI) in patients with and without SMI [20, 
21], and higher likelihood of statin prescribing [22] and revascularization [23] in younger 
individuals with SMI compared to controls.  
A recent meta-analysis noted that it is unclear at what stage along the clinical pathway 
persons with SMI loose access to CVD prevention and care [24]. Earlier studies have reported 
both lower [11, 16, 25-27], similar [16, 25, 26, 28, 29] and higher [16, 28, 30] uptake of 
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CVD-related diagnostic tests in primary care among individuals with SMI. With the exception 
of post-MI treatment, there is also a scarcity of studies on uptake of specialized examinations 
and treatment for CVD among persons with SMI. Many previous studies have focused on 
prevention and treatment of CVD in relatively young persons with SMI, likely to be in an 
early and probably less severe phase of CVD [11, 27, 30, 31]. Although some studies found 
that older individuals with SMI are less likely to receive coronary revascularizations [23, 32, 
33], CVD medications [22, 34, 35] and general medical outpatient services [22, 35], less is 
known whether the lower uptake of CVD-related diagnostic tests and cardiovascular treatment 
persists in the more severe phase of CVD, i.e. in the period prior to cardiovascular death.  
We recently documented that in a large group of 72,451 subjects who died of CVD, 
individuals with SCZ and women with BD were less likely to have CVD diagnosed before 
death [36]. In the current study, we investigate any differences in access to diagnostic tests 
and invasive treatment of CVD across health care levels. To our knowledge, there are no 
studies of the uptake of diagnostic tests and invasive treatment of CVD in individuals with 
SCZ or BD across health care sectors. Access to complete nationwide data from both primary 
and specialist health care up to nine years prior to cardiovascular death may help to pinpoint 
where along the clinical pathway disparities in cardiovascular care arise and identify 
individuals at particular risk of suboptimal treatment. 
 
Aims of the study 
In the present study we examined whether diagnoses of schizophrenia or bipolar disorder 
were associated with lower prevalence of diagnostic testing and treatment of cardiovascular 
disease prior to cardiovascular death, compared to patients without schizophrenia or bipolar 
disorder who died from cardiovascular disease. A secondary aim was to investigate if there 
was a difference between primary and specialist health care.
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Material and methods 
Study design and data sources 
We conducted a national record-linkage study, including complete data on cardiovascular 
mortality and complete data on diagnoses and health care utilization in primary and 
specialized health care for all Norwegians who died from CVD during the years 2011-2016. 
We included mortality data from the Norwegian Cause of Death Registry (CDR), and 
diagnostic data and information on health care utilization during the years 2008-2016 from the 
Norwegian Patient Registry (NPR) and the Norwegian Directorate of Health’s system for 
control and payment of health reimbursements in primary care (the KUHR database).  
The CDR provides almost complete (98%) information on causes of death based on 
death certificates coded by the physician who examined the deceased [37], supplemented by 
autopsy data in approximately 8% of the cases. The NPR contains almost complete 
information about all specialized health care (i.e. government-owned hospitals and outpatient 
clinics, and private health clinics with governmental reimbursement). Due to technical 
problems when reporting data, about 15% of contacts with private somatic health clinics with 
governmental imbursement were missing in the study period [38, 39]. Data for substance 
abuse institutions was also missing for the year 2008. As contacts with private somatic health 
clinics and SUD treatment facilities constitute a minor proportion of all contacts (10%), and 
few patients (0.1%) used these services exclusively during the period, the problem of missing 
data is probably very minor. 
The KUHR database contains administrative and clinical information on all contacts 
with general practitioners (GPs), including visits at their office or at home, telephone contacts, 
emergency room visits, as well as laboratory tests performed in primary and specialized 
health care. GPs are in contact with a large proportion of patients with SMI, and prescribe 
almost 70% of all antipsychotic drugs in Norway [40]. Reported episodes in the KUHR 
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database are considered to be almost 100% complete as GPs are funded mainly on a fee-for-
service basis.  
Diagnostic codes in the CDR and the NPR follow the International Classification of 
Diseases and Related Health Problems, 10th Revision (ICD-10), while diagnostic codes for 
primary care contacts follow the International Classification of Primary Care, 2nd version 
(ICPC-2). Accurate linkage across registries was obtained using an encrypted personal 
identification number included in all registries.  
 
Subject inclusion criteria and diagnostic and procedural categories 
We identified all deceased residents of Norway aged 18 years or older with CVD (ICD-10 
codes I00-I82) recorded as underlying cause of death in the death certificate in the years 
2011-2016, and at least one registered primary or specialized somatic health care contact in 
the period 2008-2016, thus assuring at least three years of observation time in the NPR and 
the KUHR database prior to death. Individuals registered as having died abroad were 
excluded (N=132), as well as individuals with no health care contacts in the period (N=66, of 
whom none had SMI on the death certificate).  
Patients were included in the SMI group if a diagnosis of SCZ (ICD-10 code F20 or 
ICPC-2 code P72) or BD (ICD-10 codes F30-F31 or ICPC-2 code P73) was recorded in the 
NPR or KUHR database during 2008-2016, or in the death certificate. Patients diagnosed with 
both SCZ and BD (N=94) were included in the SCZ group only. A diagnosis of CVD was 
considered present if ICD-10-codes I00-I82 or G45, or corresponding ICPC-2 diagnoses 
(codes K70-K71, K74-K80, K82-K84, K86-K87 and K89-K94) were recorded in the NPR or 
the KUHR database in the period from inclusion (January 1st, 2008) until death. Causes of 
death were sub-classified into ischemic heart disease (IHD, ICD-10 codes I20-I25), other 
forms of heart disease (ICD-10 codes I30-I52), cerebrovascular disease (ICD-10 codes I60-
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I69) and other cardiovascular diseases. CVD diagnoses recorded in primary or specialized 
health care were classified into MI, congestive heart failure, cardiac arrhythmias, valvular 
disease, pulmonary circulation disorders, peripheral vascular disorders, cerebrovascular 
disease and hypertension according to coding algorithms used in established comorbidity 
indices [41, 42]. We including also cases identified through the corresponding ICPC-2 codes 
recorded in primary care (see list of specific diagnostic codes in Supporting Information, 
Table S1). 
We used three composite measures of CVD-related procedures as main endpoints; (i) 
any CVD-related diagnostic test in primary care, (ii) any CVD-related diagnostic examination 
in specialized health care, and (iii) any invasive cardiovascular treatment procedure. CVD-
related diagnostic test conducted in primary care included electrocardiography (ECG), 24- 
hour blood pressure measurement, total cholesterol test, blood glucose test and HbA1c test. 
Specific tests for diabetes (i.e. blood glucose and HbA1c) were included in the measure of 
CVD-related diagnostic tests as diabetes is a risk factor for CVD. CVD-related diagnostic 
examinations conducted in specialized health care included blood pressure measurements, 
ECG, echocardiography, coronary angiography, right-sided heart catheterization, invasive 
electrophysiological examination of the heart, ultrasound examination of blood vessels 
(conducted in medical departments), and Doppler pressure measurements. Information on 
ultrasound examination of blood vessels conducted in radiology departments was not 
available. Any invasive cardiovascular treatment included coronary revascularization (i.e. PCI 
and CABG), arrhythmia treatment (i.e. permanent transvenous cardiac pacemaker implant, 
cardioverter defibrillator implant, electroconversion of cardiac arrhythmia and transvenous 
ablation), heart valve replacement and vascular surgery (i.e. carotid surgery, aneurysm 
surgery and peripheral vessels surgery). Definitions of invasive procedures were in 
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accordance with definitions in the Norwegian Cardiovascular Disease Registry [43] and the 
Norwegian Registry for Vascular Surgery [44], supplemented with expired and newer codes.  
 
Analysis and statistical methods 
Since the outcomes are common, we applied log-binomial instead of logistic regression to 
study the association between presence of SMI and provision of diagnostic tests and treatment 
for CVD in primary or specialized somatic care prior to cardiovascular death [45]. The log-
binomial model assumes a binary outcome, and estimate relative risk in prospective data and 
prevalence ratios (PRs) in cross-sectional data. When we examined uptake of diagnostic 
CVD-related test in primary care, the log-binomial model would not converge, we therefore 
used Poisson regression with robust error variance for estimation in this particular analysis 
[46].  
Multivariable models were adjusted for sex and age at death (age groups 18-59, 60-69, 
70-79, 80-89, and 90 and above). We also studied the impact of adding alcohol and substance 
abuse (see definitions in Table S1) and somatic comorbidities according to the Charlson’s 
comorbidity index [47, 48] to the model, after excluding CVDs from the algorithm. However, 
this neither changed estimates nor improved model goodness-of-fit significantly. We therefore 
only report results from the simplest model, presented as adjusted PRs with 95 % confidence 
intervals (CI).  
We conducted analyses for all subjects, and in sex-stratified subgroups, for the most 
common CVD-related diagnostic tests in primary care (i.e. ECG, 24-hour blood pressure 
measurement, blood glucose test and HbA1c tests) and the most common CVD-related 
diagnostic examinations in specialized care (i.e. echocardiography, coronary angiography and 
ultrasound of peripheral vessels). Finally, we conducted subgroup analyses of receipt of 
revascularization, in all subjects and among patients diagnosed with MI or other ischemic 
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heart diseases (ICD-10 codes I20, I23, I24, I25.1, I25.3-I25.9 or ICPC-2 codes K74 and K76), 
receipt of invasive arrhythmia therapy (all patients and among patients diagnosed with 
arrhythmia) (see definition in Table S1), and receipt of vascular surgery (all patients and 
among patients diagnosed with peripheral vascular disease) (see definition in Table S1) or 
carotid artery stenosis (ICD-10 code I65.2). 
To test the consistency of study findings regarding the three main endpoints, we 
conducted sensitivity analyses to examine the impact of (i) excluding patients diagnosed with 
dementia, (ii) excluding patients aged 80 and above, (iii) excluding patients with the 
ambiguous affective disorder diagnosis (ICPC-2 code P75) from the BD group, (iv) including 
also cases with CVD as contributing cause of death, (v) adjusting for person-years of 
observation, and (vi) restricting analyses of uptake of invasive CVD treatment to those who 
survived their first CVD contact in the period on the results. We also examined the impact of 
excluding relevant CVD diagnoses registered only the last month of living in the subgroup 
analyses of revascularization, invasive arrhythmia therapy and vascular surgery.  
Statistically significant results were defined at the conventional level (i.e. a two-tailed 
p-value < 0.05). Data management and analyses were conducted using SAS statistical 
software, version 9.4 (SAS Institute Inc., Cary, N.C.).  
 
Ethics 
Data files contained unique, but encrypted, personal ID numbers when made available to the 
investigators. Legal basis and exemption from professional secrecy requirements for the use 
of personal health data in research was granted by the regional committee for medical and 





Characteristics of the study population 
We included 72,385 residents of Norway aged 18 years and above who died due to CVD in 
the period 2011-2016, and who had utilized primary or specialized somatic care at least once 
in the period from January 1st, 2008 until death (Table 1). Of these, 814 (1.1%) were 
diagnosed with SCZ and 673 (0.9%) with BD. More than half (54%) of patients with SCZ and 
45% of patients with BD had their SMI diagnosis recorded in primary care only, while 13% of 
SCZ patients and 28% of BD patients had their diagnosis recorded in specialized health care 
only. The remaining patients had their diagnosis recorded in at least two registries. 
Patients with SMI had a younger age distribution and died at a mean age of 76 years, 
eight years younger than patients without SMI (p< 0.0001, Table 1). No differences in causes 
of cardiovascular death were noted between the three diagnostic groups, with IHD accounting 
for nearly 40% of all deaths in all groups. Patients with SMI had less diagnosed CVD prior to 
cardiovascular death for all CVD subtypes except pulmonary circulation disorder, in 
particular cardiac arrhythmias, hypertension and congestive heart failure. We found similar 
prevalence of diabetes and hyperlipidemia in patients with and without SMI, but more 
recorded alcohol and substance abuse and obesity among patients with SMI.  
Patients with SCZ had less, and patients with BD more, GP visits, specialized somatic 
admissions and somatic outpatient visits, and patients with SMI more telephone contacts and 
emergency room visits compared to patients without SMI (Table 2). Regardless of frequency 
of contacts, contact type and level of health care, patients with SMI had fewer contacts with a 
recorded CVD diagnosis, and a shorter time span from first CVD-examination in the 
observation period until cardiovascular death. Seventeen percent of patients with SCZ and 
11% of patients with BD had their CVD diagnosis first recorded when they died. In patients 
without SMI, this was the situation in 8% (Table 1).  
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Receipt of CVD-related diagnostic tests prior to cardiovascular death 
About four out of five patients with and without SMI underwent some kind of CVD-related 
diagnostic test in primary care prior to cardiovascular death, where patients with BD had 
slightly higher prevalence than others. About 44% of patients with SCZ and 54-55% of 
patients with BD or no SMI received some kind of CVD-related diagnostic examination in 
specialized health care (Table 2).  
Adjusted analyses showed that patients with SCZ and BD had similar prevalence of 
any CVD-related diagnostic test in primary care prior to cardiovascular death as patients 
without SMI (Figure 1). Patients with BD also had similar prevalence of specialized 
diagnostic tests as patients without SMI, while patients with SCZ had lower prevalence of 
specialized diagnostic CVD examinations (PR 0.78; 95% CI 0.73-0.85) (Table 3).  
Patients with SCZ had similar prevalence of ECG and diabetes tests in primary care, 
but lower prevalence of 24 hour blood pressure measurement (PR 0.39; 95% CI 0.28-0.55), 
compared to patients without SMI. Patients with BD had higher prevalence of blood glucose 
testing (PR 1.13; 95% CI 1.07-1.19) and HbA1c testing (PR 1.12; 95% CI 1.03-1.21, but 
similar prevalence of ECG and 24h blood pressure measurement in primary care (Table 3). 
Sex-stratified analyses showed the same overall pattern as in the main analysis regarding 
CVD-related diagnostic tests in primary care (Table 3).  
Patients with SCZ had significantly lower uptake of specialized diagnostic tests, such 
as echocardiography (PR 0.77; 95% CI 0.70-0.84), coronary angiography (PR 0.66; 95% CI 
0.55-0.79) and ultrasound of peripheral vessels (PR 0.44; 95% CI 0.32-0.61), compared to 
patients without SMI (Table 3). Patients with BD also had reduced uptake of 
echocardiography (PR 0.90; 95% CI 0.82-0.98) and coronary angiography (PR 0.81; 95% CI 
0.67-0.96), but similar uptake of ultrasound of peripheral vessels. Sex-stratified analyses 
showed the same overall pattern (Table 3).  
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Receipt of invasive cardiovascular procedures prior to death 
Twelve percent of patients with SCZ and 16% of patients with BD underwent some kind of 
invasive cardiovascular treatment procedure prior to cardiovascular death, compared to 19% 
among patients without SMI. Adjusted for sex and age at death, patients with SCZ who died 
from CVD had 42% lower prevalence (PR 0.58; 95% CI 0.48-0.70) and patients with BD 
21% lower prevalence (PR 0.79; 95% CI 0.67-0.94) of any invasive cardiovascular treatment 
prior to cardiovascular death (Figure 1).  
Adjusted subgroup analyses according to type of invasive treatment procedure showed 
35% lower prevalence (PR 0.65; 95% CI 0.50-0.84) of revascularization in patients with SCZ 
who died due to CVD, but similar prevalence of revascularization in patients with SCZ who 
were diagnosed with IHD prior to death, compared to patients without SMI (Table 4). We 
found 31% lower prevalence (PR 0.69; 95% CI 0.51-0.92) of any invasive arrhythmia 
treatment in patients with SCZ who died due to CVD, but similar prevalence in patients with 
SCZ who were diagnosed with arrhythmia prior to death. Patients with BD had similar 
prevalence of revascularization and arrhythmia therapy as patients without SMI both among 
those who died of CVD and the subset diagnosed with IHD or arrhythmia, respectively. 
Analyses of receipt of vascular surgery in patients who died from CVD showed 57% (PR 
0.43; 95% CI 0.28-0.68) and 63% (PR 0.37; 95% CI 0.22-0.62) lower prevalence in patients 
with SCZ and BD, respectively, compared to patients without SMI. Patients with BD 
diagnosed with peripheral vascular or carotid artery stenosis prior to death also had lower 
prevalence of vascular surgery (PR 0.50; 95% CI 0.31-0.82), compared to patients without 





Results of sensitivity analyses 
Sensitivity analyses that investigated the impact of (i) excluding patients diagnosed with 
dementia, (ii) excluding patients aged 80 and above, (iii) excluding patients with the 
ambiguous affective disorder diagnosis (ICPC-2 code P75) from the BD group, (iv) including 
also cases with CVD as contributing cause of death, (v) adjusting for person-years of 
observation and (vi) restricting analyses of invasive CVD treatment to those who survived 
their first CVD encounter in the period gave essentially the same estimates for PR as the 
original analysis (Figure S1 in Supporting Information). Excluding relevant CVD diagnoses 
registered only the last month of life in the subgroup analyses of revascularization, invasive 





In this nationwide registry study we found that compared to patients without SMI, subjects 
with a diagnosis of SCZ had similar prevalence of CVD-related diagnostic tests in primary 
care, but lower uptake of specialized diagnostic CVD examinations and invasive CVD 
treatment. The lower prevalence of CVD examinations was particularly pronounced for 
lengthy procedures or those that require physical contact with the patient (such as 24-hour 
blood pressure measurement, echocardiograms, coronary angiography and ultrasound of 
peripheral vessels). Patients with BD had similar prevalence of diagnostic CVD examinations 
in primary and specialized somatic care as patients without SMI, but lower prevalence of 
invasive CVD treatment. Patients with SCZ or BD with acknowledged CVD had similar 
uptake of invasive cardiovascular treatment as those without SCZ or BD. Patients with SMI 
also had fewer contacts with a recorded CVD diagnosis both in primary and specialized 
somatic care, and a shorter time span from first CVD-diagnosis in the observation period until 
cardiovascular death.  
 
Comparisons with other studies 
We are not aware of other studies examining uptake of CVD-related diagnostic tests in a 
sample of deceased patients with and without SMI, but our findings show similarities with 
other studies on adjacent topics. A previous Norwegian primary care study found similar 
likelihood of ECG, and higher frequency of HbA1c testing, in individuals with SCZ aged 25-
60 years, compared to controls with similar somatic comorbidity [30]. We found similar 
likelihood of both procedures in patients with and without SCZ, but congruent results when 
restricting the analysis to the same age groups, possibly implying increased health care 
seeking or increased awareness of elevated cardiovascular risk in younger patients with SCZ.  
15 
 
A lower prevalence of 24-hour blood pressure measurement in patients with SCZ in 
primary care is in accordance with earlier findings regarding blood pressure measurement in 
general among persons with SCZ [11, 16, 49], and a similar prevalence of blood pressure 
measurement found in individuals with BD is compatible with some [25, 28, 50], but not all 
[26] studies in the wider SMI population. The similar (SCZ) or higher (BD) prevalence of 
diabetes testing in primary care, compared to patients without SMI, also resembles earlier 
findings in the SMI population [26, 28, 51, 52]. An interprofessional primary care practice 
with mandate to care for persons with barriers to health care reported similar levels of blood 
pressure measurement and higher levels of diabetes screening in patients with SMI than in 
age- and sex-matched controls [50], implicating that tailor-made treatment for this group may 
improve uptake.  
Our results indicated a decreased prevalence of coronary angiography prior to 
cardiovascular death in patients with SCZ and BD, which is in accordance with earlier studies 
in patients with SCZ [9, 18, 33, 53-55], BD [18], psychosis [19] or mental illness in general 
[9, 56-59], particularly in older age groups [33, 56]. Our findings are also compatible with a 
study reporting lower likelihood of preventive interventions during somatic hospitalization 
among patients with SMI [60]. Little is known about receipt of echocardiography and 
ultrasound of peripheral vessels in patients with and without SMI, but patients with mental 
illness have been reported to have lower likelihood of left ventricular ejection fraction 
assessment, in which echocardiography is a common examination method [61].  
We found lower prevalence of invasive cardiovascular procedures in patients with 
SCZ or BD, in accordance with previous studies of receipt of cardiovascular surgery in 
patients with and without SMI [55, 62]. There were lower (SCZ) or similar (BD) prevalence 
of revascularization in patients who died due to CVD, but similar uptake of revascularization 
in patients with and without SCZ or BD who were diagnosed with IHD prior to death. The 
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latter finding is in contrast to earlier findings in various populations [9, 18, 23, 53-55, 63, 64], 
but consistent with a nationwide Swedish study [20], and also a recent Danish study showing 
no difference in post-MI treatment in patients with and without SCZ who had undergone 
coronary angiography, as well as studies showing similar likelihood of revascularization in 
patients with IHD and BD [63] or mood disorders [23]. The finding of similar prevalence of 
revascularization in patients with SMI also diagnosed with IHD is also compatible with a 
study in the general Norwegian population demonstrating that lower revascularization rates 
among patients with low education were explained by differences in receipt of coronary 
angiography [65].  
With the exception of revascularization, receipt of invasive cardiovascular treatment in 
persons with SMI appears to be little described in the literature [66]. However, an Israeli 
study found a 50% reduced likelihood of cardiac pacemaker implantation in patients with 
schizophrenia [55] and a US study found a reduced likelihood of receiving major surgery, 
including vascular surgery, among persons with SMI, particularly in those with SCZ [62]. 
These findings are in line with ours in the sample of those who died from CVD.  
 
Barriers to care 
Our study indicates that the differences in receipt of CVD prevention and treatment among 
persons with particularly SCZ may be driven by underdiagnosis of CVD and underutilization 
of specialized diagnostic tests rather than reduced access to primary care and disparate 
invasive treatment of acknowledged CVD.  
Explanations for lower uptake of specialized diagnostic tests in persons with SMI are 
multifactorial, and may differ between individuals with SCZ and BD. Disease-related factors 
such as limited and disorganized self-care capacity, poor communications skills, self-stigma, 
depression and social isolation, particularly in those with SCZ, may lead to delayed 
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presentation or diagnosis, and missed referrals. Earlier studies suggest that especially older 
patients with SMI may have reduced health care seeking regarding CVD [35]. Increased pain 
tolerance [67] and increased risk of silent CVD [68] have been reported in individuals with 
SCZ, possibly affecting timely health care seeking. Due to increased early cardiovascular 
mortality [69, 70], individuals with SMI may die at ages when health care providers not 
usually suspect CVD. Prevailing risk prediction algorithms for CVD also have been shown to 
underestimate the risk of CVD in individuals with SCZ [71]. Furthermore, shared genetic risk 
factors for both SCZ and CVD [72, 73] may imply a more malign course of CVD, with 
shorter time to recognize symptoms. Also, users of antipsychotic medication are at higher risk 
of adverse cardiac effects such as arrhythmias, deviations in blood pressure, heart failure, 
myocarditis and cardiomyopathy [74, 75], possibly leading to sudden cardiac death [76-78].  
Provider-level explanations put forward include time constraints, complexity of care 
and misattribution of physical symptoms to mental illness [79-81]. Discomfort with or 
stigmatizing attitudes towards patients with SMI among health care providers have been 
reported [82], particularly regarding SCZ [83, 84], and may unintendedly influence medical 
decision-making. In a study of quality of somatic treatment among older persons with SCZ, 
higher adequacy of somatic treatment was associated with lower rates of depression, fewer 
positive symptoms, more negative symptoms, and, surprisingly, fewer medical care visits 
[85]. Increased rates of GP visits, including increased rates of emergency room visits, as 
observed in the SMI group in our study, could thus be a signal of unmet medical needs. In 
another study of providers’ decision making, a history of SCZ was found to negatively affect 
primary care provider’s expectations of treatment adherence and ability to understand 
educational materials [86]. In spite of younger age, people with SMI have more 
comorbidities, including higher rates of smoking, obesity and substance use disorder [87], 
higher risk for postoperative complications [88, 89] and mortality following cardiac treatment 
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[20]. Disparities in invasive CVD treatment may thus reflect clinicians' uncertainty and 
judgments about treatment risks and compliance with postoperative care. Lack of consent, or 
lack of capacity to give informed consent, may also be an issue, as noted in a recent study 
investigating decisions about cardiac examination and treatment, where patients with SCZ 
tended to be more likely to decline both examination and treatment post MI [90].   
Finally, mismatch between patients’ health care needs and the fragmented 
organization of health care may be an important barrier to equitable somatic health care [91]. 
The current health care system relies on the individuals’ ability to initiate contact with health 
care providers. Navigating between psychiatric, primary and specialized somatic health care 
systems may constitute a particular challenge to those with SMI, reinforced by potentially 
unclear responsibilities as to who is responsible for physical health monitoring among persons 
with SMI [92]. Both patients with SMI and mental health staff point to a fragmented health 
system when asked about opportunities for improved prevention and treatment for physical 
problems among persons with SMI [91, 93]. 
It may seem as a paradox that people with BD who died from CVD died at the same 
age as patients with SCZ, and much younger than subjects without SMI, despite higher 
overall health care utilization, and generally higher education and lower impairment, than 
persons with SCZ [1]. We can only speculate what the reasons for this might be. Comorbid 
alcohol use disorder, which was more prevalent in individuals with BD, was associated with 
lower prevalence of specialized somatic examination and treatment, and may be part of the 
explanation. Higher somatic comorbidity, also observed in those with BD, including 
conditions that complicate invasive cardiovascular treatment may be another explanation. 
Individuals with BD have, as examples, increased risk of chronic obstructive pulmonary 
disease, and women with BD a higher prevalence of renal failure [94], which may complicate 
invasive cardiac therapy.  
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Strengths and limitations 
The strengths of the study include the nationwide sample with complete diagnostic data from 
both primary and specialized health care during a maximum nine-year period. Inclusion of 
everyone who died of CVD made it possible to study the utilization of CVD-related health 
care services in persons with assumed similar severity of CVD with and without a history of 
SCZ or BD. We also had the possibility to assess the impact of somatic comorbidity and 
alcohol and drug use on uptake of diagnostic tests and treatment. Our extensive sensitivity 
analyses strengthen our conclusions and our results seem solid. However, some limitations 
need mentioning.  
Firstly, although we examined a wide range of procedures, we lacked information on 
some types of diagnostics and treatment of CVD, such as pharmacological prevention and 
treatment of CVD, procedures conducted at radiology departments (such as computed 
tomographic angiography and ultrasound of peripheral vessels), and prehospital procedures 
during transportation to hospital (such as ECG or thrombolysis), which reduced the scope and 
precision in the measurement of performed diagnostic tests and treatment. We also lacked 
precise information regarding the purpose and content of some diagnostic blood tests. A large 
volume of blood tests both in primary and specialized somatic care were taken as part of 
broad batteries of biomarkers, some of which, but not all, measure risk factors for diabetes 
and CVD (such as cholesterol). We did not know the specific indication for taking these tests, 
hence did not include them in our measure of CVD-related diagnostic tests. The level of 
screening/monitoring of CVD risk factors may thus be underestimated in all patients, but 
probably more in patients without SMI as patients with SMI should also be monitored for 
adverse effects of psychopharmacological medications. Also, very common procedures, such 
as blood pressure measurements or ECG, may be underreported in administrative data, but it 
is unlikely that this differ systematically between patients with and without SMI. 
20 
 
Secondly, we lacked information on severity of CVD (such as ST-segment elevation 
MI and extent of coronary disease). Equal severity of CVD could, however, be approximated 
by the fact that they all died from the same causes of death. Previous studies have reported 
similar severity of MI among patients with SCZ [20], and similar [20] or higher [63] severity 
of MI among patients with BD, implicating possibility of underestimated disparities in access 
to invasive cardiovascular treatments among those with BD. We also lacked information on 
time since symptom onset and travel time to hospital, which may have impacted treatment 
options differentially in those with and without SMI. 
Thirdly, we lacked information on the socioeconomic status of the patients before their 
prodromal phase (e.g. their parents’ educational attainment). The results found here could thus 
be due to social stratification in treatment utilization. 
Fourthly, the validity of registry diagnoses is unknown for some disease categories. 
Previous studies have found high agreement between clinical diagnoses of SMI and research 
based diagnosis [95], and valid information regarding stroke [96] and intracranial hemorrhage 
[96] in the NPR. Studies from other Nordic countries have found high diagnostic accuracy of 
cardiovascular diagnoses in general [97, 98], atrial fibrillation and flutter [99] and 
intracerebral hemorrhage [100], but questionable validity of heart failure [101] and peripheral 
arterial disease diagnoses [102]. Diagnoses in the KUHR database has not been validated, but 
diagnoses have been found to be valid in general practice registries in other countries, 
particularly for chronic diseases [103]. The KUHR database include limited information 
regarding comorbidity, however, since most claims only have one recorded diagnosis, but our 
long follow-up time probably outweighs this limitation. The registered cause of death was not 
validated by autopsy for the large majority of patients. Still, the CDR is found to provide high 
quality information on causes of death [104]. A Norwegian study from 2011 reported very 
good agreement between mortality statistics and autopsy findings for both coronary heart 
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disease and stroke in the CDR [105], while an earlier Norwegian study investigating the 
impact of autopsies on mortality statistics, found substantial (17%) underreporting of 
cardiovascular deaths, particularly in the young and old, and in women [106]. Autopsies are, 
however, not made at random, and findings from such studies may therefore not be 
transferable to other cases. The most common error in mortality statistics is that immediate or 
intermediate causes of death are registered as the underlying cause of death [107]. Patients 
with high co-morbidity, such as patients with BD, could be underrepresented in our sample 
due to competing causes of death. We found, however, only eleven patients with a SMI 
diagnosis recorded as underlying cause of death and CVD as contributing cause of death, and 
very few with a substance use disorder recorded as underlying cause of death. Also, we found 
similar results when we included all deaths with CVD as underlying or contributing cause of 
death, as shown in the sensitivity analysis. We lacked data on sudden death (ICD-10 code 
R98), which may imply underreported cardiovascular deaths. However, only 2% of 
underlying causes of death in Norway in the years 2011-2016 were assigned to unknown or 
unspecified causes (R96–R99) [108]. Studies have reported longer postmortem time before 
discovery in individuals with SCZ compared to others [109], possibly affecting the reliability 
of cause of death codes in individuals with SCZ.  
Finally, external validity may be limited to individuals with severe CVD in countries 







In this nationwide study, we found lower prevalence of cardiovascular examinations and 
interventions prior to cardiovascular death in patients with SCZ and BD, in spite of high 
levels of primary and somatic health care use. Vulnerable individuals may thus not receive 
medically indicated cardiovascular treatment. In patients with diagnosed CVD, however, we 
found similar prevalence of invasive cardiovascular treatment among those with and without 
SMI.  
In conclusion, these results suggest that underdiagnosis and underutilization of 
specialized cardiovascular examinations, rather than poor access to primary care or restraints 
due to contraindications or perceived noncompliance with postoperative care, are the main 
obstacles to achieve more equal access to cardiovascular health care. Existing risk prediction 
algorithms has been shown to underestimate cardiovascular risk in patients with SMI. Hence, 
the health care disparities shown in our study require a proactive and tailored approach for 
correct diagnosis and treatment of cardiovascular diseases, underlined by the fact that 
cardiovascular disease in these patients may have a more malignant disease course, with 
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Table 1. Descriptive characteristics of individuals with or without schizophrenia or bipolar disorder who died 
due to cardiovascular disease at ages 18 and above. 
   SCZ  BD  No SMI  
Demographic characteristics       
 Persons, n 814  673  70,898  
  Men, n (%) 384 (47.2) 291 (43.2) 32,962 (46.5) 
 Age at death, mean (SD) 76.0 (14.6) 75.6 (13.4) 83.5 (11.3) 
  Age 18-59 at death, n (%) 122 (15.0) 83 (12.3) 3,065 (4.3) 
  Age 60-69 at death, n (%) 145 (17.8) 129 (19.2) 5,423 (7.6) 
  Age 70-79 at death, n (%) 153 (18.8) 157 (23.3) 10,844 (15.3) 
  Age 80-89 at death, n (%) 237 (29.1) 201 (29.9) 27,481 (38.8) 
  Age 90 and above at death, n (%) 157 (19.3) 103 (15.3) 24,085 (34.0) 
Causes of death       
 I20-I25 Ischemic heart disease, n (%) 327 (40.2) 252 (37.4) 25,806 (36.4) 
 I30-I52 Other forms of heart disease, n (%) 223 (27.4) 169 (25.1) 20,420 (28.8) 
 I60-I69 Cerebrovascular disease, n (%) 184 (22.6) 167 (24.8) 16,514 (23.3) 
 Other cardiovascular diseases, n (%) 80 (9.8) 85 (12.6) 8,158 (11.5) 
Time from CVD diagnosis until death       
 First CVD at date of death, n (%) 139 (17.1) 76 (11.3) 5,562 (7.8) 
 First CVD ≤ 30 days before death, n (%) 186 (22.9) 114 (16.9) 7957 (11.2) 
 Years from 1. CVD diagnosis until death, median 
(25/75 percentile) 
4.3 (2.4-6.0) 4.2 (2.7-6.2) 4.8 (3.2-6.5) 
Diagnoses, n (%)       
 Cardiovascular disease 698 (85.7) 610 (90.6) 66,351 (93.6) 
 Hypertension 390 (47.9) 384 (57.1) 43,341 (61.1) 
 Cardiac arrhythmia 298 (36.6) 262 (38.9) 35,492 (50.1) 
 Congestive heart failure 333 (40.9) 257 (38.2) 34,186 (48.2) 
 Myocardial infarction 238 (29.2) 183 (27.2) 24,278 (34.2) 
 Cerebrovascular disease †  295 (36.2) 275 (40.9) 29,986 (42.3) 
 Valvular disease 114 (14.0) 116 (17.2) 16,367 (23.1) 
 Peripheral vascular disorder 95 (11.7) 101 (15.0) 14,242 (20.1) 
 Pulmonary circulation disorder 58 (7.1) 62 (9.2) 5,043 (7.1) 
 Hyperlipidemia 73 (9.0) 84 (12.5) 7,525 (10.6) 
 Diabetes 186 (22.9) 156 (23.2) 14,726 (20.8) 
 Obesity 36 (4.4) 51 (7.6) 1489 (2.1) 
 Alcohol abuse 46 (5.7) 90 (13.4) 2,283 (3.2) 
 Drug abuse 37 (4.5) 64 (9.5) 728 (1.0) 
 Modified CCI, mean (SD) 1.60 (2.0) 1.65 (2.1) 1.67 (2.2) 
  No CC groups, n (%) 341 (41.9) 250 (37.1) 28232 (39.8) 
  ≥ 2 CC groups, n (%) 219 (26.9) 165 (24.5) 18,010 (25.4) 
Abbrevations: SCZ, Schizophrenia; BD, Bipolar disorder; SMI, Severe mental illness; SD, Standard Deviation 
† ICD-10 codes I60-I69, G45-G46 or H340, or ICPC-2 codes K89-K91. Based on data from the Norwegian Patient 
Registry (2008-2016), the Norwegian Directorate of Health’s system for control and payment of health 
reimbursements in primary care (2008-2016) and the Norwegian Cause of Death Registry (2011-2016). 
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for 




Table 2. Health care utilization prior to cardiovascular death in patients with or without schizophrenia or 
bipolar disorder who died due to cardiovascular disease at ages 18 and above. 
    SCZ BD No SMI 
Primary care utilization per person-year, median (25/75 percentile) 
  Contacts in primary care 12.9 (6.5-22.9) 15.8 (9.3-26.2) 11.4 (11.4-5.9) 
 No. of contacts according to type, median (25/75 percentile) 
  GP visits 5.9 (2.6-12.0) 9.3 (5.1-15.4) 7.0 (3.4-12.4) 
  Emergency room visits 0.4 (0.2-0.9) 0.5 (0.2-1.1) 0.4 (0.2-0.7) 
  GP telephone contacts 4.6 (2.0-9.2) 4.9 (2.2-9.5) 2.8 (1.1-6.0) 
 No. of contacts according to diagnoses, median (25/75 percentile) 
  Psychiatric symptoms/diagnoses 3.3 (1.2-7.3) 4.7 (1.7-9.8) 0.2 (0.0-1.2) 
  General symptoms/diagnoses 1.3 (0.4-3.4) 1.5 (0.5-3.5) 1.0 (0.3-1.2) 
  CVD symptoms/diagnoses 1.1 (0.1-3.8) 1.5 (0.2-4.3) 2.8 (0.7-7.5) 
  Other somatic symptoms/diagnoses 1.6 (0.5-4.0) 2.3 (1.0-5.0) 2.1 (0.7-4.4) 
 No. of patients with procedure, n (%)       
  Any CVD-related diagnostic test 621 (76.3) 566 (84.1) 56,202 (79.3) 
   Electrocardiography (ECG) 410 (50.4) 382 (56.8) 38,736 (54.6) 
   24h blood pressure measurement 31 (3.8) 57 (8.5) 5,702 (8.0) 
   Glucose measurement 492 (60.4) 464 (68.9) 43,605 (61.5) 
   HbA1c measurement 325 (39.9) 308 (45.8) 28,371 (40.0) 
          
Specialized somatic care utilization per person-year, median (25/75 percentile) 
 No. of contacts according to type, median (25/75 percentile) 
  Somatic admissions 0.5 (0.2-0.9) 0.6 (0.3-1.2) 0.5 (0.2-1.0) 
  Somatic emergency admissions 0.4 (0.2-0.8) 0.5 (0.2-1.0) 0.5 (0.2-0.8) 
  Days in somatic hospital 2.1 (0.9-4.8) 3.0 (1.0-6.4) 2.6 (0.9-5.4) 
  Somatic outpatient visits 1.0 (0.3-2.2) 1.7 (0.7-3.3) 1.6 (0.6-3.2) 
 No. of contacts according to diagnoses, median (25/75 percentile) 
  Admissions with a CVD diagnosis 0.3 (0.0-0.6) 0.3 (0.1-0.7) 0.4 (0.1-0.7) 
  Outpatient visits with a CVD diagnosis 0.0 (0.0-0.3) 0.0 (0.0-0.4) 0.1 (0.0-0.5) 
 No. of patients with procedure, n (%)       
  Any diagnostic CVD examination 359 (44.1) 366 (54.4) 38,907 (54.9) 
   Echocardiography 277 (34.0) 272 (40.4) 30,389 (42.9) 
   Coronary angiography 97 (11.9) 98 (14.6) 10,026 (14.1) 
   Ultrasound of peripheral vessels 34 (4.2) 73 (10.8) 6,516 (9.2) 
  Any invasive CVD procedure 98 (12.0) 109 (16.2) 13,217 (18.6) 
   Revascularization 54 (6.6) 54 (8.0) 5,684 (8.0) 
   Arrhythmia treatment 42 (5.2) 44 (6.5) 5,378 (7.6) 
   Vascular surgery 19 (2.3) 14 (2.1) 3,693 (5.2) 
Abbrevations: SCZ, Schizophrenia; BD, Bipolar disorder; SMI, Severe mental illness; GP, General practitioner; 
CVD, Cardiovascular disease. Based on data from the Norwegian Patient Registry (2008-2016), the Norwegian 
Directorate of Health’s system for control and payment of health reimbursements in primary care (2008-2016) 
and the Norwegian Cause of Death Registry (2011-2016). 
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for 






Table 3. Adjusted Prevalence Ratios (PR) with 95% Confidence Intervals (CI) for receipt of diagnostic CVD tests 
prior to cardiovascular death in individuals with schizophrenia (SCZ) or bipolar disorder (BD), according to 
patient group, sex and type of procedure. 
   All patients  Men  Women 
    PR †‡ 95% CI  N  PR †‡ 95% CI  n  PR †‡ 95% CI 
Diagnostic tests in primary care          
 Electrocardiography (ECG)           
  Schizophrenia 0.95 (0.89-1.02)  194 0.93 (0.84-1.03)  216 0.97 (0.88-1.06) 
  Bipolar disorder 1.06 (0.99-1.13)  173 1.05 (0.96-1.16)  212 1.06 (0.97-1.16) 
 24h Blood pressure measurement          
  Schizophrenia 0.39 (0.28-0.55)  14 0.34 (0.20-0.56)  17 0.45 (0.28-0.72) 
  Bipolar disorder 0.83 (0.65-1.07)  30 0.89 (0.63-1.26)  28 0.77 (0.54-1.10) 
 Glucose test           
  Schizophrenia 1.00 (0.95-1.06)  228 1.00 (0.92-1.08)  264 1.00 (0.93-1.08) 
  Bipolar disorder 1.13 (1.07-1.19)  210 1.17 (1.09-1.26)  257 1.09 (1.02-1.17) 
 Glycated hemoglobin (HbA1c) test          
  Schizophrenia 0.99 (0.91-1.07)  163 1.00 (0.89-1.12)  162 0.97 (0.86-1.10) 
  Bipolar disorder 1.12 (1.03-1.21)  149 1.16 (1.04-1.30)  162 1.07 (0.95-1.20) 
             
Diagnostic tests in specialized health care         
 Echocardiography           
  Schizophrenia 0.77 (0.70-0.84)  138 0.74 (0.65-0.85)  139 0.79 (0.69-0.91) 
  Bipolar disorder 0.90 (0.82-0.98)  136 0.93 (0.82-1.05)  137 0.84 (0.74-0.96) 
 Coronary angiography           
  Schizophrenia 0.66 (0.55-0.79)  58 0.61 (0.48-0.77)  39 0.72 (0.54-0.97) 
  Bipolar disorder 0.81 (0.67-0.96)  66 0.93 (0.75-1.15)  32 0.64 (0.46-0.89) 
 Ultrasound of peripheral vessels          
  Schizophrenia 0.44 (0.32-0.61)  19 0.46 (0.30-0.72)  15 0.41 (0.25-0.67) 
  Bipolar disorder 1.09 (0.88-1.36)  35 1.04 (0.76-1.42)  39 1.12 (0.83-1.51) 
Abbrevations: PR, Prevalence Ratio; CI, Confidence Interval; n, no. of patients with procedure  
† Adjusted for sex, age at death, alcohol and drug use disorder and somatic comorbidity   
‡ Bold figures: Significant association at p-value <0.05        
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for 
control and payment of health reimbursements in primary care (2008-2016) and the Norwegian Cause of Death 
Registry (2011-2016). 




Table 4. Adjusted Prevalence Ratios (PR) with 95% Confidence Intervals (CI) for receipt of invasive 
cardiovascular treatment prior to cardiovascular death in individuals with schizophrenia (SCZ) or bipolar 
disorder (BD), according to patient group, inclusion criteria and type of procedure. 
   Patients Patients with 
procedure 
PR †‡ 95% CI 
PCI or CABG      
 Patients with CVD as underlying cause of death      
  Schizophrenia 814 54  0.65 (0.50-0.84) 
  Bipolar disorder 673 54  0.79 (0.61-1.01) 
 Patients with diagnosed IHD prior to death      
  Schizophrenia 327 54  0.82 (0.65-1.03) 
  Bipolar disorder 272 54  0.94 (0.75-1.18) 
Arrhythmia therapy      
 Patients with CVD as underlying cause of death      
  Schizophrenia 814 42  0.69 (0.51-0.92) 
  Bipolar disorder 673 44  0.87 (0.65-1.15) 
 Patients with diagnosed arrhythmia prior to death     
  Schizophrenia 298 42  0.86 (0.65-1.14) 
  Bipolar disorder 262 44  0.97 (0.74-1.27) 
Peripheral vascular surgery      
 Patients with CVD as underlying cause of death      
  Schizophrenia 814 19  0.43 (0.28-0.68) 
  Bipolar disorder 673 14  0.37 (0.22-0.62) 
 Patients with diagnosed peripheral vascular disease prior to death    
  Schizophrenia 101 19  0.73 (0.49-1.09) 
  Bipolar disorder 103 14  0.50 (0.31-0.82) 
Abbrevations: PR, Prevalence Ratio; CI, Confidence Interval; PCI, Percutaneous coronary intervention; CABG, 
Coronary artery bypass surgery; CVD, Cardiovascular disease; IHD, Ischemic heart disease. 
† Adjusted for sex, age at death, alcohol and drug use disorder and somatic comorbidity   
‡ Bold figures: Significant association at p-value <0.05. 
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for 
control and payment of health reimbursements in primary care (2008-2016) and the Norwegian Cause of Death 
Registry (2011-2016). 
              






Figure 1. Adjusted Prevalence Ratios (PR) with 95% lower (LCL) and upper (UCL) Confidence Limits for receipt of 
diagnostic CVD tests or invasive cardiovascular treatment prior to cardiovascular death in individuals with 
schizophrenia (SCZ) or bipolar disorder (BD), according to patient group and type of procedure.  
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for 








Table S1 Definitions of patient groups 
Figure S1 Results of sensitivity analyses. Adjusted Prevalence Ratios (PR) with 95% lower 
(LCL) and upper (UCL) Confidence Limits for receipt of diagnostic CVD tests or invasive 
cardiovascular treatment prior to cardiovascular death in individuals with schizophrenia 





Table S1 Definitions of patient groups 
Patient group ICD-10 codes ICPC-2 codes 
Congestive Heart Failure I43, I50, I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, 
P29.0 
K71, K77 
Cardiac arrhythmias I47-I49, I44.1-I44.3, I45.6, I45.9, R00.0-R00.1, R00.8, 
T82.1, Z45.0, Z95.0 
K05, K78-K80 
Valvular disease I05-I08, I34-I39, A52.0, I09.1, I09.8, Q23.0-Q23.3, Z95.2-
Z95.4 
K83 
Pulmonary circulation disorders I26-I27, I28.0, I28.8-I28.9 K82, K93 
Peripheral vascular disorders I70-I71, I73.1, I73.8-I73.9, I77.1, I79.0, I79.2, K55.1, K55.8-
K55.9, Z95.8, Z95.9 
K92 
Hypertension, uncomplicated I10 K86 
Hypertension, complicated I11-I13, I15 K87 
Paralysis G81-G82, G04.1, G11.4, G80.1-G80.2, G83.0-G83.4, G83.9 - 
Other neurological disorders G10-G13, G20-G22, G32, G35-G37, G40-G41, R56, G25.4-
G25.5, G31.2, G31.8-G31.9, G93.1, G93.4, R47.0 
N07, N86-N88 
 
Chronic pulmonary disease J40-J47, J60-J67, I27.8-I27.9, J68.4, J70.1, J70.3 K82, R79, R95-R96  
Diabetes, uncomplicated E10.0-E10.1, E10.9-E11.1, E11.9-E12.1, E12.9-E13.1, 
E13.9-E14.1, E14.9 
T90 
Diabetes, complicated E10.2-E10.8, E11.2-E11.8, E12.2-E12.8, E13.2-E13.8, 
E14.2-E14.8 
T89 
Hypothyroidism E00-E03, E890 T86 
Renal failure N18-N19, I12.0, I13.1, N25.0, Z49.0-Z49.2, Z94.0, Z99.2 - 
Liver disease B18, I85, K70, K72-K74, I86.4, I98.2, K71.1, K71.3-K71.5, 
K71.7, K76.0, K76.2-K76.9, Z94.4 
D97 
Peptic ulcer disease excluding 
bleeding 
K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9 D85-D86 
 
AIDS/HIV B20-B22, B24 B90 
Lymphoma C81-C85, C88, C96, C90.0, C90.2 B72, B74 
Metastatic cancer C77-C80 - 
Solid tumor without metastasis C0-C1, C6, C20-C26, C30-C34, C37-C41, C43, C45-C58, 
C70-C76, C97 
D74-D75, D77, L71, N74, 
R84-R85, T71, U75-U77, 
W72, X75-X77, Y77-Y78 
Rheumatoid arthritis/collagen 
vascular diseases 
M05-M06, M08, M30, M32-M35, M45, L94.0-L94.1, 
L94.3, M12.0, M12.3, M31.0-M31.3, M46.1, M46.8-M46.9 
L88 
Coagulopathy D65-D68, D69.1, D69.3-D69.6 - 
Obesity E66 T82-T83 
Weight loss E40-E46, R64, R63.4 T08 
Fluid and electrolyte disorders E86-E87, E22.2 T11 
Blood loss anemia D50.0 - 
Deficiency anemia D51-D53, D50.8-D50.9 B80-B81 
Alcohol abuse F10, E52, T51, G62.1, I42.6, K29.2, K70.0, K70.3, K70.9, 
Z50.2, Z71.4, Z72.1 
P15, P16 
Drug abuse F11-F16, F18-F19, Z71.5, Z72.2 P18-P19 
Lipidemia E78 T93 






Figure S1 Results of sensitivity analyses. Adjusted Prevalence Ratios (PR) with 95% lower (LCL) and upper (UCL) Confidence 
Limits for receipt of diagnostic CVD tests or invasive cardiovascular treatment prior to cardiovascular death in individuals 
with schizophrenia (SCZ) or bipolar disorder (BD), according to patient group, health care sector and type of procedure.  
Data sources: The Norwegian Patient Registry (2008-2016), the Norwegian Directorate of Health’s system for control and 
payment of health reimbursements in primary care (2008-2016) and the Norwegian Cause of Death Registry (2011-2016). 
 
Model (i): Excluding patients diagnosed with dementia 
Model (ii): Excluding patients aged 80 and above 
Model (iii): Excluding patients with the ambiguous affective disorder diagnosis (ICPC-2 code P75) from the BD group  
Model (iv): Including also cases with CVD as contributing cause of death 
Model (v): Adjusting for person-years of observation 
Model (vi): Excluding persons who died at their first CVD encounter in the period 
